MARCO VALGIMIGLI, MD, PhD

Index of contents

1

Personal Details 2

2

Education / Further Education 3

3 3.1 3.2 3.3

Professional Experience Research Activities Clinical Activities Administrative and Leadership Experience

4 4 5 6

4 4.1 4.2 4.3 4.4 4.5

Details of Occupation Surgical Subjects Organisational Responsibilities Teaching Scientific Work Promotion of Junior Researchers

7 7 8 12 12 21

5

Research Methodology 24

6 6.1 6.2

Various Awards Memberships

25

7 7.1 7.2 7.2.1 7.2.2 7.2.3 7.2.4 7.2.5 7.2.6

7.2.7 7.3

Publications H-Index List of Publications Original Articles Review Articles Guidelines and Consensus Articles Editorials Letter to the Editor Case Reports

Book Chapters The Five Most Important Original Papers

26 27 28 28 89 95 105 106 108

109 112

2

1. Personal Details Prof. Marco Valgimigli

Date of Birth: March 06, 1972, Forlì (Italy) Nationality: Italian Marital Status: Defacto Children: Riccardo, 25/02/2007

Alessandro, 30/09/2010 Asia, 10/10/2018

Languages: Italian, English, German, French (basic), Dutch (basic) Office Address: Inselspital, University Hospital Bern Department of Cardiology

Freiburgstrasse CH- 3010 Bern Switzerland

Tel: 0041 31 63 2 47 14 E-Mail: marco.valgimigli@insel.ch Home Address: Buristrasse 43 3006 Bern Switzerland From June 1, 2020 Via Lepori 16 6900 Massagno Switzerland

07/05/2020

3

2. Education / Further Education

Education 1991 High School degree in foreign languages (60/60) 1991-1997 Faculty of Medicine, University of Bologna, Bologna, Italy

University Degrees 1997 Doctor in Medicine and Surgery (equivalent to M.D.)

University of Bologna, Italy, Magna cum laude Thesis: Piscaglia F, Zironi G, Gaiani S, Mazziotti A, Cavallari A,

Gramantieri L, Valgimigli M., Bolondi L. Systemic and Splanchnic Hemodynamic changes after liver translpantation for cirrhosis: a long term prospective study. Hepatology. 30:58-64, 1999.

2003 Degree in Cardiological Sciences University of Ferrara, Ferrara, Italy, Magna cum laude

2006 PhD degree in Interventional Cardiology

Erasmus Medical Center, Rotterdam, The Netherlands with a thesis entitled “High-risk percutaneous intervention in the drug eluting stent era” Promoters Professors P.W. Serruys and P. de Feyter

4

3. Professional Experience

3.1 Research Activities 1997-1999 Residency in Internal and Emergency Medicine Sciences,

winning a national grant University of Bologna, Bologna, Italy, (Prof Bolondi, Mentor)

2004-2005 Clinical and Research Fellowship in Interventional Cardiology,

Erasmus University, Thoraxcenter, Rotterdam, The Netherlands (Mentor, Prof P.W. Serruys)

2006 Centre Hospitalier Universitaire de Caen, Avenue Côte de Nacre

14033 Caen, Normandy, France, Cedex (under the assistance of Prof M. Hamon)

2006-2013 University Hospital of Ferrara, Cardiology Department, Ferrara, Italy

2013-2015 Erasmus Medical Center, Rotterdam, The Netherlands

2015 - current Bern University Hospital,

Cardiology department Bern, Switzerland

5

3.2 Clinical Activities: 1995-1997 Student-fellow at 1 Internal Medicine Unit Departement, S.

Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy 1997-1997 Clerkship in Cardiology at Hospital de Santa Maria, Lisbon,

Portugal 1997-1999 Post-graduate fellow at Emergency Medicine Unit, S. Orsola-

Malpighi Hospital, University of Bologna, Bologna, Italy 1999-2000 Post-graduate fellow at Coronary Care Unit, S. Anna Hospital,

University of Ferrara, Ferrara, Italy 2000-2002 Post-graduate fellow at Haemodynamic Unit, Spedali Civili,

University of Brescia, Brescia, Italy 2002-2003 Post-graduate Resident-fellow at Haemodynamic Unit, S. Anna

Hospital, University of Ferrara, Ferrara, Italy 2004-2005 Research (PhD training) and clinical fellowship in Interventional

Cardiology, Erasmus University, Thoraxcenter, Rotterdam, The Netherlands

2006-2006 Training in complex PCI procedures through radial access at the

Centre Hospitalier Universitaire de Caen, Avenue Côte de Nacre Caen, Normandy, France, Cedex (under the assistance of Prof M. Hamon)

2006-2009 Senior attending cardiologist at the University Hospital of Ferrara

working full time in the catheterization laboratory 2009-2013 Director of the Catheterization Laboratory at the University

Hospital of Ferrara, Ferrara, Italy 2013-2015 Associate Professor of Cardiology at Erasmus Medical Center

and Senior Interventional Cardiologist, Thoraxcenter, Rotterdam, The Netherlands

2015-current Head of clinical research of the Cardiology department, and full-

time interventional cardiologist at Inselspital, Bern University Hospital, Switzerland.

2016-current Extraordinary Professor for invasive cardiology Bern University

Hospital, Bern, Switzerland.

6

3.3 Administrative and Leadership Experience 2009-2013 Director of the Catheterization Laboratory at the University

Hospital of Ferrara, Ferrara, Italy, Responsible of 6 Interventional Cardiologists and 10 Catheterisation Laboratory Nurses and 5 Technicians

2013-2015 Director of Clinical Research in the field of anti-thrombotics and innovative pharmacological treatment modalities at the Thoraxcentrum, Eramus Medical Center and responsabile person for the interaction between the Erasmus University and clincal research organizations (CRO), including Cardialysis for the planning, execution and oversight of all investigator-driven clinical research activites.

2015-current Director of Clinical Research of the Cardiology department, Inselspital, Bern University Hospital, Switzerland. Responsabile for the organization, planning and execution of sponsor- and investigator-initiated clinical research in the field of cardiology and interventional cardiology. Local referent for the Cardiopath PhD program, an international PhD program led by the University of Naples, Federico II, involving the University of Bern, Switzerland and the Cardiovascular center OLV, Aalst, Belgium.

7

4. Details of Occupation 4.1 Surgical (Interventional) Subjects

Operation (Intervention) Catalogue

Interventions conducted as operator (2006 – end of October 2018) Diagnostic coronary angiography 8946 Percutaneous coronary interventions 5022 PFO and LAA closures 190 Transcatheter aortic valve implantation (TAVI) 269 Valvuloplasty 29 Right heart catheterisation 2687 Mitral Clip 22 Paravalvular leak closure 3

Interventions conducted as assistant (2002 -2006) Diagnostic coronary angiography 1079 Percutaneous coronary interventions 567 PFO and LAA closures 5 Valvuloplasty 10 Percutaneous trans-spetal myocardial ablation 23 Right heart catheterisation 106

Interventions conducted as instructor (2006 – end of November 2017) Diagnostic coronary angiography 5867 Percutaneous coronary interventions 3455 PFO and LAA closures 85 Valvuloplasty 19 Right heart catheterisation 578 TAVI 169 Mitral Clip 22 Paravalvular leak closure 3

8

4.2 Organisational Responsibilities

2007-2013 Head of Invasive Cardiology, University Hospital Ferrara, Cardiology Department, Ferrara, Italy

2006-2013 Head of Research, University Hospital Ferrara, Cardiology Department, Ferrara, Italy

2013-2015 Group Leader, cardiac research on anti-thrombotic agents, University Clinic for Cardiology, Department Thorax, University Hospital Erasmus Medical Center Rotterdam, The Netherlands

2015-current Extraordinary Professorship for invasive cardiology and Head of Clinical Research, Bern University Hospital, Bern, Switzerland

2018 Chief and Professor of Cardiology (succession of Prof. Daniel

Wagner) University Hospital Lausanne, Switzerland secondo loco (primo loco: Prof. O. Müller) 2018 – current Member of Scientific Advisory Board University Hospital Basel Department of Clinical Research

9

European Society of Cardiology (ESC)

2006-2017 Committee Member, ESC Press Committee

2007- current Fellow of the European Society of Cardiology (ESC)

2013-2016 Editor of the ESC Congress News

2013- 2015 Committee Member, Congress Program Committee

2015- 2017 Chair, Congress Program Committee

2013-2017 European Association of Percutaneous Coronary intervention (EAPCI) Board member

Clinical Practice Guidelines Committee from the European Society of Cardiology

2011-2011 Reviewer ESC Guidelines for the Diagnosis and Treatment of Non-ST Segment Elevation Acute Coronary Syndromes

2011-2012 Task Force Member ESC Guidelines for the Management of ST-Segment Elevation Myocardial Infarction

2012-2014 Task Force Member ESC Guidelines on Myocardial Revascularization Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)

2012-2014 Reviewer Coordinator ESC Guidelines for the Diagnosis and Treatment of Stable Coronary Artery Disease

2013-2015 Task Force Member (Section Coordinator) ESC Guidelines for the Diagnosis and Treatment of Non-ST Segment Elevation Acute Coronary Syndromes

2015-2017 Chair–Task Force ESC Guidelines DAPT Focused Update on Myocardial Revascularization

Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)

10

2015-2017 Task Force Member (Section Coordinator) ESC Guidelines for the Diagnosis and Treatment of ST Segment Elevation Myocardial Infarction

2016-2018 Reviewer ESC Scientific Document Group. Fourth universal definition of

myocardial infarction (2018).

2017-2019 Task Force Member of the ESC guidelines for the diagnosis and treatment of patients with stable coronary artery disease.

2019 Task Force Member of the 2020 ESC Guidelines for the

management of atrial fibrillation

2020 Chair of the Joint EAPCI, ACCA and EAPC Paper on Anti-thrombotic treatment strategies for secondary prevention in patients with established coronary atherosclerotic disease

European Association of Percutaneous Coronary Intervention

2011-2016 Chair, Research Committee from the European Association of Percutaneous Coronary Intervention (EAPCI)

International Courses on Percutaneous Cardiovascular Interventions

2010- Current Committee Program Member, PCR–course on cardiovascular interventions, EuroPCR, Paris, France

2011-2016 Committee member Program, TCT–course on cardiovascular interventions, New York, USA

2016- Current Associate director TCT Program Commitee–course on cardiovascular interventions, New York, USA

Live-Case Transmissions

2013 Live-case Transmission for Rotterdam Course on Biovascular Scaffold

2014 Live-case Transmission for Rotterdam Course on Biovascular Scaffold

2015 Live-case Transmission for Prague Cardiovascular Course

11

Editorial Board Member

Since 2012 Journal of the American College of Cardiology – Cardiovascular Interventions

Since 2013 EuroIntervention

Since 2010 Future Cardiology

Since 2015 Asia Pacific Intervention

Since 2018 European Heart Journal: Acute Cardiovascular Care

Since 2018 Circulation Cardiovascular Intervention

Clinical Event Committee Member

2009 Member, RESOLUTE Trial

2010 Member, NEVO 2 Trial

2011 Member, NEXT Trial

2013 Member, EXECUTIVE Trial

2015 Member, RESERVOIR I Trial

2019 Member, EURO-SHOCK Trial

Data Safety Monitoring Board Committee Member

2017-current DSMB Chair of the Revacept, a Novel Inhibitor of Platelet Adhesion in Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Interventions: A Phase II, Multicentre, Randomised, Dose-Finding, Double-Blind and Placebo-Controlled Study

Review for Peer Reviewed Journals

Cardiology Circulation, Journal of the American College of Cardiology (JACC), European Heart Journal, EuroIntervention, Circulation Cardiovascular Interventions, Journal of the American College of Cardiology Cardiovascular Interventions, American Heart Journal, American Journal of Cardiology, Catheterization and Cardiovascular

12

Interventions, Journal of Invasive Cardiology, Heart, Journal of Cardiovascular, JAMA Cardiology

Internal Medicine New England Journal of Medicine (NEJM), Lancet, Journal of the American Medical Association (JAMA), British Medicine Journal, Archieves of Internal Medicine, Annals of Internal Medicine.

4.3 Teaching

2013 Contract professor of invasive cardiology for nurses at the University of Ferrara (target audience: care staff)

2013 Contract professor of invasive cardiology for radiology technicians at the University of Ferrara (target audience: care staff)

2013 Contract professor of invasive cardiology for residents in the specialization course of Cardiology at the University Hospital of Ferrara Italy (target audience: Doctors in Medicine attending the specialization course in cardiology)

2014-2015 Responsible Person of the COEUR (Cardiovascular Research School) course on anti-thrombotics devoted to PhD students of the Erasmus Medical Center institution (target audience: PhD students comprising doctors in medicine or biology)

2015-current Invovled in the organisation and execution of the weekly journal clubs and Grand Rounds with staff members and visiting professors at Inselspital, Bern.

4.4 Scientific work Financial support of the Ministery for University and Scientific and

Technological research [MURST]

Project: Tailoring the choice of P2Y12 oral receptor blockers by integrating loss of function alleles to phenotype assessment via point of care testing versus standard of care in patients who undergo percutaneous coronary intervention: a randomized multicenter trial

Support: Ministry for University and Scientific and Technological Research [MURST]

Number of partner: 10 Own function: Principal Investigator Period: 2012-2015 Total amount: Euro 336'700.00

13

Financial support from REGIONE EMILIA ROMAGNA

Project: Single High-Dose BoluS TiRofibAn and Sirolimus Eluting STEnt versus Abciximab and Bare Metal Stent in Acute MYocardial Infarction (STRATEGY) Study

Support: Regione Emilia Romagna Number of partner: 1 Own function: Principal Investigator Period: 2003-2006 Total amount: Euro 250'000.00

Financial support from SNSF - Swiss National Science Foundation

Project: GLASSY: GLOBAL LEADERS Adjudication Sub-Study Support: SNSF Number of partner: 19 (including Bern) Own function: Principal Investigator Period: 2018 Total amount: CHF 19’200.00 (SNF)

Financial support from Swissheart Foundation (Schweizerische Herzstiftung) Project: Establishing Reference Values for the Diagnosis of Coronary

Artery Ectasia in Current Support: Swiss Foundation of Cardiology Own function: Principal Investigator Period: 2019 Total amount: CHF 80’000.00

Financial support from Innosuisse – Agenzia svizzera per la promozione dell’innovazione Project: MOCA I Microvascular Obstruction with the CoFI™ System

Assessment Support: Innosuisse & CorFlow Number of Partner: 4 Own function: Principal Investigator Period: 2019 - 2020 Total amount: 265’920.00

14

Investigator Initiated Trials

Project: MULTISTRATEGY: MULTIcentre evaluation of Single high-dose bolus TiRofiban versus Abciximab with sirolimus eluting sTEnt or Bare Metal Stent in Acute Myocardial Infarction studY

Support: University of Ferrara, support from Merck Number of partner: 16 Own function: Principal Investigator Period: 2004-2008 Total amount: Euro 500'000.00

Project: 3T/2R: Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel

Support: University of Ferrara, industry support from MERCK Number of partner: 12 Own function: Principal Investigator Period: 2005-2009 Total amount: Euros 700'000.00

Project: FABOLUS SYNCHRO: Facilitation through Abciximab by dropping infusion line in patients undergoing coronary stenting. Synergy with clopidogrel at high loading dose regimen.

Support: University of Ferrara, industry support from Eli Lilly Number of partner: 1 Own function: Principal Investigator Period: 2006-2008 Total amount: Euro 150'000.00

Project: FABOLUS PRO: Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse

Support: University of Ferrara, industry support from Correvio Number of partner: 1 Own function: Principal Investigator Period: 2009-2011 Total amount: Euro 250'000.00

Project: PRODIGY: PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study

Support: University of Ferrara, industry support from Sanofi and Abbott Vascular

Number of partner: 3

15

Own function: Principal Investigator Period: 2005-2008 Total amount: Euro 150'000.00

Project: ZEUS: Zotarolimus-eluting Endeavor sprint stent in Uncertain DEScandidates

Support: University of Ferrara, industry support from Medtronic Number of partner: 19 Own function: Principal Investigator Period: 2009-2011 Total amount: Euro 650'000.00

Project: MATRIX: Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX)

Support: Italian Society of Interventional Cardiology, industry support from The Medicines Company and Terumo

Number of partner: 79 Own function: Principal Investigator Period: 2011-2017 Total amount: Euro 3'267’000.00

Project: Global LEADERS: Comparative effectiveness of 1 month of ticagrelor plus aspirin followed by ticagrelor monotherapy versus a current-day intensive dual antiplatelet therapy in all-comers patients undergoing percutaneous coronary intervention with bivalirudin and biomatrix family drug-eluting stent use.

Support: ECRI–European Cardiovascular Research Insitute, industry support from a consortium with Biosensors, Astra Zeneca and The Medicines Company

Number of partner: 5 Own function: Co-Principal Investigator Period: 2013-2018 Total amount: Euro 33'000'000.00

Project: GLASSY: GLOBAL LEADERS Adjudication Sub-Study Support: Inselspital, Bern University Hospital, and ECRI–European

Cardiovascular Research Insitute Number of partner: 19 (including Bern) Own function: Principal Investigator Period: 2017-2018 Total amount: CHF 650'000.00

16

Project: HIGH-TECH: Hunting for the off-target properties of Ticagrelor on Endothelial function and other circulating biomarkers in humans

Support: Erasmus Medical Center, industry support from Astra Zeneca Number of partner: 5 (including Bern) Own function: Principal Investigator Period: 2015-2017 Total amount: Euro 443'000.00

Project: FABOLUS FASTER: Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over prasugreL: a mUlticenter Randomized Open-label Trial in patientS With ST-elevation Myocardial inFarction Referred for primAry percutaneouS inTERvention

Support: Inselspital, Bern University Hospital, industry support from Medicure

Number of partner: 6 (including Bern) Own function: Chair and Principal Investigator Period: 2017-2019 Total amount: CHF 707'000.00

Project: MASTER-DAPT: Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen

Support: ECRI, Cardialysis, Bern University Hospital, Terumo Medical Corporation

Number of partner: 100 (including Bern) Own function: Chair and Principal Investigator Period: 2017-2019 Total amount: Euro 11’500’000.00

Project: SWISS APERO: Comparison of Amplatzer Amulet vs Watchman device in patients undergoing left atrial appendage closure

Support: Inselspital, Bern University Hospital, industry support from Abbott Vascular

Number of partner: 4 (including Bern) Own function: Chair and Principal Investigator Period: 2018-2019 Total amount: CHF 400'000.00

Project: XIENCE 28 SHORT DAPT Support: Abbott Vascular Number of partner: 50 (including Bern) Own function: Co-Principal Investigator Period: 2018-2019 Total amount: Euro 5’000’000.00

17

Trials Initiated by Industry

Project: EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome

Support: EISAI Number of partner: 29 Own function: Local Principal Investigator Period: 2007-2009 Total amount: Euro 67’000.00

Project: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

Support: Anthera Pharmaceuticals Number of partner: 362 Own function: Local Principal Investigator Period: 2010-2012 Total amount: Euro 38’000.00

Project: LANCELOT-ACS: Lessons from Antagonizing the Cellular Effect of Thrombin-Acute Coronary Syndrome

Support: EISAI Number of partner: 440 Own function: Local Principal Investigator Period: 2004-2008 Total amount: Euro 40’000.00

Project: STABILITY: Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Unterstützung: GlaxoSmithKline

Number of partner: 663 Own function: Local Principal Investigator Period: 2008-2010 Total amount: Euro 85’000.00

Project: STREAM: Strategic Reperfusion Early after Myocardial Infarction Support: Boehringer Ingelheim Number of partner: 99 Own function: Local Principal Investigator Period: 2008-2010 Total amount: Euro 33’540.00

18

Project: SOLID-TIMI 52: Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52

Support: GlaxoSmithKline Number of partner: 99 Own function: Local Principal Investigator Period: 2008-2010 Total amount: Euro 53’540.00

Project: EXAMINATION: Evaluation of the Xience-V stent in Acute Myocardial INfArcTION

Support: Abbott Vascular Number of partner: 12 Own function: Executive Committee member und local Principal Investigator Period: 2009-2011 Total amount: Euro 767’400.00

Project: TRACER: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome

Support: Merck Number of partner: 818 Own function: Steering Committee member und local Principal Investigator Period: 2009-2011 Total amount: Euro 960’500.00

Project: FAME 2: Fractional Flow Reserve versus Angiography for Multi- vessel Evaluation 2

Support: St. Jude Number of partner: 28 Own function: local Principal Investigator Period: 2011-2012 Total amount: Euro 28’800.00

Project: BIOSOLVE 3: Acute performance of a drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo lesions in native coronary arteries

Support: Biotroniks Number of partner: 8 Own function: local Principal Investigator Period: 2015-current Total amount: CHF 56.000

19

Project: P2Y12 Open label, randomized, study to assess the onset of platelet aggregation inhibition after a single subcutaneous injection of ACT-246475 in adults with acute myocardial infarction

Support: IDORSIA Number of Partner: 6 Own function: Principal Investigator Period: 2018

National Coordinator and Steering Committee Member of the following Trials:

TRACER: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome Sponsor: Merck

ODISSEY OUTCOMES: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome Sponsor: Sanofi

AUGUSTUS: An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention Sponsor: Bristol-Myers Squibb

EXCEL: Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial Sponsor: Abbott Vascular

REGULATE-PCI: Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Sponsor: Regado Biosciences, Inc. ENTRUST: Evaluation of the Safety and Efficacy of an Edoxaban-based Antithrombotic Regimen in Patients with Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) with Stent Placement Sponsor: Daiichi Sankyo

20

Executive Committee Member of the following Trials:

ENTRUST-AF-PCI: Evaluation of the Safety and Efficacy of an Edoxaban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement. Sponsor Daiichi Sankyo, Inc.

ENVISAGE-TAVI-AF: Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) - in Atrial Fibrillation Sponsor Daiichi Sankyo, Inc.

GALILEO: Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes Sponsor Bayer

21

4.5 Promotion of Junior Researchers

PhD/Cardiology Students

Patrizia Malagutti Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, Cicchitelli G, Olivares A, Parrinello G, Percoco G, Guardigli G, Mele D, Pirani R, Ferrari R. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation. 111(7):863-870, 2005.

Elisa Merli Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli G, Antelli A, Canistro D, Francolini G, Macrì G, Mastrorilli F, Paolini M, Ferrari R.Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. J Am Coll Cardiol. 43(11):2000-2008, 2004.

Olga Soukhomovskaia Valgimigli M, Rigolin GM, Fucili A, Porta MD, Soukhomovskaia O, Malagutti P, Bugli AM, Bragotti LZ, Francolini G, Mauro E, Castoldi G, Ferrari R. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation. 110(10):1209-1212, 2004.

Elisa Cangiano Cangiano E, Cavazza C, Campo G, Valgimigli M, Francolini G, Malagutti P, Pratola C, Ferrari R. Different clinical models of CD34 + cells mobilization in patients with cardiovascular disease. J Thromb Thrombolysis. 32(1):1-8, 2011.

Gianluca Campo Campo G, Valgimigli M, Frangione A, Luccarelli S, Cangiano E, Cavazza C, Fileti L, Ferrari R; 3T/2R Investigators. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel). J Am Coll Cardiol. 55(3):255-256, 2010.

Carlo Penzo Valgimigli M, Campo G, Penzo C, Tebaldi M, Biscaglia S, Ferrari R; RADAR Investigators. Transradial coronary catheterization and intervention across the whole spectrum of Allen test results. J Am Coll Cardiol. 63(18):1833-1841, 2014.

22

Mentor of PhD students:

• Giuseppe Gargiulo (topic of interest: pharmacologic and mechanical strategies to balance ischemic and bleeding complications during and after percutaneous cardiovascular interventions; PhD thesis discussion: January 2019)

• Roberto Galea (topic of interest: predittori di complessita’ procedural e di efficacia e sicurezza a breve e lungo termine in pazienti sottoposti a chiusura percutanea dell’auricola sinistra: analisi retrospettiva di un centro ad alto volume; PhD thesis discussion August 2018)

• Francesco Costa (topic of interest:pharmaco-mechanical strategies to optimize the balance between ischemia and bleeding after percutaneous coronary intervention; PhD thesis discussion: April 2018)

• Marianna Adamo (topic of interest: effect of different formulations of tirofiban on thrombocytopenia and clinical outcomes in patients with acute coronary syndrome; PhD thesis discussion: tbd)

• Fortunato Iacovelli (topic of interest: angiographic analysis and outcomes of patients undergoing percutaneous coronary interventions; PhD thesis discussion: May 2019)

• Marco Angellillis (topic of interest: percutaneous closure of left atrial appendage in patients at high ischemic and bleeding risk; PhD thesis discussion: tbd)

Mentor for EAPCI Fellowship recipients

2014-2015 Dr Francesco Costa, Messina, Italy

2015-2016 Dr. Giusepe Gargiulo, Naples, Italy 2018-2018 Dr. Andreas Mitsis, Patra Achaias, Greece

23

External Reviewer/Committee memebr for PhD Thesis 2010 Dr. Emanuele Meliga Erasmus University Medical Center Rotterdam, The Netherlands

2015 Dr. Lorenz Räber Erasmus University Medical Center Rotterdam, The Netherlands

2015 Dr. Michael Magro Erasmus University Medical Center Rotterdam, The Netherlands

2017 Dr. Christian Puelacher Perioperative Myocardial Injury in Non-cardiac Surgery - Incidence, Patient Characteristics, Outcome, and Possible Strategies to Improve Outcome University of Basel, Switzerland

2018 Dr. Francesco Costa Pharmaco-mechanical strategies to optimize the balance between ischemia and bleeding after percutaneous coronary intervention Erasmus Medical Center Rotterdam, The Netherlands

2019 Dr. Rohit Mansingh

Coronary vulnerability Erasmus Medical Center Rotterdam, The Netherlands

Habilitation 2019 Dr. med. Nasser Dhayat Nephrology and Hypertension and Clinical Pharmacology University of Bern Bern, Switzerland 2018 Dr Rebecca Hasler MD MSc Orthopedic Surgery / Traumatology

University of Bern Bern, Switzerland

2018 Dr. Jean-Sébastien Rougier PhD Molekulare Medizin

University of Bern Bern, Switzerland

24

5 Research Methodology Clinical

Multicentric studies Planing, organisation and conduction of several randomized controlled studies to investigate the safety and efficacy of percutaneous implanted prostheses (coronary stents, prostheses for congenital defects, heart valves).

Cohort studies Cohort studies with large patient numbers to establish the long term safety from stent thrombosis.

Meta-Analysis Co-investigator of different meta-analysis regarding safety.

25

6 Various 6.1 Awards

Winner of the “Best Scientific contribution Award” with a research project entitled: “Apoptotic activity of serum is increased in patients with pancoronary syndrome” October 2002, Verona, Italy, on behalf of GISE (Gruppo Italiano Studi di Emodinamica)

Winner of the “Scholarship from Italian Society of Cardiology” with a scientific contribution entitled: “Pathophysiological and clinical implications of bone marrow stem cells spontaneous mobilisation in Acute Coronary Syndromes and Heart Failure” Rome 2003, Italy, SIC (Italian Society of Cardiology)

Finalist TCT Young Investigator Award, October 2005, Washington

6.2 Memberships

Italian Society of Cardiology (SIC)

Associazione Nazionale Medici Cardiologi Ospedalieri (AMNCO)

BIG Registry (Dutch National Society of Medical Doctors)

Fellow of the European Society of Cardiology (FESC)

Italian society of Interventional Cardiology (GISE)

Schweizerische Gesellschaft für Kardiologie/Société Suisse de Cardiologie/Società Svizzera di Cardiologia

26

7. Publications ORCID ID: https://orcid.org/0000-0002-4353-7110 Highly Cited researcher in the field of Clinical Medicine – 2019 Among the 1% most cited researchers in 2019 (Source ISI Web)

Highly Cited researcher in the field of Clinical Medicine – 2018 Among the 1% most cited researchers in 2018 (Source ISI Web)

27

Highly Cited researcher in the field of Clinical Medicine – 2017 Among the 1% most cited researchers in 2017 (Source ISI Web)

7.1 H-index Publication range 1997-Present Number of documents: 572 Number of citations. 40182 total citations by 27007 documents H-INDEX: 85 Source Scopus (accessed on 07.05.2020)

28

7.2 List of Publications

7.2.1 Original Articles

1. Hara H, Kogame N, Takahashi K, Modolo R, Chichareon P, Tomaniak M, Ono M,Kawashima H, Gao C, Wang R, Valkov VD, Vom Dahl J, Steinwender C, Geisler T,Lemos Neto PA, Macaya Miguel C, Garg S, Jüni P, Hamm C, Steg PG, Valgimigli M, Vranckx P, Windecker S, Farooq V, Onuma Y, Serruys PW; GLOBAL LEADERS Trial Investigators. Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. Catheter Cardiovasc Interv. 2020 Apr 15. doi: 10.1002/ccd.28898. [Epub ahead of print] PubMed PMID: 32294317.

2. Chandiramani R, Cao D, Claessen BE, Sorrentino S, Guedeney P, Blum M,

Goel R, Roumeliotis A, Krucoff M, Kozuma K, Ge J, Seth A, Makkar R, Bangalore S, Bhatt DL, Angiolillo DJ, Ruster K, Wang J, Saito S, Neumann FJ, Hermiller J, Valgimigli M, Mehran R. Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies. J Am Heart Assoc. 2020 Apr 7;9(7):e014611. doi: 10.1161/JAHA.119.014611. Epub 2020 Mar 30. PubMed PMID: 32223396.

3. Tomaniak M, Chichareon P, Modolo R, Takahashi K, Chang CC, Kogame N,

Spitzer E, Buszman PE, van Geuns RM, Valkov V, Steinwender C, Geisler T, Prokopczuk J, Sabaté M, Zmudka K, Rademaker-Havinga T, Tijssen JGP, Jüni P, Hamm C, Steg PG, Onuma Y, Vranckx P, Valgimigli M, Windecker S, Baber U, Anderson R, Dominici M, Serruys PW. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. EuroIntervention. 2020 Apr 3;15(18):e1605-e1614. doi: 10.4244/EIJ-D-19-00699. PubMed PMID: 31845894.

4. Komajda M, Cosentino F, Ferrari R, Kerneis M, Kosmachova E, Laroche C,

Maggioni AP, Rittger H, Steg PG, Szwed H, Tavazzi L, Valgimigli M, Gale CP; CICD investigators group. Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. Eur J Prev Cardiol. 2020 Mar 31:2047487320912491. doi: 10.1177/2047487320912491. [Epub ahead of print] Erratum in: Eur J Prev Cardiol. 2020 Apr 29;2047487320924592. PubMed PMID: 32228040.

5. Sorrentino S, Claessen BE, Chandiramani R, Guedeney P, Vogel B, Baber U,

Rau V, Wang J, Krucoff M, Kozuma K, Ge J, Seth A, Makkar R, Liu Y, Bangalore S, Bhatt DL, Angiolillo DJ, Saito S, Neumann FJ, Hermiller J, Valgimigli M, Mehran R. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk:

29

A Patient-Level Stratified Analysis From Four Postapproval Studies. Circulation. 2020 Mar 17;141(11):891-901. doi: 10.1161/CIRCULATIONAHA.119.041619. Epub 2020 Jan 29. PubMed PMID: 31992063.

6. Chichareon P, Modolo R, Kawashima H, Takahashi K, Kogame N, Chang CC,

Tomaniak M, Ono M, Walsh S, Suryapranata H, Cotton J, Koning R, Akin I, Kukreja N, Wykrzykowska J, Piek JJ, Garg S, Hamm C, Steg PG, Jüni P, Vranckx P, Valgimigli M, Windecker S, Onuma Y, Serruys PW. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. JACC Cardiovasc Interv. 2020 Mar 9;13(5):634-646. doi: 10.1016/j.jcin.2019.12.018. PubMed PMID: 32139222.

7. Gargiulo G, Valgimigli M, Sunnåker M, Vranckx P, Frigoli E, Leonardi S,

Spirito A, Gragnano F, Manavifar N, Galea R, De Caterina AR, Calabrò P, Esposito G, Windecker S, Hunziker L. Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. Rev Esp Cardiol (Engl Ed). 2020 Mar 6. pii: S1885-5857(20)30034-7. doi: 10.1016/j.rec.2020.01.005. [Epub ahead of print] English, Spanish. PubMed PMID: 32151464.

8. Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF,

Vinereanu D, Granger CB, Goodman SG, Aronson R, Windecker S, Thiele H, Valgimigli M, Mehran R, Alexander JH. Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation. 2020 Mar 3;141(9):781-783. doi: 10.1161/CIRCULATIONAHA. 119.044584. Epub 2019 Nov 11. PubMed PMID: 31707833.

9. van der Hoeven NW, Janssens GN, Everaars H, Nap A, Lemkes JS, de Waard

GA, van de Ven PM, van Rossum AC, Escaned J, Mejia-Renteria H, Ten Cate TJF, Piek JJ, von Birgelen C, Valgimigli M, Diletti R, Riksen NP, Van Mieghem NM, Nijveldt R, van Leeuwen MAH, van Royen N. Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial. J Am Heart Assoc. 2020 Mar 3;9(5):e014411. doi: 10.1161/JAHA.119.014411. Epub 2020 Mar 3. PubMed PMID: 32122216.

10. Gargiulo G, Esposito G, Cirillo P, Nagler M, Minuz P, Campo G, Gragnano F,

Manavifar N, Piccolo R, Avvedimento M, Tebaldi M, Wahl A, Hunziker L, Billinger M, Heg D, Windecker S, Valgimigli M. Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial. J Cardiovasc Transl Res. 2020 Feb 24. doi: 10.1007/s12265-020-09969-4. [Epub ahead of print] PubMed PMID: 32096064.

30

11. Ueki Y, Bär S, Losdat S, Otsuka T, Zanchin C, Zanchin T, Gragnano F, Gargiulo G, Siontis GCM, Praz F, Lanz J, Hunziker L, Stortecky S, Pilgrim T, Heg D, Valgimigli M, Windecker S, Räber L. Validation of Bleeding Risk Criteria (ARC-HBR) in Patients Undergoing Percutaneous Coronary Intervention and Comparison with Contemporary Bleeding Risk Scores. EuroIntervention. 2020 Feb 18. pii: EIJ-D-20-00052. doi: 10.4244/EIJ-D-20-00052. [Epub ahead of print] PubMed PMID: 32065586.

12. Bianco M, D'ascenzo F, Raposeiras Roubin S, Kinnaird T, Peyracchia M,

Ariza-Solé A, Cerrato E, Manzano-Fernández S, Gravinese C, Templin C, Destefanis P, Velicki L, Luciano A, Xanthopoulou I, Rinaldi M, Rognoni A, Varbella F, Boccuzzi G, Omedè P, Montabone A, Bernardi A, Taha S, Rossini R, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Blanco PF, Giustetto C, Garay A, Quadri G, Queija BC, Srdanovic I, Paz RC, Fernández MC, Pousa IM, Gallo D, Morbiducci U, Dominguez-Rodriguez A, Lopez-Cuenca Á, Cequier A, Alexopoulos D, Iñiguez-Romo A, Pozzi R, Assi EA, Valgimigli M. Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. Int J Cardiol. 2020 Feb 15;301:200-206. doi: 10.1016/j.ijcard.2019.11.132. Epub 2019 Nov 22. PubMed PMID: 31785951.

13. Chichareon P, Modolo R, Kogame N, Takahashi K, Chang CC, Tomaniak M,

Botelho R, Eeckhout E, Hofma S, Trendafilova-Lazarova D, Kőszegi Z, Iñiguez A, Wykrzykowska JJ, Piek JJ, Garg S, Hamm C, Steg PG, Jüni P, Vranckx P, Valgimigli M, Windecker S, Onuma Y, Serruys PW. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. Atherosclerosis. 2020 Feb;295:45-53. doi: 10.1016/j.atherosclerosis.2020.01.002. Epub 2020 Jan 15. PubMed PMID: 32006758.

14. Bikdeli B, McAndrew T, Crowley A, Chen S, Mehdipoor G, Redfors B, Liu Y,

Zhang Z, Liu M, Zhang Y, Francese DP, Erlinge D, James SK, Han Y, Li Y, Kastrati A, Schüpke S, Stables RH, Shahzad A, Steg PG, Goldstein P, Frigoli E, Mehran R, Valgimigli M, Stone GW. Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. Thromb Haemost. 2020 Feb;120(2):348-362. doi: 10.1055/s-0039-1700872. Epub 2019 Dec 9. PubMed PMID: 31820428; PubMed Central PMCID: PMC7040882.

15. Ono M, Chichareon P, Tomaniak M, Kawashima H, Takahashi K, Kogame N,

Modolo R, Hara H, Gao C, Wang R, Walsh S, Suryapranata H, da Silva PC, Cotton J, Koning R, Akin I, Rensing BJWM, Garg S, Wykrzykowska JJ, Piek JJ, Jüni P, Hamm C, Steg PG, Valgimigli M, Windecker S, Storey RF, Onuma Y, Vranckx P, Serruys PW. The association of body mass index with long-term

31

clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. Clin Res Cardiol. 2020 Jan 31. doi: 10.1007/s00392-020-01604-1. [Epub ahead of print] PubMed PMID: 32006156.

16. Kleinecke C, Yu J, Neef P, Buffle E, de Marchi S, Fuerholz M, Nietlispach F,

Valgimigli M, Streit SR, Fankhauser M, Duenninger E, indecker S, Meier B, Gloekler S. Clinical outcomes of Watchman vs. Amplatzer occluders for left atrial appendage closure (WATCH at LAAC). Europace. 2020 Jan 31. pii: euaa001. doi: 10.1093/europace/euaa001. [Epub ahead of print] PubMed PMID: 32003774.

17. Costa F, van Klaveren D, Colombo A, Feres F, Räber L, Pilgrim T, Hong MK,

Kim HS, Windecker S, Steyerberg EW, Valgimigli M; PRECISE-DAPT Study Investigators. A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. Am Heart J. 2020 Jan 30;223:44-47. doi: 10.1016/j.ahj.2020.01.014. [Epub ahead of print] PubMed PMID: 32151822.

18. Tomaniak M, Chichareon P, Klimczak-Tomaniak D, Takahashi K, Kogame N,

Modolo R, Wang R, Ono M, Hara H, Gao C, Kawashima H, Rademaker-Havinga T, Garg S, Curzen N, Haude M, Kochman J, Gori T, Montalescot G, Angiolillo DJ, Capodanno D, Storey RF, Hamm C, Vranckx P, Valgimigli M, Windecker S, Onuma Y, Serruys PW, Anderson R. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clin Res Cardiol. 2020 Jan 10. doi: 10.1007/s00392-019-01586-9. [Epub ahead of print] PubMed PMID: 31925529.

19. Dangas GD, Tijssen JGP, Wöhrle J, Søndergaard L, Gilard M, Möllmann H,

Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimarães AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Schäfer U, Seeger J, Tchétché D, Thomitzek K, Valgimigli M, Vranckx P, Welsh RC, Wildgoose P, Volkl AA, Zazula A, van Amsterdam RGM, Mehran R, Windecker S; GALILEO Investigators. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. N Engl J Med. 2020 Jan 9;382(2):120-129. doi: 10.1056/NEJMoa1911425. Epub 2019 Nov 16. PubMed PMID: 31733180.

20. Chang CC, Chichareon P, Modolo R, Takahashi K, Kogame N, Tomaniak M,

Gao C, Royaards KJ, Cequier A, Oldroyd K, Steg PG, Hamm C, Jüni P, Valgimigli M, Windecker S, Onuma Y, Stables RH, Jan van Geuns R, Serruys PW. Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. Eur Heart J Cardiovasc Pharmacother. 2020 Jan 1;6(1):22-30. doi: 10.1093/ehjcvp/pvz051. PubMed PMID: 31841136.

32

21. Potpara TS, Mujovic N, Proietti M, Dagres N, Hindricks G, Collet JP,

Valgimigli M, Heidbuchel H, Lip GYH. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Europace. 2020 Jan 1;22(1):33-46. doi: 10.1093/europace/euz259. Erratum in: Europace. 2020 Feb 1;22(2):176. PubMed PMID: 31603196.

22. Garcia-Garcia HM, Adamo M, Soud M, Yacob O, Picchi A, Sardella G, Frigoli

E, Limbruno U, Rigattieri S, Diletti R, Boccuzzi G, Zimarino M, Contarini M, Russo F, Calabrò P, Andò G, Varbella F, Garducci S, Palmieri C, Briguori C, Karagiannis A, Valgimigli M. Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study. Catheter Cardiovasc Interv. 2019 Dec 28. doi: 10.1002/ccd.28661. [Epub ahead of print] PubMed PMID: 31883294.

23. Garg S, Chichareon P, Kogame N, Takahashi K, Modolo R, Chang CC,

Tomaniak M, Fath-Ordoubadi F, Anderson R, Oldroyd KG, Stables RH, Kukreja N, Chowdhary S, Galasko G, Hoole S, Zaman A, Hamm CW, Steg PG, Jüni P, Valgimigli M, Windecker S, Onuma Y, Serruys PW. Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. Catheter Cardiovasc Interv. 2019 Dec 19. doi: 10.1002/ccd.28649. [Epub ahead of print] PubMed PMID: 31854112.

24. Chang CC, Spitzer E, Chichareon P, Takahashi K, Modolo R, Kogame N,

Tomaniak M, Komiyama H, Yap SC, Hoole SP, Gori T, Zaman A, Frey B, Ferreira RC, Bertrand OF, Koh TH, Sousa A, Moschovitis A, van Geuns RJ, Steg PG, Hamm C, Jüni P, Vranckx P, Valgimigli M, Windecker S, Serruys PW, Soliman O, Onuma Y. Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). Am J Cardiol. 2019 Dec 15;124(12):1833-1840. doi: 10.1016/j.amjcard.2019.08.049. Epub 2019 Sep 26. PubMed PMID: 31648781.

25. Takahashi K, Kogame N, Tomaniak M, Chichareon P, Chang CC, Modolo R,

Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, van Geuns RJ, Dominici M, Huber K, Buszman P, Bolognese L, Tumscitz C, Żmudka K, Aminian A, Vrolix M, Petrov I, Wykrzykowska JJ, de Winter RJ, Hamm C, Steg PG, Onuma Y, Valgimigli M, Windecker S, Vranckx P, Garg S, Serruys PW. Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. Clin Res Cardiol. 2019 Dec 11. doi: 10.1007/s00392-019-01585-w. [Epub ahead of print] PubMed PMID: 31828504.

33

26. Tomaniak M, Chichareon P, Takahashi K, Kogame N, Modolo R, Chang CC, Spitzer E, Neumann FJ, Plante S, Hernández Antolin R, Jambrik Z, Gelev V, Brunel P, Konteva M, Beygui F, Morelle JF, Filipiak KJ, van Geuns RJ, Soliman O, Tijssen J, Rademaker-Havinga T, Storey RF, Hamm C, Steg PG, Windecker S, Onuma Y, Valgimigli M, Serruys PW. Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. Eur Heart J Cardiovasc Pharmacother. 2019 Dec 9. pii: pvz052. doi: 10.1093/ehjcvp/pvz052. [Epub ahead of print] PubMed PMID: 31876907.

27. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, Valgimigli

M. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019 Dec 7;40(46):3757-3767. doi: 10.1093/eurheartj/ehz732. PubMed PMID: 31651946.

28. Iglesias JF, Heg D, Roffi M, Tüller D, Lanz J, Rigamonti F, Muller O, Moarof

I, Cook S, Weilenmann D, Kaiser C, Cuculi F, Valgimigli M, Jüni P, Windecker S, Pilgrim T. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. J Am Heart Assoc. 2019 Nov 19;8(22):e013607. doi: 10.1161/JAHA.119.013607. Epub 2019 Nov 7. PubMed PMID: 31696762; PubMed Central PMCID: PMC6915288.

29. Okuno T, Khan F, Asami M, Praz F, Heg D, Winkel MG, Lanz J, Huber A,

Gräni C, Räber L, Stortecky S, Valgimigli M, Windecker S, Pilgrim T. Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prostheses. JACC Cardiovasc Interv. 2019 Nov 11;12(21):2173-2182. doi: 10.1016/j.jcin.2019.07.027. Epub 2019 Sep 26. PubMed PMID: 31564593.

30. Chichareon P, Modolo R, Kerkmeijer L, Tomaniak M, Kogame N, Takahashi K,

Chang CC, Komiyama H, Moccetti T, Talwar S, Colombo A, Maillard L, Barlis P, Wykrzykowska J, Piek JJ, Garg S, Hamm C, Steg PG, Jüni P, Valgimigli M, Windecker S, Onuma Y, Mehran R, Serruys PW. Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial. JAMA Cardiol. 2019 Nov 6:1-10. doi: 10.1001/jamacardio.2019.4296. [Epub ahead of print] PubMed PMID: 31693078; PubMed Central PMCID: PMC7029729.

31. Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW,

Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg

34

PG, Heg D, Jüni P, Windecker S, Valgimigli M; GLASSY Investigators. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. J Am CollCard iol. 2019 Nov 5;74(18):2223-2234. doi: 10.1016/j.jacc.2019.08.1038. PubMed PMID: 31672177.

32. Gragnano F, Manavifar N, Gargiulo G, Sunnåker M, Galea R, Frigoli E,

Calabrò P, Windecker S, Valgimigli M. Femoral Access With or Without Vascular Closure Device or Radial Access in Acute Coronary Syndrome. JACC Cardiovasc Interv. 2019 Oct 28;12(20):2116-2118. doi: 10.1016/j.jcin.2019.06.027. PubMed PMID: 31648772.

33. Serruys PW, Chichareon P, Modolo R, Leaman DM, Reiber JHC,

Emanuelsson H, Di Mario C, Pijls NHJ, Morel MA, Valgimigli M, Farooq V, van Klaveren D, Capodanno D, Andreini D, Bourantas CV, Davies J, Banning AP, Escaned J, Piek JJ, Echavarría-Pinto M, Taylor CA, Thomsen B, Collet C, Pompilio G, Bartorelli AL, Glocker B, Dressler O, Stone GW, Onuma Y. The SYNTAX score on its way out or …towards artificial intelligence: part I. EuroIntervention. 2019 Oct 25. pii: EIJ-D-19-00543A. doi: 10.4244/EIJ-D-19-00543A. [Epub ahead of print] PubMed PMID: 31651399.

34. Serruys PW, Chichareon P, Modolo R, Leaman DM, Reiber JHC,

Emanuelsson H, Di Mario C, Pijls NHJ, Morel MA, Valgimigli M, Farooq V, van Klaveren D, Capodanno D, Andreini D, Bourantas CV, Davies J, Banning AP, Escaned J, Piek JJ, Echavarría-Pinto M, Taylor CA, Thomsen B, Collet C, Pompilio G, Bartorelli AL, Glocker B, Dressler O, Stone GW, Onuma Y. The SYNTAX score on its way out or …towards artificial intelligence: part II. EuroIntervention. 2019 Oct 25. pii:EIJ-D-19-00543B. doi: 10.4244/EIJ-D-19-00543B. [Epub ahead of print] PubMed PMID: 31651398.

35. Takahashi K, Serruys PW, Chichareon P, Chang CC, Tomaniak M, Modolo R,

Kogame N, Magro M, Chowdhary S, Eitel I, Zweiker R, Ong P, Ottesen MM, Tijssen JGP, Wykrzykowska JJ, de Winter RJ, Garg S, Stoll HP, Hamm C, Steg PG, Onuma Y, Valgimigli M, Vranckx P, Carrie D, Windecker S. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. J Am Coll Cardiol. 2019 Oct 22;74(16):2015-2027. doi: 10.1016/j.jacc.2019.08.997. PubMed PMID: 31623758.

36. de Faria AP, Modolo R, Chichareon P, Chang CC, Kogame N, Tomaniak M,

Takahashi K, Rademaker-Havinga T, Wykrzykowska J, de Winter RJ, Ferreira RC, Sousa A, Lemos PA, Garg S, Hamm C, Juni P, Vranckx P, Valgimigli M, Windecker S, Onuma Y, Steg PG, Serruys PW. Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. Can J Cardiol. 2019 Oct 19. pii: S0828-282X(19)31350-9. doi: 10.1016/j.cjca.2019.10.015. [Epub ahead of print] PubMed PMID: 32139280.

35

37. Komajda M, Cosentino F, Ferrari R, Laroche C, Maggioni A, Steg PG, Tavazzi L,Kerneis M, Valgimigli M, Gale CP; CICD investigators group . Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry. Eur Heart J Qual Care Clin Outcomes. 2019 Oct 11. pii: qcz057. doi: 10.1093/ehjqcco/qcz057. [Epub ahead of print] PubMed PMID: 31605146.

38. Tomaniak M, Chichareon P, Onuma Y, Deliargyris EN, Takahashi K, Kogame

N, Modolo R, Chang CC, Rademaker-Havinga T, Storey RF, Dangas GD, Bhatt DL, Angiolillo DJ, Hamm C, Valgimigli M, Windecker S, Steg PG, Vranckx P, Serruys PW; GLOBAL LEADERS Trial Investigators. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. JAMA Cardiol. 2019 Sep 26. doi: 10.1001/jamacardio.2019.3355. [Epub ahead of print] PubMed PMID: 31557763; PubMed Central PMCID: PMC6764000.

39. Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, Déry JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman R, Alexopoulos D, Kim HS, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE, Shuldiner AR. Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients. Eur Heart J Cardiovasc Pharmacother. 2019 Sep 3. pii: pvz045. doi: 10.1093/ehjcvp/pvz045. [Epub ahead of print]

40. Takahashi K, Chichareon P, Modolo R, Kogame N, Chang CC, Tomaniak M, Moschovitis A, Curzen N, Haude M, Jung W, Holmvang L, Garg S, Tijssen JGP, Wykrzykowska JJ, de Winter RJ, Hamm C, Steg PG, Stoll HP, Onuma Y, Valgimigli M, Vranckx P, Windecker S, Serruys PW. Impact of Ticagrelor Monotherapy on Two-Year Clinical Outcomes in Patients with Long Stenting: A Post Hoc Analysis of the Global Leaders Trial. EuroIntervention. 2019 Sep 10. pii: EIJ-D-19-00498. doi: 10.4244/EIJ-D-19-00498. [Epub ahead of print]

41. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin

V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019 Sep 2. pii: S0140-6736(19)31872-0. doi: 10.1016/S0140-6736(19)31872-0. [Epub ahead of print]

42. Gragnano F, Spedicato V, Frigoli E, Gargiulo G, Di Maio D, Fimiani F, Fioretti V,

Annoiato C, Cimmino M, Esposito F, Chianese S, Scalise M, Fimiani L, Franzese M, Monda E, Schiavo A, Cesaro A, De Michele A, Scalise R, Caracciolo A, Andò G, Stabile E, Windecker S, Calabrò P, Valgimigli M. ECG analysis in patients

36

with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. J Electrocardiol. 2019 Aug 28;57:44-54. doi: 10.1016/j.jelectrocard.2019.08.045. [Epub ahead of print]

43. Iglesias JF, Muller O, Heg D, Roffi M, Kurz DJ, Moarof I, Weilenmann D, Kaiser

C, Tapponnier M, Stortecky S, Losdat S, Eeckhout E, Valgimigli M, Odutayo A, Zwahlen M, Jüni P, Windecker S, Pilgrim T. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 2019 Aug 30. pii: S0140-6736(19)31877-X. doi: 10.1016/S0140-6736(19)31877-X. [Epub ahead of print]

44. Costa F, Brugaletta S, Pernigotti A, Flores-Ulmanzor E, Ortega-Paz L, Cequier

A, Iniguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, van Es GA, Backx B, Valgimigli M, Serruys P, Sabaté M. Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention? Circ Cardiovasc Interv. 2019 Sep;12(9):e007705. doi: 10.1161/CIRCINTERVENTIONS.118.007705. Epub 2019 Aug 27

45. Valgimigli M, Manavifar N. Ticagrelor in patients with diabetes and previous PCI

Lancet. 2019 Aug 30. pii: S0140-6736(19)31957-9. doi: 10.1016/S0140-6736(19)31957-9. [Epub ahead of print]

46. Zanchin C, Ueki Y, Zanchin T, Häner J, Otsuka T, Stortecky S, Koskinas KC,

Siontis GCM, Praz F, Moschovitis A, Hunziker L, Valgimigli M, Pilgrim T, Heg D, Windecker S, Räber L. Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice. JACC Cardiovasc Interv. 2019 Sep 9;12(17):1665-1675. doi: 10.1016/j.jcin.2019.04.046. Epub 2019 Aug 14.

47. Kogame N, Chichareon P, De Wilder K, Takahashi K, Modolo R, Chang CC,

Tomaniak M, Komiyama H, Chieffo A, Colombo A, Garg S, Louvard Y, Jüni P, G Steg P, Hamm C, Vranckx P, Valgimigli M, Windecker S, Stoll HP, Onuma Y, Janssens L, Serruys PW. Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. Catheter Cardiovasc Interv. 2019 Aug 13. doi: 10.1002/ccd.28428. [Epub ahead of print]

48. Okuno T, Asami M, Khan F, Praz F, Heg D, Lanz J, Kassar M, Khalique OK,

Gräni C, Brugger N, Räber L, Stortecky S, Valgimigli M, Windecker S, Pilgrim T. Does isolated mitral annular calcification in the absence of mitral valve disease affect clinical outcomes after transcatheter aortic valve replacement? Eur Heart J Cardiovasc Imaging. 2019 Aug 13. pii: jez208. doi: 10.1093/ehjci/jez208. [Epub ahead of print]

37

49. Serruys PW, Takahashi K, Chichareon P, Kogame N, Tomaniak M, Modolo R, Chang CC, Komiyama H, Soliman O, Wykrzykowska JJ, de Winter RJ, Ferrario M, Dominici M, Buszman P, Bolognese L, Tumscitz C, Benit E, Stoll HP, Hamm C, Steg PG, Onuma Y, Jüni P, Windecker S, Vranckx P, Colombo A, Valgimigli M. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. Eur Heart J. 2019 Aug 14;40(31):2595-2604. doi: 10.1093/eurheartj/ehz453

50. Baber U, Stefanini GG, Giustino G, Stone GW, Leon MB, Sartori S, Aquino M,

Steg PG, Windecker S, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari DE, von Birgelen C, Dangas GD, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 Jul;12(7):e007734. doi: 10.1161 / CIRCINTERVENTIONS. 118.007734. Epub 2019 Jul 10.

51. Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj

AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Erratum in: Lancet Diabetes Endocrinol. 2019 Jul 8;:. Lancet Diabetes Endocrinol. 2019 Jul 29;:

52. Chichareon P, Onuma Y, van Klaveren D, Modolo R, Kogame N, Takahashi K,

Chang CC, Tomaniak M, Asano T, Katagiri Y, van Geuns RM, Bolognese L, Tumscitz C, Vrolix M, Petrov I, Garg S, Naber CK, Sabaté M, Iqbal J, Wykrzykowska JJ, Piek JJ, Spitzer E, Jüni P, Hamm C, Steg PG, Valgimigli M, Vranckx P, Windecker S, Serruys PW. Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. EuroIntervention. 2019 Aug 9;15(6):e539-e546. doi: 10.4244/EIJ-D-19-00184.

53. Cammaroto G, Costa F, Ruiz MVG, Andò G, Vicini C, Montevecchi F, Galletti C,

Galletti F, Valgimigli M. Obstructive sleep apnoea syndrome and endothelial function: potential impact of different treatment strategies-meta-analysis of prospective studies. Eur Arch Otorhinolaryngol. 2019 Aug;276(8):2331-2338. doi: 10.1007/s00405-019-05486-6. Epub 2019 Jun 13.

54. Morici N, Tavecchia GA, Antolini L, Caporale MR, Cantoni S, Bertuccio P, Sacco

A, Meani P, Viola G, Brunelli D, Oliva F, Lombardi F, Segreto A, Oreglia JA, La Vecchia C, Cattaneo M, Valgimigli M, Savonitto S. Use of PRECISE-DAPT Score and Admission Platelet Count to Predict Mortality Risk in Patients With

38

Acute Coronary Syndrome. Angiology. 2019 Oct;70(9):867-877. doi: 10.1177/ 0003319719848547. Epub 2019 May 14

55. Piccolo R, Bonaa KH, Efthimiou O, Varenne O, Baldo A, Urban P, Kaiser C,

Remkes W, Räber L, de Belder A, van 't Hof AWJ, Stankovic G, Lemos PA, Wilsgaard T, Reifart J, Rodriguez AE, Ribeiro EE, Serruys PWJC, Abizaid A, Sabaté M, Byrne RA, de la Torre Hernandez JM, Wijns W, Jüni P, Windecker S, Valgimigli M; Coronary Stent Trialists' Collaboration. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2019 Jun 22;393(10190):2503-2510. doi: 10.1016/S0140-6736(19)30474-X. Epub 2019 May 2

56. Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G,

Gilard M, Feres F, Costa RA, Morice MC, Georges JL, Valgimigli M, Bhatt DL, Mauri L, Charytan DM. Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis. Clin J Am Soc Nephrol. 2019 Jun 7;14(6):810-822. doi: 10.2215/CJN.12901018. Epub 2019 Apr 22.

57. Ueki Y, Karagiannis A, Zanchin C, Zanchin T, Stortecky S, Koskinas KC, Siontis

GCM, Praz F, Otsuka T, Hunziker L, Heg D, Moschovitis A, Seiler C, Billinger M, Pilgrim T, Valgimigli M, Windecker S, Räber L. Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines. JACC Cardiovasc Interv. 2019 May 13;12(9):820-830. doi: 10.1016/j.jcin. 2018.12.005. Epub 2019 Apr 10

58. Siontis GC, Branca M, Serruys P, Silber S, Räber L, Pilgrim T, Valgimigli M,

Heg D, Windecker S, Hunziker L. Impact of left ventricular function on clinical outcomes among patients with coronary artery disease. Eur J Prev Cardiol. 2019 Aug;26(12):1273-1284. doi: 10.1177/2047487319841939. Epub 2019 Apr 9

59. Garcia-Garcia HM, Picchi A, Sardella G, Adamo M, Frigoli E, Limbruno U,

Rigattieri S, Diletti R, Boccuzzi G, Zimarino M, Contarini M, Russo F, Calabro' P, Andò G, Varbella F, Garducci S, Palmieri C, Briguori C, Kuku KO, Rothenbühler M, Karagiannis A, Valgimigli M. Comparison of intra-procedural vs. post-stenting prolonged bivalirudin infusion for residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing: the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study. Eur Heart J Cardiovasc Imaging. 2019 Mar 28. pii: jez040. [Epub ahead of print]

60. Picchi A, Garcia-Garcia HM, Sardella G, Adamo M, Frigoli E, Limbruno U,

Rigattieri S, Diletti R, Boccuzzi G, Zimarino M, Contarini M, Russo F, Calabro P, Andò G, Varbella F, Garducci S, Palmieri C, Briguori C, Kuku KO, Rothenbühler M, Karagiannis A, Valgimigli M. OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting Prolonged Bivalirudin Infusion: The MATRIX OCT Study. JACC Cardiovasc

39

Imaging. 2019 May;12(5):934-936. doi: 10.1016/j.jcmg.2018.10.030. Epub 2019 Jan 16.

61. Palmerini T, Bruno AG, Gilard M, Morice MC, Valgimigli M, Montalescot G, Collet JP, Della Riva D, Bacchi-Reggiani ML, Steg PG, Diallo A, Vicaut E, Helft G, Nakamura M, Généreux P, Vahl TP, Stone GW. Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation. Circ Cardiovasc Interv. 2019 Mar;12(3):e007541. doi: 10.1161/CIRCINTERVENTIONS.118.007541

62. Leonardi S, Franzone A, Piccolo R, McFadden E, Vranckx P, Serruys P, Benit

E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, van Geuns RJ, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg G, Heg D, Juni P, Windecker S, Valgimigli M. Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). BMJ Open. 2019 Mar 9;9(3):e026053. doi: 10.1136/bmjopen-2018-026053

63. Chichareon P, Modolo R, van Klaveren D, Takahashi K, Kogame N, Chang CC,

Katagiri Y, Tomaniak M, Asano T, Spitzer E, Buszman P, Prokopczuk J, Fath-Ordoubadi F, Buysschaert I, Anderson R, Oldroyd KG, Merkely B, Garg S, Wykrzykowska JJ, Piek JJ, Jüni P, Hamm C, Steg PG, Valgimigli M, Vranckx P, Windecker S, Onuma Y, Serruys PW. Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS studyInt J Cardiol. 2019 Feb 20. pii: S0167-5273(18)36315-0. doi: 10.1016/j.ijcard.2019.02.043.

64. Lanz J, Wyss D, Räber L, Stortecky S, Hunziker L, Blöchlinger S, Reineke D,

Englberger L, Zanchin T, Valgimigli M, Heg D, Windecker S, Pilgrim T. Mechanical complications in patients with ST-segment elevation myocardial infarction: A single centre experience PLoS One. 2019 Feb 22;14(2):e0209502. doi: 10.1371/journal.pone.0209502. eCollection 2019

65. Gargiulo G, Carrara G, Frigoli E, Leonardi S, Vranckx P, Campo G, Varbella F, Calabrò P, Zaro T, Bartolini D, Briguori C, Andò G, Ferrario M, Limbruno U, Colangelo S, Sganzerla P, Russo F, Nazzaro MS, Esposito G, Ferrante G, Santarelli A, Sardella G, Windecker S, Valgimigli M. Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome J Am Coll Cardiol. 2019 Feb 26;73(7):758-774. doi: 10.1016/j.jacc.2018.12.023

66. Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, Hong MK, Kim

HS, Colombo A, Steg PG, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M; PRECISE-DAPT Study Investigators. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. J Am Coll Cardiol. 2019 Feb 26;73(7):741-754. doi: 10.1016/j.jacc.2018.11.048

40

67. Frigoli E, Smits P, Vranckx P, Ozaki Y, Tijssen J, Jüni P, Morice MC, Onuma Y,

Windecker S, Frenk A, Spaulding C, Chevalier B, Barbato E, Tonino P, Hildick-Smith D, Roffi M, Kornowski R, Schultz C, Lesiak M, Iñiguez A, Colombo A, Alasnag M, Mullasari A, James S, Stankovic G, Ong PJL, Rodriguez AE, Mahfoud F, Bartunek J, Moschovitis A, Laanmets P, Leonardi S, Heg D, Sunnåker M, Valgimigli M. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study Am Heart J. 2019 Mar;209:97-105.

68. Rothenbühler M, Valgimigli M, Odutayo A, Frigoli E, Leonardi S, Vranckx P, Turturo M, Moretti L, Amico F, Uguccioni L, Contarini M, Gómez-Hospital JA, Mainar V, Creaco M, Petronio AS, Cremonesi A, Tamburino C, Fresco C, Bonmassari R, Díaz Fernández JF, Romagnoli E, Beyersmann J, Heg D, Jüni P. Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial. Eur Heart J. 2019 Jan 26.

69. Picchi A, Garcia-Garcia HM, Sardella G, Adamo M, Frigoli E, Limbruno U,

Rigattieri S, Diletti R, Boccuzzi G, Zimarino M, Contarini M, Russo F, Calabro P, Andò G, Varbella F, Garducci S, Palmieri C, Briguori C, Kuku KO, Rothenbühler M, Karagiannis A, Valgimigli M. OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting Prolonged Bivalirudin Infusion: The MATRIX OCT Study JACC Cardiovasc Imaging. 2019 May; 12(5):934-936. Epub 2019 Jan 16. No abstract available.

70. van Leeuwen MAH, van der Hoeven NW, Janssens GN, Everaars H, Nap A,

Lemkes JS, de Waard GA, van de Ven PM, van Rossum AC, Ten Cate TJF, Piek JJ, von Birgelen C, Escaned J, Valgimigli M, Diletti R, Riksen NP, Van Mieghem NM, Nijveldt R, van Royen N. Evaluation of Microvascular Injury in Revascularized Patients with ST Elevation Myocardial Infarction Treated with Ticagrelor versus Prasugrel: The REDUCE-MVI Trial. Circulation. 2018 Oct 30. doi: 10.1161/CIRCULATIONAHA.118.035931

71. Kang J, Park KW, Palmerini T, Stone GW, Lee MS, Colombo A, Chieffo A, Feres

F, Abizaid A, Bhatt DL, Valgimigli M, Hong MK, Jang Y, Gilard M, Morice MC, Park DW, Park SJ, Jeong YH, Park J, Koo BK, Kim HS. Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. Thromb Haemost. 2019 Jan;119(1):149-162. Epub 2018 Dec 31

72. Asami M, Pilgrim T, Lanz J, Heg D, Franzone A, Piccolo R, Langhammer B, Praz

F, Räber L, Valgimigli M, Roost E, Windecker S, Stortecky S. Prognostic Relevance of Left Ventricular Myocardial Performance After Transcatheter

41

Aortic Valve Replacement. Circ Cardiovasc Interv. 2019 Jan;12(1):e006612. doi: 10.1161/CIRCINTERVENTIONS.118.006612.

73. Yamaji K, Zanchin T, Zanchin C, Stortecky S, Koskinas KC, Hunziker L, Praz F,

Blöchlinger S, Moro C, Moschovitis A, Seiler C, Valgimigli M, Billinger M, Pilgrim T, Heg D, Windecker S, Räber L. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization. Circ Cardiovasc Interv. 2018 Sep;11(9):e006741. doi: 10.1161/CIRCINTERVENTIONS.118.006741.

74. Gargiulo G, Patialiakas A, Piccolo R, Thury A, Colangelo S, Campo G, Tebaldi

M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C, Windecker S, Valgimigli M. Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. Int J Cardiol. 2019 Feb 15; 277:60-65. doi: 10.1016/j.ijcard.2018.09.120. Epub 2018 Oct 2

75. Katsikis A, Chichareon P, Cavalcante R, Collet C, Modolo R, Onuma Y,

Stankovic G, Louvard Y, Vranckx P, Valgimigli M, Windecker S, Serruys PW. Application of the MADS classification system in a "mega mammoth" stent trial: Feasibility and preliminary clinical implications. Catheter Cardiovasc Interv. 2018 Oct 5. doi: 10.1002/ccd.27461.

76. Andò G, Gragnano F, Calabrò P, Valgimigli M. Radial vs femoral access for the

prevention of acute kidney injury (AKI) after coronary angiography or intervention: A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2018 Sep 23. doi: 10.1002/ccd.27903.

77. Van Mieghem NM, Unverdorben M, Valgimigli M, Mehran R, Boersma E, Baber

U, Hengstenberg C, Shi M, Chen C, Saito S, Veltkamp R, Vranckx P, Dangas GD. EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial. Am Heart J. 2018 Aug 29;205:63-69

78. Valgimigli M, Frigoli E, Leonardi S, Vranckx P, Rothenbühler M, Tebaldi M,

Varbella F, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andó G, Ferrario M, Limbruno U, Garbo R, Sganzerla P, Russo F, Nazzaro M, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, de Cesare N, Tosi P, van ’t Hof A, Omerovic E, Brugaletta S, Windecker S, Heg D, Jüni P, on behalf of the MATRIX Investigators Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet. 2018 Sep 8;392(10150):835-848

42

79. Ortega-Paz L, Valgimigli M. Reply: Pleiotropic Effects of Ticagrelor Beyond Its

Potent Antiplatelet Effects Contributing to Additional Clinical Benefits. JACC Cardiovasc Interv. 2018 Sep 10;11(17):1785-1786. doi: 10.1016/j.jcin. 2018.06.041.

80. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg G, Heg D, van Es GA,

McFadden E, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S, on behalf of the GLOBAL LEADERS Investigators Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018 Aug 24. pii: S0140-6736

81. Schur N, Brugaletta S, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P,

Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Valgimigli M, Serruys PW, Ademi Z, Schwenkglenks M, Sabaté M. Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial. PLoS One. 2018 Aug 16;13(8):e0201985. doi: 10.1371/journal.pone.0201985. eCollection 2018

82. Degrauwe S, Roffi M, Lauriers N, Muller O, Giorgio Masci P, Valgimigli M,

Iglesias JF. Influence of Intravenous Fentanyl Compared with Morphine on Ticagrelor Absorption and Platelet Inhibition in Patients with St-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Rationale and Design of the Perseus Randomized Trial.Eur Heart J Cardiovasc Pharmacother. 2018 Aug 8. doi: 10.1093/ehjcvp/pvy031

83. Ariotti S, Ortega-Paz L, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis

KM, Rimoldi SF, Janssens G, Gianni U, van den Berge JC, Karagiannis A, Windecker S, Valgimigli M; HI-TECH Investigators Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study. JACC Cardiovasc Interv. 2018 May 17. pii: S1936-8798(18)30946-4

84. Morici N, Piccinelli E, Brunelli D, Sacco A, Viola G, Oreglia JA, Oliva F,

Valgimigli M. Real-world application of currently available decision models for dual antiplatelet therapy duration in acute coronary syndrome. J Cardiovasc Med (Hagerstown). 2018 Jun;19(6):310-313.

85. Gargiulo G, da Costa BR, Frigoli E, Palmieri C, Nazzaro MS, Falcone C, Liso A, Vigna C, Abate F, Comeglio M, Diletti R, Gabrielli G, Di Lorenzo E, Mazzarotto P, Zimarino M, Moretti C, Colombo A, Penzo C, Pasquetto G, Brugaletta S,

43

Ferrari F, Casu G, Guiducci V, Dellavalle A, Liistro F, Mauro C, Van't Hof AWJ, Omerovic E, Curello S, de la Torre Hernandez JM, De Servi S, Belloni F, Windecker S, Valgimigli M. Impact of Sex on Comparative Outcomes of Bivalirudin versus Unfractionated Heparin in Patients with Acute Coronary Syndromes Undergoing Invasive Management A pre-specified analysis of the MATRIX trial. EuroIntervention. 2018 May 15. pii: EIJ-D-18-00247. doi: 10.4244/EIJ-D-18-00247.

86. Zanchin T, Temperli F, Karagiannis A, Zanchin C, Räsänen M, Koskinas KC, Stortecky S, Hunziker L, Praz F, Blöchlinger S, Moro C, Moschovitis A, Seiler C, Billinger M, Heg D, Pilgrim T, Valgimigli M, Windecker S, Räber L. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry. Circ Cardiovasc Interv. 2018 May;11(5):e006132. doi: 10.1161/CIRCINTERVENTIONS. 117.006132.

87. Bergmeijer TO, Reny JL, Pakyz RE, Gong L, Lewis JP, Kim EY, Aradi D, Fernandez-Cadenas I, Horenstein RB, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Déry JP, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Simon T, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Hulot JS, Mitchell BD, Schwab M, Ritchie MD, Klein TE, Shuldiner AR; ICPC Investigators. Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). Am Heart J. 2018 Apr;198:152-159. doi: 10.1016/j.ahj.2017.12.010. Epub 2017 Dec 17.

88. Lupi A, Bona RD, Meliga E, Capodanno D, Schaffer A, Bongo AS, Gaudio G,

Guasti L, Alexopoulos D, Valgimigli M, Porto I. Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry. Thromb Haemost. 2018 Apr 4. doi: 10.1055/s-0038-1635578.

89. Ortega-Paz L, Brugaletta S, Ariotti S, Akkerhuis KM, Karagiannis A, Windecker

S, Valgimigli M; Hunting for the off-target properties of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) Investigators. Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea. Circulation. 2018 May 24. pii: CIRCULATIONAHA.118.034489

90. Spitaleri G, Brugaletta S, Scalone G, Moscarella E, Ortega-Paz L, Pernigotti A, Gomez-Lara J, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Valgimigli M, Serruys PW, Sabaté M. Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous

44

Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial). Am J Cardiol. 2018 Feb 7. pii: S0002-9149(18) 30157-7. doi: 10.1016/ j.amjcard. 2018.01.015.

91. Ariotti S, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF,

Janssens GN, Ortega-Paz L, Gianni U, van den Berge JC, Karagiannis A, Windecker S, Valgimigli M; HI-TECH Investigators.Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function. J Am Coll Cardiol. 2018 Mar 20;71(11):1289-1291. doi: 10.1016/j.jacc.2018.01.027.

92. Gargiulo G, Carrara G, Frigoli E, Vranckx P, Leonardi S, Ciociano N, Campo G,

Varbella F, Calabrò P, Garducci S, Iannone A, Briguori C, Andò G, Crimi G, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Zavalloni D, Santarelli A, Sardella G, Tresoldi S, de Cesare N, Sciahbasi A, Zingarelli A, Tosi P, van 't Hof A, Omerovic E, Brugaletta S, Windecker S, Valgimigli M. Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. J Am Coll Cardiol. 2018 Mar 20;71(11):1231-1242. doi: 10.1016/j.jacc.2018.01.033.

93. Koskinas KC, Nakamura M, Räber L, Colleran R, Kadota K, Capodanno D, Wijns

W, Akasaka T, Valgimigli M, Guagliumi G, Windecker S, Byrne RA. Current Use of Intracoronary Imaging in Interventional Practice - Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. Circ J. 2018 Mar 15. doi: 10.1253/circj.CJ-17-1144.

94. Koskinas KC, Nakamura M, Räber L, Colleran R, Kadota K, Capodanno D, Wijns

W, Akasaka T, Valgimigli M, Guagliumi G, Windecker S, Byrne RA. Current use of intracoronary imaging in interventional practice - Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. EuroIntervention. 2018 Mar 15. pii: EIJY18M03_01. doi: 10.4244/EIJY18M03_01.

95. Angelillis M, Gargiulo G, Moschovitis A, Fürholz M, Shakir S, Piazza N, Räber

L, Meier B, Gloekler S, Windecker S, Valgimigli M. Computed tomography detection and quantification of left atrial appendage residual patency as collateral finding after percutaneous closure. Int J Cardiol. 2018 Jun 1;260:42-46. doi: 10.1016/j.ijcard. 2018.02.108. Epub 2018 Mar 3.

96. Andò G, Jolly SS, Valgimigli M. Operators' experience with radial access for

cardiac catheterization in patients with acute coronary syndromes. Int J Cardiol. 2018 Apr 15;257:35. doi: 10.1016/j.ijcard.2017.10.034.

97. Asami M, Lanz J, Stortecky S, Räber L, Franzone A, Heg D, Hunziker L, Roost

E, Siontis GC, Valgimigli M, Windecker S, Pilgrim T. The Impact of Left

45

Ventricular Diastolic Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2018 Mar 26;11(6):593-601. doi: 10.1016/j.jcin.2018.01.240. Epub 2018 Mar 2.

98. Asami M, Stortecky S, Praz F, Lanz J, Räber L, Franzone A, Piccolo R, Siontis

GCM, Heg D, Valgimigli M, Wenaweser P, Roost E, Windecker S, Pilgrim T. Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Imaging. 2018 Feb 9. pii: S1936-878X(18)30012-3. doi: 10.1016/j.jcmg.2017.12.015.

99. Lee SY, Hong MK, Palmerini T, Kim HS, Valgimigli M, Feres F, Colombo A,

Gilard M, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Stone GW. Short-Term Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Elderly Patients: A Meta-Analysis of Individual Participant Data From 6 Randomized Trials. JACC Cardiovasc Interv. 2018 Mar 12;11(5):435-443. doi: 10.1016/j.jcin.2017.10.015. Epub 2018 Feb 14.

100. Spitaleri G, Tebaldi M, Biscaglia S, Westra J, Brugaletta S,

Erriquez A, Passarini G, Brieda A, Leone AM, Picchi A, Ielasi A, Girolamo DD, Trani C, Ferrari R, Reiber JHC, Valgimigli M, Sabatè M, Campo G. Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment-Elevation Myocardial Infarction and Multivessel Disease. Circ Cardiovasc Interv. 2018 Feb;11(2):e006023. doi: 10.1161/ CIRCINTERVENTIONS.117.006023.

101. Hwang D, Park KW, Lee JM, Rhee TM, Hong MK, Jang Y,

Valgimigli M, Colombo A, Gilard M, Palmerini T, Stone GW, Kim HS. Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease. Am Heart J. 2018 Mar;197:103-112. doi: 10.1016/j.ahj.2017.11.013. Epub 2017 Dec 6.

102. Sciahbasi A, Frigoli E, Sarandrea A, Calabrò P, Rubartelli P,

Cortese B, Tomassini F, Zavalloni D, Tebaldi M, Calabria P, Rigattieri S, Zingarelli A, Sardella G, Lupi A, Rothenbühler M, Heg D, Valgimigli M. Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study. Am Heart J. 2018 Feb;196:113-118. doi: 10.1016/j.ahj.2017.10.014. Epub 2017 Oct 28.

103. Vranckx P, Lewalter T, Valgimigli M, Tijssen JG, Reimitz PE,

Eckardt L, Lanz HJ, Zierhut W, Smolnik R, Goette A. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. Am Heart J. 2018 Feb;196:105-112. doi: 10.1016/j.ahj.2017.10.009. Epub 2017 Oct 23.

104. Pilgrim T, Lee JKT, O'Sullivan CJ, Stortecky S, Ariotti S,

Franzone A, Lanz J, Heg D, Asami M, Praz F, Siontis GCM, Vollenbroich R,

46

Räber L, Valgimigli M, Roost E, Windecker S. Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis. Open Heart. 2018 Jan 20;5(1):e000695. doi: 10.1136/openhrt-2017-000695. eCollection 2018.

105. Komajda M, Kerneis M, Tavazzi L, Balanescu S, Cosentino F,

Cremonesi A, Ferrari R, Kownator S, Szwed H, Mintale I, Olivari Z, Rittger H, Shlyakhto EV, Slapikas R, Steg PG, Valgimigli M, Van Belle E, Tsioufis K, Majda W, Laroche C, Maggioni AP; ESC–CICD Pilot Registry Investigators. The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. Eur J Prev Cardiol. 2018 Mar;25(4):377-387. doi: 10.1177/2047487317751955. Epub 2018 Jan 16.

106. A collaboration of international cardiovascular societies. Nelson

DW, Damluji AA, Patel N, Valgimigli M, Windecker S, Byrne R, Nolan J, Patel T, Brilakis E, Banerjee S, Mayol J, Cantor WJ, Alfonso CE, Rao SV, Moscucci M, Cohen MG.Influence of operator experience and PCI volume on transfemoral access techniques: Cardiovasc Revasc Med. 2017 Dec 27. pii: S1553-8389(17)30468-2. doi: 10.1016/j.carrev. 2017.12.013.

107. Chandrasekhar J, Baber U, Sartori S, Stefanini GG, Sarin M,

Vogel B, Farhan S, Camenzind E, Leon MB, Stone GW, Serruys PW, Wijns W, Steg PG, Weisz G, Chieffo A, Kastrati A, Windecker S, Morice MC, Smits PC, von Birgelen C, Mikhail GW, Itchhaporia D, Mehta L, Kim HS, Valgimigli M, Jeger RV, Kimura T, Galatius S, Kandzari D, Dangas G, Mehran R. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. JACC Cardiovasc Interv. 2018 Jan 8;11(1):53-65. doi: 10.1016/j.jcin.2017.11.020.

108. Gargiulo G, Ariotti S, Vranckx P, Leonardi S, Frigoli E, Ciociano

N, Tumscitz C, Tomassini F, Calabrò P, Garducci S, Crimi G, Andò G, Ferrario M, Limbruno U, Cortese B, Sganzerla P, Lupi A, Russo F, Garbo R, Ausiello A, Zavalloni D, Sardella G, Esposito G, Santarelli A, Tresoldi S, Nazzaro MS, Zingarelli A, Petronio AS, Windecker S, da Costa BR, Valgimigli M. Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial. JACC Cardiovasc Interv. 2018 Jan 8;11(1):36-50. doi: 10.1016/j.jcin. 2017.09.014.

109. Gargiulo G, Heg D, Ferrari F, Percoco G, Campo G, Tumscitz

C, Colombo F, Zuffi A, Castriota F, Cremonesi A, Windecker S, Valgimigli M. Stent and Dual Antiplatelet Therapy Duration Comparisons in the Setting of a Multicenter Randomized Controlled Trial: Can the Operator Experience Affect the Study Results? J Am Heart Assoc. 2017 Dec 23;6(12). pii: e007150. doi: 10.1161/JAHA.117.007150.

47

110. Spitaleri G, Moscarella E, Brugaletta S, Pernigotti A, Ortega-Paz

L, Gomez-Lara J, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Valgimigli M, Serruys PW, Sabaté M. Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. EuroIntervention. 2018 Mar 20;13(16):1939-1945. doi: 10.4244/EIJ-D-17-00608.

111. Faggioni M, Baber U, Afshar AE, Giustino G, Sartori S,

Sorrentino S, Steg PG, Stefanini GG, Windecker S, Leon MB, Stone GW, Wijns W, Serruys PW, Valgimigli M, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, Von Birgelen C, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Dangas GD, Morice MC, Mehran R. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2018 Jan 8;11(1):68-76. doi: 10.1016/j.jcin.2017.06.060. Epub 2017 Dec 13

112. Iglesias JF, Muller O, Zaugg S, Roffi M, Kurz DJ, Vuilliomenet

A, Weilenmann D, Kaiser C, Tapponnier M, Heg D, Valgimigli M, Eeckhout E, Jüni P, Windecker S, Pilgrim T. A comparison of an ultrathin strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. EuroIntervention. 2017 Dec 5. pii: EIJ-D-17-00734. doi: 10.4244/EIJ-D-17-00734.

113. Damluji AA, Nelson DW, Valgimigli M, Windecker S, Byrne RA,

Cohen F, Patel T, Brilakis ES, Banerjee S, Mayol J, Cantor WJ, Alfonso CE, Rao SV, Moscucci M, Cohen MG. Transfemoral Approach for Coronary Angiography and Intervention: A Collaboration of International Cardiovascular Societies. JACC Cardiovasc Interv. 2017 Nov 27;10(22):2269-2279. doi: 10.1016/j.jcin. 2017. 08. 035

114. Franzone A, Stortecky S, Pilgrim T, Asami M, Lanz J, Heg D,

Langhammer B, Piccolo R, Lee JKT, Praz F, Räber L, Valgimigli M, Roost E, Windecker S. Incidence and impact of renal dysfunction on clinical outcomes after transcatheter aortic valve implantation. Int J Cardiol. 2017 Oct 3. pii: S0167-5273(17)33885-8. doi: 10.1016/j.ijcard.2017.09.201.

115. Moscarella E, Spitaleri G, Brugaletta S, Sentí Farrarons S, Pernigotti A, Ortega-Paz L, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Valgimigli M, Serruys PW, Sabaté M. Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction

48

After Everolimus-Eluting or Bare-Metal Stent Implantation. Am J Cardiol. 2017 Nov 1;120(9):1460-1466. doi: 10.1016/j.amjcard.2017.07.040.

116. Piccolo R, Feres F, Abizaid A, Gilard M, Morice MC, Hong MK, Kim HS, Colombo A, Bhatt DL, Palmerini T, Stone GW, Windecker S, Valgimigli M. Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis. JACC Cardiovasc Interv. 2017 Aug 28;10(16):1621-1630. doi: 10.1016 /j.jcin. 2017. 06. 001

117. Piccolo R, Pilgrim T, Franzone A, Valgimigli M, Haynes A,

Asami M, Lanz J, Räber L, Praz F, Langhammer B, Roost E, Windecker S, Stortecky S. Frequency, Timing, and Impact of Access-Site and Non-Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2017 Jul 24;10(14):1436-1446. doi: 10.1016 /j.jcin. 2017.04. 034.

118. van Boven N, van Domburg RT, Kardys I, Umans VA, Akkerhuis

KM, Lenzen MJ, Valgimigli M, Daemen J, Zijlstra F, Boersma E, van Geuns RJ. Development and validation of a risk model for long-term mortality after percutaneous coronary intervention: The IDEA-BIO Study. Catheter Cardiovasc Interv. 2017 Jul 14. doi: 10.1002/ccd.27182.

119. Giustino G, Harari R, Baber U, Sartori S, Stone GW, Leon MB, Windecker S, Serruys PW, Kastrati A, Von Birgelen C, Kimura T, Stefanini GG, Dangas GD, Wijns W, Steg PG, Morice MC, Camenzind E, Weisz G, Smits PC, Sorrentino S, Sharma M, Farhan S, Faggioni M, Kandzari D, Galatius S, Jeger RV, Valgimigli M, Itchhaporia D, Mehta L, Kim HS, Chieffo A, Mehran R. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol. 2017 Jun 28. doi: 10.1001/jamacardio.2017.1978.

120. Ariotti S, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis

KM, Rexhaj E, Janssens G, Ortega-Paz L, Rizzotti D, van den Berge JC, Heg D, Francolini G, Windecker S, Valgimigli M; HI-TECH Investigators. Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial. Am Heart J. 2017 Jul;189:128-136. doi: 10.1016/j.ahj.2017.03.017.

121. Piccolo R, Gargiulo G, Franzone A, Santucci A, Ariotti S, Baldo

A, Tumscitz C, Moschovitis A, Windecker S, Valgimigli M. Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. Ann Intern Med. 2017 Jun 13. doi: 10.7326/M16-2389.

122. Franzone A, Stortecky S, Räber L, Heg D, Yamaji K, Piccolo R,

Asami M, Lanz J, Praz F, Koskinas K, Zanchin T, Wenaweser P, Valgimigli M,

49

Jüni P, Pilgrim T, Windecker S. Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts. Int J Cardiol. 2017 May 17. pii: S0167-5273(17)30953-1. doi: 10.1016/ j.ijcard.2017.05.071.

123. Andò G, Cortese B, Russo F, Rothenbühler M, Frigoli E,

Gargiulo G, Briguori C, Vranckx P, Leonardi S, Guiducci V, Belloni F, Ferrari F, de la Torre Hernandez JM, Curello S, Liistro F, Perkan A, De Servi S, Casu G, Dellavalle A, Fischetti D, Micari A, Loi B, Mangiacapra F, Russo N, Tarantino F, Saia F, Heg D, Windecker S, Jüni P, Valgimigli M; MATRIX Investigators. Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX. J Am Coll Cardiol. 2017 May 11. pii: S0735-1097(17)36897-3. doi: 10.1016/j.jacc.2017.02.070.

124. Head SJ, da Costa BR, Beumer B, Stefanini GG, Alfonso F,

Clemmensen PM, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Kappetein AP, Kastrati A, Knuuti J, Kolh P, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Windecker S, Jüni P, Sousa-Uva M. Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2017 May 2. doi: 10.1093/ejcts/ezx115.

125. Franzone A, Pilgrim T, Arnold N, Heg D, Langhammer B,

Piccolo R, Roost E, Praz F, Räber L, Valgimigli M, Wenaweser P, Jüni P, Carrel T, Windecker S, Stortecky S. Rates and predictors of hospital readmission after transcatheter aortic valve implantation. Eur Heart J. 2017 Apr 18. doi: 10.1093/eurheartj/ehx182.

126. Palmerini T, Bacchi Reggiani L, Della Riva D, Romanello M,

Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Ahn JM, Park SJ, Schüpke S, Kastrati A, Montalescot G, Steg PG, Diallo A, Vicaut E, Helft G, Biondi-Zoccai G, Xu B, Han Y, Genereux P, Bhatt DL, Stone GW. Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. J Am Coll Cardiol. 2017 Apr 25;69(16):2011-2022. doi: 10.1016/j.jacc.2017.02.029.

127. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L,

Moliterno DJ, Armstrong PW, White HD, Held C, Aylward PE, Van de Werf F, Harrington RA, Mahaffey KW, Tricoci P. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017 Mar 14;38(11):804-810. doi: 10.1093 /eurheartj /ehw525.

128. Sciahbasi A, Frigoli E, Sarandrea A, Rothenbühler M, Calabrò

P, Lupi A, Tomassini F, Cortese B, Rigattieri S, Cerrato E, Zavalloni D, Zingarelli

50

A, Calabria P, Rubartelli P, Sardella G, Tebaldi M, Windecker S, Jüni P, Heg D, Valgimigli M. Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD-Matrix Trial. J Am Coll Cardiol. 2017 May 23;69(20):2530-2537. doi: 10.1016/j.jacc.2017.03.018.

129. Vranckx P, Frigoli E, Rothenbühler M, Tomassini F, Garducci S,

Andò G, Picchi A, Sganzerla P, Paggi A, Ugo F, Ausiello A, Sardella G, Franco N, Nazzaro M, de Cesare N, Tosi P, Falcone C, Vigna C, Mazzarotto P, Di Lorenzo E, Moretti C, Campo G, Penzo C, Pasquetto G, Heg D, Jüni P, Windecker S, Valgimigli M; MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. Eur Heart J. 2017 Apr 7;38(14):1069-1080. doi: 10.1093/eurheartj/ehx048.

130. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F,

Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M for the PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017 Mar 11;389(10073):1025-1034. doi: 10.1016/S0140-6736(17)30397-5.

131. Ortega-Paz L, Brugaletta S, Giacchi G, Ishida K, Cequier A,

Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tespili M, den Heijer P, Valgimigli M, Serruys PW, Sabaté M. Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the 5-year follow-up of the EXAMINATION trial. EuroIntervention. 2017 Feb 28. pii: EIJ-D-16-00512. doi: 10.4244/EIJ-D-16-00512

132. Gargiulo G, Santucci A, Piccolo R, Franzone A, Ariotti S, Baldo

A, Esposito G, Moschovitis A, Windecker S, Valgimigli M. Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial. Catheter Cardiovasc Interv. 2017 Oct 1;90(4):E73-E84. doi: 10.1002/ccd.26921

133. Windecker S, Tijssen J, Giustino G, Guimarães AH, Mehran R,

Valgimigli M, Vranckx P, Welsh RC, Baber U, van Es GA, Wildgoose P, Volkl AA, Zazula A, Thomitzek K, Hemmrich M, Dangas GD. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. Am Heart J. 2017 Feb;184:81-87

134. Vollenbroich R, Stortecky S, Praz F, Lanz J, Franzone A, Zuk K,

Heg D, Valgimigli M, O'Sullivan CJ, Heinisch C, Roost E, Wenaweser P, Windecker S, Pilgrim T. The impact of functional vs degenerative mitral

51

regurgitation on clinical outcomes among patients undergoing transcatheter aortic valve implantation. Am Heart J. 2017 Feb;184:71-80

135. Nairooz R, Valgimigli M, Rochlani Y, Pothineni NV, Raina S,

Sardar P, Mukherjee D, Naidu SS, Shavelle DM. Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. Int J Cardiol. 2017 Feb 15;229:82-89

136. Franzone A, O'Sullivan CJ, Stortecky S, Heg D, Lanz J,

Vollenbroich R, Praz F, Piccolo R, Asami M, Roost E, Räber L, Valgimigli M, Windecker S, Pilgrim T. Prognostic Impact of Invasive Hemodynamic Measurements in Combination with Clinical and Echocardiographic Characteristics on 2-year Clinical Outcomes of Patients undergoing Transcatheter Aortic Valve Implantation. EuroIntervention. 2017 Jan 25. pii: EIJ-D-16-00790. doi: 10.4244/EIJ-D-16-00790

137. Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L,

Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Sangiorgi D, Biondi-Zoccai G, Généreux P, Angelini GD, Pufulete M, White J, Bhatt DL, Stone GW. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J. 2017 Jan 21. pii: ehw627. doi: 10.1093/eurheartj/ehw627

138. Piccolo R, Magnani G, Ariotti S, Gargiulo G, Marino M, Santucci

A, Franzone A, Tebaldi M, Heg D, Windecker S, Valgimigli M. Ischemic and Bleeding Outcomes in Elderly Patients Undergoing a Prolonged versus Shortened Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention. Insights from the PRODIGY randomized trial. EuroIntervention. 2017 Jan 3;12(13)

139. Diletti R, Ishibashi Y, Felix C, Onuma Y, Nakatani S, van Mieghem NM, Regar E, Valgimigli M, de Jaegere PP, van Ditzhuijzen N, Fam JM, Ligthart JM, Lenzen MJ, Serruys PW, Zijlstra F, Jan van Geuns R. Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease. Catheter Cardiovasc Interv. 2016 Nov 29. doi: 10.1002/ccd.26832

140. Capodanno D, Gargiulo G, Buccheri S, Chieffo A, Meliga E,

Latib A, Park SJ, Onuma Y, Capranzano P, Valgimigli M, Narbute I, Makkar RR, Palacios IF, Kim YH, Buszman PE, Chakravarty T, Sheiban I, Mehran R, Naber C, Margey R, Agnihotri A, Marra S, Leon MB, Moses JW, Fajadet J, Lefèvre T, Morice MC, Erglis A, Alfieri O, Serruys PW, Colombo A, Tamburino C; DELTA Investigators. Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc

52

Analysis of the DELTA Registry. JACC Cardiovasc Interv. 2016 Nov 28;9(22):2280-2288

141. De Maria GL, Fahrni G, Alkhalil M, Cuculi F, Dawkins S,

Wolfrum M, Choudhury RP, Forfar JC, Prendergast BD, Yetgin T, van Geuns RJ, Tebaldi M, Channon KM, Kharbanda RK, Rothwell PM, Valgimigli M, Banning AP. A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score). EuroIntervention. 2016 Nov 20;12(10):1223-1230

142. Gargiulo G, Windecker S, da Costa BR, Feres F, Hong MK,

Gilard M, Kim HS, Colombo A, Bhatt DL, Kim BK, Morice MC, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ. 2016 Nov 3;355:i5483

143. Lee SY, Hong MK, Shin DH, Kim JS, Kim BK, Ko YG, Choi D,

Jang Y, Kim HS, Valgimigli M, Colombo A, Gilard M, Palmerini T, Stone GW. Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents. Circ Cardiovasc Interv. 2016 Nov;9(11)

144. Adamo M, Byrne RA, Baumbach A, Haude M, Windecker S,

Valgimigli M. Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey. EuroIntervention. 2016 Oct 20;12(9):1154-1163

145. Leonardi S, Frigoli E, Rothenbühler M, Navarese E, Calabró P,

Bellotti P, Briguori C, Ferlini M, Cortese B, Lupi A, Lerna S, Zavallonito-Parenti D, Esposito G, Tresoldi S, Zingarelli A, Rigattieri S, Palmieri C, Liso A, Abate F, Zimarino M, Comeglio M, Gabrielli G, Chieffo A, Brugaletta S, Mauro C, Van Mieghem NM, Heg D, Jüni P, Windecker S, Valgimigli M; MATRIX Investigators. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ. 2016 Sep 27;354:i4935

146. Giustino G, Mastoris I, Baber U, Sartori S, Stone GW, Leon MB,

Serruys PW, Kastrati A, Windecker S, Valgimigli M, Dangas GD, Von Birgelen C, Smits PC, Kandzari D, Galatius S, Wijns W, Steg PG, Stefanini GG, Aquino M, Morice MC, Camenzind E, Weisz G, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Chieffo A, Mehran R. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Cardiovasc Interv. 2016 Sep 26;9(18):1890-901

53

147. Lee SY, Hong MK, Shin DH, Kim JS, Kim BK, Ko YG, Choi D,

Jang Y, Kim HS, Valgimigli M, Palmerini T, Stone GW. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. Clin Res Cardiol. 2016 Sep 8

148. Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F,

Abizaid A, Costa RA, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Gilard M, Morice MC, Sawaya F, Sardella G, Genereux P, Redfors B, Leon MB, Bhatt DL, Stone GW, Colombo A. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. J Am Coll Cardiol. 2016 Aug 25

149. Franzone A, Piccolo R, Gargiulo G, Ariotti S, Marino M, Santucci

A, Baldo A, Magnani G, Moschovitis A, Windecker S, Valgimigli M. Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial. JAMA Cardiol. 2016 Aug 30

150. Gargiulo G, Ariotti S, Santucci A, Piccolo R, Baldo A, Franzone

A, Magnani G, Marino M, Esposito G, Windecker S, Valgimigli M. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial. JACC Cardiovasc Interv. 2016 Sep 12;9(17):1780-9

151. Stefanini GG, Behan M, Valgimigli M, Oldroyd KG, Leon MB.

Will LEADERS-FREE change my practice? A randomised double-blind comparison of the BioFreedom™ drug-coated stent vs. the Gazelle™ bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. EuroIntervention. 2016 Aug 20;12(6):798-800

152. Adamo M, Ariotti S, Costa F, Curello S, Moschovitis A, de Vries

T, White HD, Windecker S, Valgimigli M. Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM Trial. JACC Cardiovasc Interv. 2016 Aug 22;9(16):1667-76

153. Ferko N, Ferrante G, Hasegawa JT, Schikorr T, Soleas IM,

Hernandez JB, Sabaté M, Kaiser C, Brugaletta S, de la Torre Hernandez JM, Galatius S, Cequier A, Eberli F, de Belder A, Serruys PW, Valgimigli M. Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials. Catheter Cardiovasc Interv. 2016 Aug 16

154. Xhepa E, Tada T, Kufner S, Ndrepepa G, Byrne RA, Kreutzer J,

Ibrahim T, Tiroch K, Valgimigli M, Tölg R, Cassese S, Fusaro M, Schunkert H,

54

Laugwitz KL, Mehilli J, Kastrati A. Long-term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR-LEFT-MAIN and ISAR-LEFT-MAIN 2 randomized clinical trials. Catheter Cardiovasc Interv. 2016 Aug 12

155. Pyxaras SA, Hunziker L, Chieffo A, Meliga E, Latib A, Park SJ,

Onuma Y, Capranzano P, Valgimigli M, Narbute I, Makkar RR, Palacios IF, Kim YH, Buszman PP, Chakravarty T, Sheiban I, Mehran R, Margey R, Agnihotri A, Marra S, Capodanno D, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, Alfieri O, Serruys PW, Colombo A, Naber CK. Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. EuroIntervention. 2016 Aug 5;12(5):e623-31

156. Sawaya FJ, Morice MC, Spaziano M, Mehran R, Didier R, Roy

A, Valgimigli M, Kim HS, Woo Park K, Hong MK, Kim BK, Jang Y, Feres F, Abizaid A, Costa RA, Colombo A, Chieffo A, Giustino G, Stone GW, Bhatt DL, Palmerini T, Gilard M. Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials. Catheter Cardiovasc Interv. 2016 Jul 18

157. Ferrante G, Rao SV, Jüni P, Da Costa BR, Reimers B,

Condorelli G, Anzuini A, Jolly SS, Bertrand OF, Krucoff MW, Windecker S, Valgimigli M. Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv. 2016 Jul 25;9(14):1419-34

158. Siontis GC, Piccolo R, Praz F, Valgimigli M, Räber L, Mavridis

D, Jüni P, Windecker S. Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries: A Network Meta-Analysis. JACC Cardiovasc Interv. 2016 Jul 11;9(13):1324-34

159. Piccolo R, Franzone A, Koskinas KC, Räber L, Pilgrim T,

Valgimigli M, Stortecky S, Rat-Wirtzler J, Silber S, Serruys PW, Jüni P, Heg D, Windecker S. Effect of Diabetes Mellitus on Frequency of Adverse Events in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Am J Cardiol. 2016 Aug 1;118(3):345-52

160. Pilgrim T, Vranckx P, Valgimigli M, Stefanini GG, Piccolo R, Rat J,

Rothenbühler M, Stortecky S, Räber L, Blöchlinger S, Hunziker L, Silber S, Jüni P, Serruys PW, Windecker S. Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. Am Heart J. 2016 May;175:56-65

55

161. Santucci A, Byrne RA, Baumbach A, Colleran R, Haude M, Windecker S,

Valgimigli M. Appraising the safety and efficacy profile of left atrial appendage closure in 2016 and the future clinical perspectives. Results of the EAPCI LAAC survey. EuroIntervention. 2016 May 17;12(1):112-8

162. Fam JM, Felix C, van Geuns RJ, Onuma Y, Van Mieghem NM, Karanasos

A, van der Sijde J, De Paolis M, Regar E, Valgimigli M, Daemen J, de Jaegere P, Zijlstra F, Diletti R. Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study. EuroIntervention. 2016 May 17;12(1):30-7

163. Rao SV, Nolan J, Fraser DG, Mamas MA, Bertrand OF, Pancholy SB,

Bernat I, Dharma S, Kedev S, Jolly SS, Valgimigli M. Efficacy of Radial Versus Femoral Access in the Acute Coronary Syndrome: Is It the Operator or the Operation That Matters? JACC Cardiovasc Interv. 2016 May 9;9(9):978-9

164. Janssens GN, van Leeuwen MA, van der Hoeven NW, de Waard GA,

Nijveldt R, Diletti R, Zijlstra F, von Birgelen C, Escaned J, Valgimigli M, van Royen N. Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study. J Cardiovasc Transl Res. 2016 Jun;9(3):249-56

165. Giustino G, Baber U, Aquino M, Sartori S, Stone GW, Leon MB, Genereux

P, Dangas GD, Chandrasekhar J, Kimura T, Salianski O, Stefanini GG, Steg PG, Windecker S, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, Von Birgelen C, Saporito R, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. JACC Cardiovasc Interv. 2016 Apr 11;9(7):674-84

166. Crimi G, Leonardi S, Costa F, Adamo M, Ariotti S, Valgimigli M. Role of

stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. Int J Cardiol. 2016 Jun 1;212:110-7

167. Franzone A, Heg D, Räber L, Valgimigli M, Piccolo R, Zanchin T, Yamaji

K, Stortecky S, Blöchlinger S, Hunziker L, Praz F, Jüni P, Windecker S, Pilgrim T. External validity of the "all-comers" design: insights from the BIOSCIENCE trial. Clin Res Cardiol. 2016 Sep;105(9):744-54

56

168. Gargiulo G, Costa F, Ariotti S, Biscaglia S, Campo G, Esposito G, Leonardi S, Vranckx P, Windecker S, Valgimigli M. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. Am Heart J. 2016 Apr;174:95-102

169. van der Sijde JN, Karanasos A, van Ditzhuijzen NS, Okamura T, van

Geuns RJ, Valgimigli M, Ligthart JM, Witberg KT, Wemelsfelder S, Fam JM, Zhang B, Diletti R, de Jaegere PP, van Mieghem NM, van Soest G, Zijlstra F, van Domburg RT, Regar E. Safety of optical coherence tomography in daily practice: a comparison with intravascular ultrasound. Eur Heart J Cardiovasc Imaging. 2016 Mar 18

170. Ariotti S, Adamo M, Costa F, Patialiakas A, Briguori C, Thury A, Colangelo

S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Ferlini M, Vranckx P, Valgimigli M; ZEUS Investigators. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. JACC Cardiovasc Interv. 2016 Mar 14;9(5):426-36

171. Costa F, van Leeuwen MA, Daemen J, Diletti R, Kauer F, van Geuns RJ,

Ligthart J, Witberg K, Zijlstra F, Valgimigli M, Van Mieghem NM. The Rotterdam Radial Access Research: Ultrasound-Based Radial Artery Evaluation for Diagnostic and Therapeutic Coronary Procedures. Circ Cardiovasc Interv. 2016 Feb;9(2):e003129

172. Romaguera R, Gómez-Hospital JA, Gomez-Lara J, Brugaletta S, Pinar E, Jiménez-Quevedo P, Gracida M, Roura G, Ferreiro JL, Teruel L, Montanya E, Fernandez-Ortiz A, Alfonso F, Valgimigli M, Sabate M, Cequier A. A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial. JACC Cardiovasc Interv. 2016 Jan 11;9(1):42-50

173. Baber U, Giustino G, Sartori S, Aquino M, Stefanini GG, Steg PG,

Windecker S, Leon MB, Wijns W, Serruys PW, Valgimigli M, Stone GW, Dangas GD, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Mastoris I, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016 Jan 11;9(1):28-38

174. Giustino G, Baber U, Salianski O, Sartori S, Stone GW, Leon MB, Aquino

M, Stefanini GG, Steg PG, Windecker S, O' Donoghue M, Wijns W, Serruys PW,

57

Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Dangas GD, Cha JY, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Genereux P, Chieffo A, Mehran R. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. Circ Cardiovasc Interv. 2016 Jan;9(1):e002995

175. Cassese S, Kufner S, Xhepa E, Byrne RA, Kreutzer J, Ibrahim T, Tiroch

K, Valgimigli M, Tölg R, Fusaro M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. Clin Res Cardiol. 2016 Jul;105(7):575-84

176. Pighi M, Tomai F, Petrolini A, de Luca L, Tarantini G, Barioli A, Colombo

P, Klugmann S, Ferlini M, Ormezzano MF, Loi B, Calabrò P, Bianchi RM, Faggian G, Forni A, Vassanelli C, Valgimigli M, Ribichini F. Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study. J Cardiovasc Transl Res. 2016 Feb;9(1):40-8

177. Mont'Alverne-Filho JR, Rodrigues-Sobrinho CR, Medeiros F, Falcão FC,

Falcão JL, Silva RC, Croce KJ, Nicolau JC, Valgimigli M, Serruys PW, Lemos PA. Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study. Catheter Cardiovasc Interv. 2016 Jun;87(7):1187-93

178. Vranckx P, Valgimigli M, Windecker S, Steg PG, Hamm C, Jüni P,

Garcia-Garcia HM, van Es GA, Serruys PW. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention. 2015 Nov 23;11(7)

179. Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong

PW, Steg PG, Bode C, Cohen MG, Buller C, Laanmets P, Valgimigli M, Marandi T, Fridrich V, Cantor WJ, Merkely B, Lopez-Sendon J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J, Sinnaeve PR, Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, Lopes RD, Hasselblad V, Becker RC, Alexander JH; REGULATE-PCI Investigators. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet. 2016 Jan 23;387(10016):349-56

180. Sabaté M, Brugaletta S, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo

P, Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, van Es GA, Backx B, Valgimigli M, Serruys PW. Clinical outcomes in patients with

58

ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet. 2016 Jan 23;387(10016):357-66

181. Colombo A, Basavarajaiah S, Limbruno U, Picchi A, Lettieri C, Valgimigli

M, Sciahbasi A, Prati F, Calabresi M, Pierucci D, Guglielmotti A. A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis. EuroIntervention. 2015 Dec 23;11(8)

182. Costa F, Tijssen JG, Ariotti S, Giatti S, Moscarella E, Guastaroba P, De

Palma R, Andò G, Oreto G, Zijlstra F, Valgimigli M. Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy. J Am Heart Assoc. 2015 Dec 7;4(12)

183. Meloni M, Cesselli D, Caporali A, Mangialardi G, Avolio E, Reni C,

Fortunato O, Martini S, Madeddu P, Valgimigli M, Nikolaev E, Kaczmarek 8, Angelini GD, Beltrami AP, Emanueli C. Cardiac Nerve Growth Factor Overexpression Induces Bone Marrow-derived Progenitor Cells Mobilization and Homing to the Infarcted Heart. Mol Ther. 2015 Dec;23(12):1854-66

184. Costa F, Adamo M, Ariotti S, Ferrante G, Navarese EP, Leonardi S,

Garcia-Garcia H, Vranckx P, Valgimigli M. Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. EuroIntervention. 2016 Feb;11(11):e1222-30

185. Meloni M, Cesselli D, Caporali A, Mangialardi G, Avolio E, Reni C,

Fortunato O, Martini S, Madeddu P, Valgimigli M, Nikolaev E, Kaczmarek L, Angelini GD, Beltrami AP, Emanueli C. Cardiac nerve growth factor overexpression induces bone marrow-derived progenitor cells mobilization and homing to the infarcted heart. Mol Ther. doi:10.1038/mt.2015.167, 2015

186. Costa F, Adamo M, Ariotti S, Ferrante G, Navarese EP, Leonardi S, Garcia-Garcia H, Vranckx P, Valgimigli M. Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. EuroIntervention. 11(4). pii:20150619_02. doi:10.4244/EIJY15M08_04, 2015

187. Komajda M, Weidinger F, Kerneis M, Cosentino F, Cremonesi A, Ferrari

R, Kownator S, Steg PG, Tavazzi L, Valgimigli M, Szwed H, Majda W, Olivari Z, Van Belle E, Shlyakhto EV, Mintale I, Slapikas R, Rittger H, Mendes M, Tsioufis C, Balanescu S, Laroche C, Maggioni AP. EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). Eur Heart J. pii: ehv437, 2015

59

188. Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine MS, Braunwald E, Bhatt DL. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. pii: ehv443, 2015

189. Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò

P, Garducci S, Rubartelli P, Briguori C, Andó G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, N de Cesare, Rigattieri S, Zingarelli A, Tosi P, van ’t Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg H, Jüni P, Vranckx P, for the MATRIX Investigators. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med. 2015, Sep 10;373(11):997-1009. doi: 10.1056/NEJMoa1507854

190. Valgimigli M, Costa F, Byrne R, Haude M, Baumbach A, Windecker S.

Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention. 2015 May 19;11(1):68-74. doi: 10.4244/EIJV11I1A11.

191. Karanasos A, Van Mieghem N, van Ditzhuijzen N, Felix C, Daemen J,

Autar A, Onuma Y, Kurata M, Diletti R, Valgimigli M, Kauer F, van Beusekom H, de Jaegere P, Zijlstra F, van Geuns RJ, Regar E. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. Circ Cardiovasc Interv. 2015 May;8(5). pii: e002369. doi: 10.1161/CIRCINTERVENTIONS.114.002369.

192. Ferrante G, Valgimigli M, Pagnotta P, Presbitero P. Bivalirudin versus

heparin in patients with acute myocardial infarction: A meta-analysis of randomized trials. Catheter Cardiovasc Interv. 2015 Apr 24. doi: 10.1002/ccd.25955.

193. Adamo M, Costa F, Vranckx P, Leonardi S, Navarese EP, Garcia-Garcia

HM, Valgimigli M. Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. Int J Cardiol. 2015 Jul 1;190:242-5. doi: 10.1016/j.ijcard.2015.04.159.

194. Buccheri D, Valgimigli M, Cortese B. Current-era biovascular scaffolds

seen by experts: An experience-based survey. Int J Cardiol. 2015 Jun 1;188:16-8. doi: 10.1016/j.ijcard.2015.03.437.

195. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer

MK, Ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk

60

stratification after percutaneous coronary intervention. Eur Heart J. 2015 Apr 20. pii: ehv104.

196. Navarese EP, Andreotti F, Schulze V, Kołodziejczak M, Buffon A,

Brouwer M, Costa F, Kowalewski M, Parati G, Lip GY, Kelm M, Valgimigli M. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015 Apr 16;350:h1618. doi: 10.1136/bmj.h1618.

197. Andò G, Cortese B, Frigoli E, Gagnor A, Garducci S, Briguori C, Rubartelli

P, Calabrò P, Valgimigli M. MATRIX investigators. Acute kidney injury after percutaneous coronary intervention: Rationale of the AKI-MATRIX (acute kidney injury-minimizing adverse hemorrhagic events by TRansradial access site and systemic implementation of angioX) sub-study. Catheter Cardiovasc Interv. 2015 Apr 9. doi: 10.1002/ccd.25932.

198. Campos CM, Garcia-Garcia HM, van Klaveren D, Ishibashi Y, Cho YK,

Valgimigli M, Räber L, Jonker H, Onuma Y, Farooq V, Garg S, Windecker S, Morel MA, Steyerberg EW, Serruys PW. Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5433 patients enrolled in contemporary coronary stent trials. Int J Cardiol. 2015 May 6;187:111-5. doi: 10.1016/j.ijcard.2015.03.248.

199. Campos CM, Costa F, Garcia-Garcia HM, Bourantas C, Suwannasom P,

Valgimigli M, Morel MA, Windecker S, Serruys PW. Anatomic characteristics and clinical implications of angiographic coronary thrombus: insights from a patient-level pooled analysis of SYNTAX, RESOLUTE, and LEADERS Trials. Circ Cardiovasc Interv. 2015 Apr;8(4). pii: e002279. doi: 10.1161/ CIRCINTERVENTIONS.114.002279.

200. Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T,

Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbühler M, Vranckx P, Jüni P; MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015 Mar 13. pii: S0140-6736(15)60292-6. doi: 10.1016/S0140-6736(15)60292-6.

201. Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo

G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015 Mar 3;65(8):805-15. doi: 10.1016/j.jacc.2014.11.053.

61

202. Costa F, Vranckx P, Leonardi S, Moscarella E, Ando G, Calabro P, Oreto G, Zijlstra F, Valgimigli M. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. Eur Heart J. 2015 May 21;36(20):1242-51. doi: 10.1093/eurheartj/ehv038.

203. Crimi G, Leonardi S, Costa F, Ariotti S, Tebaldi M, Biscaglia S, Valgimigli

M.Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. Insights from the all-comer PRODIGY trial. Catheter Cardiovasc Interv. 2015 Feb 20. doi: 10.1002/ccd.25822.

204. Palmerini T, Sangiorgi D, Valgimigli M, Biondi-Zoccai G, Feres F, Abizaid

A, Costa RA, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Mariani A, Della Riva D, Genereux P, Leon MB, Bhatt DL, Bendetto U, Rapezzi C, Stone GW. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol. 2015 Mar 24;65(11):1092-102. doi: 10.1016/j.jacc.2014.12.046.

205. Picchi A, Limbruno U, Andò G, Brugaletta S, Cortese B, De Carlo M,

Garcia-Garcia HM, Palmieri C, Regar E, Rigattieri S, Sardella G, Zimarino M, Valgimigli M. Optical coherence tomography appraisal of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing intraprocedural versus post-stenting prolonged bivalirudin infusion. Rationale and design of the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT substudy. EuroIntervention. 2015 Mar 22;10(11):1311-7. doi: 10.4244/EIJY15M02_10.

206. Ielasi A, Brugaletta S, Silvestro A, Cequier A, Iñiguez A, Serra A,

Hernandez-Antolin R, Mainar V, Valgimigli M, den Heijer P, Bethencourt A, Vazquez N, Serruys P, Sabate M, Tespili M. Everolimus-eluting stent versus bare-metal stent in elderly (≥75 years) versus non-elderly (<75 years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the examination trial. Int J Cardiol. 2015 Jan 20;179:73-8. doi: 10.1016/j.ijcard.2014.10.038.

207. Cortese B, Valgimigli M. Current know how on the absorb BVS

technology: An experts' survey. Int J Cardiol. 2015 Feb 1;180:203-5. doi: 10.1016/j.ijcard. 2014 .11.168.

208. Navarese EP, Schulze V, Andreotti F, Kowalewski M, Kołodziejczak M,

Kandzari DE, Rassaf T, Gorny B, Brockmeyer M, Meyer C, Berti S, Kubica J, Kelm M, Valgimigli M. Comprehensive Meta-Analysis of Safety and Efficacy of

62

Bivalirudin Versus Heparin With or Without Routine Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndrome. JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):201-13. doi: 10.1016/j.jcin.2014.10.003.

209. Andò G, Costa F, Boretti I, Trio O, Valgimigli M. Benefit of radial

approach in reducing the incidence of acute kidney injury after percutaneous coronary intervention: a meta-analysis of 22,108 patients. Int J Cardiol. 2015 Jan 20;179:309-11. doi: 10.1016/j.ijcard.2014.11.053.

210. De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, Jagic

N, Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd K, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Limacher A, Nüesch E, Jüni P; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014 Sep 25;371(13):1208-17. doi: 10.1056/NEJMoa1408758. Erratum in: N Engl J Med. 2014 Oct 9;371(15):1465.

211. Rubboli A, Saia F, Sciahbasi A, Bacchi-Reggiani ML, Steffanon L,

Briguori C, Calabrò P, Palmieri C, Rizzi A, Imperadore F, Sangiorgi GM, Valgimigli M, Carosio G, Steffenino G, Galvani M, Di Pasquale G, La Vecchia L, Maggioni AP, Bolognese L; WARfarin and Coronary STENTing (WAR-STENT) Study Group. Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. J Invasive Cardiol. 2014 Nov;26(11):563-9.

212. Valgimigli M, Sabaté M, Kaiser C, Brugaletta S, de la Torre Hernandez

JM, Galatius S, Cequier A, Eberli F, de Belder A, Serruys PW, Ferrante G. Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. BMJ. 2014 Nov 4;349:g6427. doi: 10.1136/bmj.g6427.

213. Valgimigli M; MATRIX investigators. Design and rationale for the

Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program. Am Heart J. 2014 Dec;168(6):838-45.e6. doi: 10.1016/j.ahj.2014.08.013.

214. STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown

R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. Darapladib for preventing ischemic events in stable

63

coronary heart disease. N Engl J Med. 2014 May 1;370(18):1702-11. doi: 10.1056/NEJMoa1315878.

215. Sciahbasi A, Calabrò P, Sarandrea A, Rigattieri S, Tomassini F, Sardella

G, Zavalloni D, Cortese B, Limbruno U, Tebaldi M, Gagnor A, Rubartelli P, Zingarelli A, Valgimigli M. Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX - RAdiation Dose study (RAD-MATRIX). Cardiovasc Revasc Med. 2014 Jun;15(4):209-13. doi: 10.1016/j.carrev.2014.03.010.

216. Vranckx P, Leonardi S, Tebaldi M, Biscaglia S, Parrinello G, Rao SV,

Mehran R, Valgimigli M. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. Eur Heart J. 2014 Oct 1;35(37):2524-9. doi: 10.1093/eurheartj/ehu161.

217. Bourantas CV, Zhang YJ, Garg S, Iqbal J, Valgimigli M, Windecker S,

Mohr FW, Silber S, Vries Td, Onuma Y, Garcia-Garcia HM, Morel MA, Serruys PW. Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. Heart. 2014 Aug;100(15):1158-64. doi: 10.1136/heartjnl-2013-305180.

218. Iqbal J, Vergouwe Y, Bourantas CV, Klaveren DV, Zhang YJ, Campos CM, García-García HM, Morel MA, Valgimigli M, Windecker S, Steyerberg EW, Serruys PW. Predicting 3-year mortality after percutaneous coronary intervention: updated logistic clinical SYNTAX score based on patient-level data from 7 contemporary stent trials. JACC Cardiovasc Interv. 2014 May;7(5):464-70. doi: 10.1016/j.jcin.2014.02.007.

219. Serra A, Hernández-Antolín R, Mainar V, Valgimigli M, Tespili M, den

Heijer P, Bethencourt A, Vázquez N, Serruys PW, Sabaté M; EXAMINATION investigators. Optimization in stent implantation by manual thrombus aspiration in ST-segment-elevation myocardial infarction: findings from the EXAMINATION trial. Fernández-Rodríguez D, Regueiro A, Brugaletta S, Martín-Yuste V, Masotti M, Cequier A, Iñíguez A, Circ Cardiovasc Interv. 2014 Jun;7(3):294-300. doi: 10.1161 /CIRCINTERVENTIONS.113.000964.

220. Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di

Nisio M, Silletta MG, Maione A, Alfonso F, Clemmensen PM, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head S, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter D, Schauerte P, Sousa Uva M, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Kolh P, Jüni P. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. 2014 Jun 23;348:g3859. doi: 10.1136/bmj.g3859.

64

221. Valgimigli M, Tricoci P, Huang Z, Aylward PE, Armstrong PW, Van de

Werf F, Leonardi S, White HD, Widimsky P, Harrington RA, Cequier A, Chen E, Lokhnygina Y, Wallentin L, Strony J, Mahaffey KW, Moliterno DJ. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol. 2014 Sep 1;114(5):665-73. doi: 10.1016/j.amjcard. 2014.05.054.

222. Guagliumi G, Capodanno D, Saia F, Musumeci G, Tarantini G, Garbo R,

Tumminello G, Sirbu V, Coccato M, Fineschi M, Trani C, De Benedictis M, Limbruno U, De Luca L, Niccoli G, Bezerra H, Ladich E, Costa M, Biondi Zoccai G, Virmani R; OCTAVIA Trial Investigators. Mechanisms of atherothrombosis and vascular response to primary percutaneous coronary intervention in women versus men with acute myocardial infarction: results of the OCTAVIA study. JACC Cardiovasc Interv. 2014 Sep;7(9):958-68. doi: 10.1016/j.jcin.2014.05.011.

223. Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R,

Lambert Y, Danays T, Soulat L, Halvorsen S, Ortiz FR, Vandenberghe K, Regelin A, Bluhmki E, Bogaerts K, Van de Werf F; STREAM investigators. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation. 2014 Sep 30;130(14):1139-45. doi: 10.1161/CIRCULATIONAHA.114.009570.

224. Prati F, Romagnoli E, Valgimigli M, Burzotta F, De Benedictis M,

Ramondo A, Mehran R, Stella PR. Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: the DEMONSTRATE study. Int J Cardiol. 2014 Oct 20;176(3):904-9. doi: 10.1016/j.ijcard.2014.08.031.

225. Campo G, Punzetti S, Malagù M, Ferrari R, Valgimigli M. Two-year

outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODIGY trial substudy. Int J Cardiol. 2014 May 1;173(2):343-5. doi: 10.1016/j.ijcard.2014.03.028.

226. O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG,

Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP; SOLID-TIMI 52 Investigators, Steen DL. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014 Sep 10;312(10):1006-15. doi: 10.1001 /jama.2014.11061.

227. Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF,

Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ,

65

Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM, Swahn E, Collet JP, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaut Prehospital ticagrelor in ST-segment elevation myocardial infarction. E, Hamm CW; ATLANTIC Investigators. N Engl J Med. 2014 Sep 11;371(11):1016-27. doi: 10.1056/NEJMoa1407024.

228. Hamon M, Bonello L, Marso S, Rao SV, Valgimigli M, Verheugt F,

Gershlick A, Wang Y, Prats J, Steg GP, Deliargyris E Comparison of bivalirudin versus heparin(s) during percutaneous coronary interventions in patients receiving prasugrel: a propensity-matched study. Clin Cardiol. 2014 Jan;37(1):14-20. doi: 10.1002/clc.22208.

229. Campo G, Tebaldi M, Vranckx P, Biscaglia S, Tumscitz C, Ferrari R,

Valgimigli M. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). J Am Coll Cardiol. 2014 Feb 18;63(6):506-12. doi: 10.1016/j.jacc.2013.09.043.

230. Valgimigli M, Patialiakas A, Thury A, Colangelo S, Campo G, Tebaldi M,

Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study. Am Heart J. 2013 Nov;166(5):831-8. doi: 10.1016/j.ahj.2013.07.033.

231. Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS,

Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE; VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014 Jan 15;311(3):252-62. doi: 10.1001/jama.2013.282836.

232. Latib A, Takagi K, Chizzola G, Tobis J, Ambrosini V, Niccoli G, Sardella

G, DiSalvo ME, Armigliato P, Valgimigli M, Tarsia G, Gabrielli G, Lazar L, Maffeo D, Colombo A. Excimer Laser LEsion modification to expand non-dilatable stents: the ELLEMENT registry. Cardiovasc Revasc Med. 2014 Jan;15(1):8-12.doi:10.1016/j.carrev.2013.10.005.

233. Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M,

Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Jüni P, Windecker S. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From

66

an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. JACC Cardiovasc Interv. 2014 Jan;7(1):55-63. doi: 10.1016/j.jcin.2013. 07.012.

234. Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C,

Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008.

235. Sabaté M, Brugaletta S, Cequier A, Iñiguez A, Serra A, Hernádez-Antolín

R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vázquez N, Backx B, Serruys PW. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. JACC Cardiovasc Interv. 2014 Jan;7(1):64-71. doi: 10.1016/j.jcin.2013.09.006.

236. Valgimigli M, Calabrò P, Cortese B, Frigoli E, Garducci S, Rubartelli P,

Andò G, Santarelli A, Galli M, Garbo R, Repetto A, Ierna S, Briguori C, Limbruno U, Violini R, Gagnor A; MATRIX investigators. Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial. J Cardiovasc Transl Res. 2014 Feb;7(1):101-11. doi: 10.1007/s12265-013-9537-1.

237. Storey RF, Kotha J, Smyth SS, Moliterno DJ, Rorick TL, Moccetti T,

Valgimigli M, Dery JP, Cornel JH, Thomas GS, Huber K, Harrington RA, Hord E, Judge HM, Chen E, Strony J, Mahaffey KW, Tricoci P, Becker RC, Jennings LK. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost. 2014 May 5;111(5):883-91. doi: 10.1160/TH13-07-0624.

238. Manari A, Varani E, Guastaroba P, Menozzi M, Valgimigli M, Menozzi A,

Magnavacchi P, Franco N, Marzocchi A, Casella G. Long-term outcome in patients with ST segment elevation myocardial infarction and multivessel disease treated with culprit-only, immediate, or staged multivessel percutaneous revascularization strategies: Insights from the REAL registry. Catheter Cardiovasc Interv. 2014 Nov 15;84(6):912-22. doi: 10.1002/ccd.25374.

239. Manari A, Magnavacchi P, Puggioni E, Vignali L, Fiaccadori E, Menozzi

M, Tondi S, Robotti S, Ferrari D, Valgimigli M. Acute kidney injury after primary angioplasty: effect of different hydration treatments. J Cardiovasc Med (Hagerstown). 2014 Jan;15(1):60-7. doi: 10.2459/JCM.0b013e3283641bb8.

67

240. Buchanan GL, Chieffo A, Meliga E, Mehran R, Park SJ, Onuma Y,

Capranzano P, Valgimigli M, Narbute I, Makkar RR, Palacios IF, Kim YH, Buszman PP, Chakravarty T, Sheiban I, Naber C, Margey R, Agnihotri A, Marra S, Capodanno D, Allgar V, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, Alfieri O, Serruys PW, Colombo A. Comparison of percutaneous coronary intervention (with drug-eluting stents) versus coronary artery bypass grafting in women with severe narrowing of the left main coronary artery (from the Women-Drug-Eluting stent for LefT main coronary Artery disease Registry). Am J Cardiol. 2014 Apr 15;113(8):1348-55. doi: 10.1016/j.amjcard.2014.01.409.

241. Valgimigli M, Campo G, Penzo C, Tebaldi M, Biscaglia S, Ferrari R;

RADAR Investigators. Transradial coronary catheterization and intervention across the whole spectrum of Allen test results. J Am Coll Cardiol. 2014 May 13;63(18):1833-41. doi: 10.1016/j.jacc.2013.12.043.

242. Naganuma T, Chieffo A, Meliga E, Capodanno D, Park SJ, Onuma Y,

Valgimigli M, Jegere S, Makkar RR, Palacios IF, Costopoulos C, Kim YH, Buszman PP, Chakravarty T, Sheiban I, Mehran R, Naber C, Margey R, Agnihotri A, Marra S, Capranzano P, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, Alfieri O, Serruys PW, Colombo A. Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for ostial/midshaft lesions in unprotected left main coronary artery from the DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. JACC Cardiovasc Interv. 2014 Apr;7(4):354-61. doi: 10.1016/j.jcin.2013.11.014.

243. Parodi G, La Manna A, Di Vito L, Valgimigli M, Fineschi M, Bellandi B,

Niccoli G, Giusti B, Valenti R, Cremonesi A, Biondi-Zoccai G, Prati F. Stent-related defects in patients presenting with stent thrombosis: differences at optical coherence tomography between subacute and late/very late thrombosis in the Mechanism Of Stent Thrombosis (MOST) study. EuroIntervention. 2013 Dec;9(8):936-44. doi: 10.4244/EIJV9I8A157.

244. Fortuna D, Nicolini F, Guastaroba P, De Palma R, Di Bartolomeo S, Saia

F, Pacini D, Grilli R; RERIC (Regional Registry of Cardiac Surgery); REAL (Regional Registry of Coronary Angioplasties) Investigators. Coronary artery bypass grafting vs percutaneous coronary intervention in a 'real-world' setting: a comparative effectiveness study based on propensity score-matched cohorts. Eur J Cardiothorac Surg. 2013 Jul;44(1):e16-24. doi: 10.1093/ejcts/ezt197.

245. Mehilli J, Richardt G, Valgimigli M, Schulz S, Singh A, Abdel-Wahab M,

Tiroch K, Pache J, Hausleiter J, Byrne RA, Ott I, Ibrahim T, Fusaro M, Seyfarth M, Laugwitz KL, Massberg S, Kastrati A; Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. ISAR-LEFT-MAIN 2

68

Study Investigators. J Am Coll Cardiol. 2013 Dec 3;62(22):2075-82. doi: 10.1016/j.jacc.2013.07.044.

246. Stefanini GG, Baber U, Windecker S, Morice MC, Sartori S, Leon MB,

Stone GW, Serruys PW, Wijns W, Weisz G, Camenzind E, Steg PG, Smits PC, Kandzari D, Von Birgelen C, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet. 2013 Dec 7;382(9908):1879-88. doi: 10.1016/S0140-6736(13)61782-1.

247. Ribichini F, Romano M, Rosiello R, La Vecchia L, Cabianca E,

Caramanno G, Milazzo D, Loschiavo P, Rigattieri S, Musarò S, Pironi B, Fiscella A, Amico F, Indolfi C, Spaccarotella C, Bartorelli A, Trabattoni D, Della Rovere F, Rolandi A, Beqaraj F, Belli R, Sangiorgio P, Villani R, Berni A, Sheiban I, Lopera Quijada MJ, Cappi B, Ribaldi L, Vassanelli C; EXECUTIVE Trial Investigators. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease). JACC Cardiovasc Interv. 2013 Oct;6(10):1012-22. doi: 10.1016/j.jcin. 2013.05.016.

248. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert

Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F; STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013 Apr 11;368(15):1379-87. doi: 10.1056/NEJMoa1301092.

249. Contini GA, Nicolini F, Fortuna D, Pacini D, Gabbieri D, Vignali L,

Valgimigli M, Manari A, Zussa C, Guastaroba P, De Palma R, Grilli R, Gherli T. Five-year outcomes of surgical or percutaneous myocardial revascularization in diabetic patients. Int J Cardiol. 2013 Sep 30;168(2):1028-33. doi: 10.1016/j.ijcard.2012. 10.030

250. Farooq V, Vergouwe Y, Généreux P, Bourantas CV, Palmerini T, Caixeta

A, Garcìa-Garcìa HM, Diletti R, Morel MA, McAndrew TC, Kappetein AP, Valgimigli M, Windecker S, Dawkins KD, Steyerberg EW, Serruys PW, Stone GW.Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Validation of the Logistic Clinical SYNTAX (Synergy Between Percutaneous Coronary Interventions With Taxus and Cardiac Surgery) Score. JACC Cardiovasc Interv. 2013 Jul;6(7):737-45. doi: 10.1016/ j.jcin.2013.04.004.

251. Gomez-Lara J, Brugaletta S, Gomez-Hospital JA, Ferreiro JL, Roura G,

Romaguera R, Martin-Yuste V, Masotti M, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A,

69

Vazquez N, Serruys P, Sabate M, Cequier A. Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction: Insights from the EXAMINATION trial. Am Heart J. 2013 Jul;166(1):119-126.e1. doi: 10.1016/j.ahj.2013.04.012.

252. Fortunato O, Spinetti G, Specchia C, Cangiano E, Valgimigli M,

Madeddu P. Migratory activity of circulating progenitor cells and serum SDF-1α predict adverse events in patients with myocardial infarction. Cardiovasc Res. 2013 Nov 1;100(2):192-200. doi: 10.1093/cvr/cvt153.

253. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M,

Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW. Clinical Outcomes with Drug-Eluting and Bare Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction: Evidence from a Comprehensive Network Meta-analysis. J Am Coll Cardiol. 2013 Jun 6. doi:pii: S0735-1097(13)02161-X. 10.1016/j.jacc.2013.05.022.

254. Saia F, Marino M, Campo G, Valgimigli M, Guastaroba P, Taglieri N,

Tondi S, Manari A, Guiducci V, Sangiorgio P, Varani E, Magnavacchi P, De Palma R, Marzocchi A. Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] Study). Am J Cardiol. 2013 Jun 5. doi:pii: S0002-9149(13)01122-3. 10.1016/j.amjcard.2013.05.010.

255. Niccoli G, Rigattieri S, De Vita MR, Valgimigli M, Corvo P, Fabbiocchi F,

Romagnoli E, De Caterina AR, La Torre G, Lo Schiavo P, Tarantino F, Ferrari R, Tomai F, Olivares P, Cosentino N, D'Amario D, Leone AM, Porto I, Burzotta F, Trani C, Crea F. Open-Label, Randomized, Placebo-Controlled Evaluation of Intracoronary Adenosine or Nitroprusside After Thrombus Aspiration During Primary Percutaneous Coronary Intervention for the Prevention of Microvascular Obstruction in Acute Myocardial Infarction: The REOPEN-AMI Study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC Cardiovasc Interv. 2013 Jun;6(6):580-589. doi: 10.1016/j.jcin.2013.02.009.

256. Valgimigli M, Park SJ, Kim HS, Park KW, Park DW, Tricoci P, Ferrante

G. Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: A meta-analysis of randomized trials. Int J Cardiol. 2013 Apr 13. doi:pii: S0167-5273(13)00466-X. 10.1016/j.ijcard.2013.03.047.

257. Brugaletta S, Sabate M, Martin-Yuste V, Masotti M, Shiratori Y, Alvarez-

Contreras L, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gomez-Lara J, Backx B, Serruys PW. Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction: Insights from the

70

EXAMINATION trial. Int J Cardiol. 2013 Apr 8. pii: S0167-5273(13)00455-5. doi: 10.1016/j.ijcard.2013.03.036.

258. Rubboli A, Sciahbasi A, Briguori C, Saia F, Palmieri C, Moroni LA,

Calabrò P, Leone AM, Franco N, Valgimigli M, Varani E, Santi M, Pasqualini P, Capecchi A, Piccalò G, Margheri M, di Pasquale G, Galvani M, Bolognese L, Gonzini L, Maggioni AP; WARfarin and coronary STENTing registry. In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry. J Invasive Cardiol. 2013 Apr;25(4):170-6.

259. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R; PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J. 2013 Mar;34(12):909-19. doi: 10.1093/eurheartj/ehs460.

260. Aradi D, Komócsi A, Price MJ, Cuisset T, Ari H, Hazarbasanov D, Trenk D, Sibbing D, Valgimigli M, Bonello L; On behalf of the Tailored Antiplatelet Treatment Study Collaboration. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol. 2013 Sep 1;167(5):2140-8. doi: 10.1016/j.ijcard.2012.05.100

261. Chieffo A, Latib A, Caussin C, Presbitero P, Galli S, Menozzi A, Varbella

F, Mauri F, Valgimigli M, Arampatzis C, Sabate M, Erglis A, Reimers B, Airoldi F, Laine M, Palop RL, Mikhail G, Maccarthy P, Romeo F, Colombo A. A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: the AVIO trial. Am Heart J. 2013 Jan;165(1):65-72. doi: 10.1016/j.ahj.2012.09.017.

262. Biscaglia S, Tebaldi M, Vranckx P, Campo G, Valgimigli M. Effects of

pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention. J Thromb Haemost. 2013 Jan;11(1):192-4. doi: 10.1111/jth.12049.

263. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F,

White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators. Thrombin-receptor

71

antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719.

264. Sciahbasi A, Biondi-Zoccai G, Romagnoli E, Valgimigli M, Rasoul S,

van't Hof A, Lioy E, Stone GW. Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials. Int J Cardiol. 2012 Mar 8;155(2):243-8. doi: 10.1016/j.ijcard.2010.10.010.

265. Farooq V, Vergouwe Y, Räber L, Vranckx P, Garcia-Garcia H, Diletti R,

Kappetein AP, Morel MA, de Vries T, Swart M, Valgimigli M, Dawkins KD, Windecker S, Steyerberg EW, Serruys PW. Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. Eur Heart J. 2012 Oct 19.

266. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar

V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gómez-Hospital JA, Baz JA, Martin-Yuste V, van Geuns RJ, Alfonso F, Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1-year results of a randomised controlled trial. Lancet. 2012 Oct 27;380(9852):1482-90. doi: 10.1016/S0140-6736(12) 61223-9

267. Chieffo A, Meliga E, Latib A, Park SJ, Onuma Y, Capranzano P, Valgimigli M, Jegere S, Makkar RR, Palacios IF, Kim YH, Buszman PE, Chakravarty T, Sheiban I, Mehran R, Naber C, Margey R, Agnihotri A, Marra S, Capodanno D, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, Alfieri O, Serruys PW, Colombo A Drug-Eluting Stent for Left Main Coronary Artery Disease: The DELTA Registry: A Multicenter Registry Evaluating Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Left Main Treatment. JACC Cardiovasc Interv. 2012 Jul;5(7):718-27.

268. Hamon M, Rao SV, Steg G, Valgimigli M, Verheugt F, Marso S, Gershlick

A, Wang Y, Deliargyris E. Bivalirudin versus unfractionated heparin in percutaneous coronary intervention of patients having received initial fondaparinux treatment: a propensity matched study. EuroIntervention. 2012 Aug;8(4):486-92. doi: 10.4244/EIJV8I4A76.

269. Biondi-Zoccai G, Valgimigli M, Margheri M, Marzocchi A, Lettieri C,

Stabile A, Petronio AS, Binetti G, Bolognese L, Bellone P, Sardella G, Contarini M, Sheiban I, Marra S, Piscione F, Romeo F, Colombo A, Sangiorgi G. Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: The INtegrilin plus STenting to Avoid

72

myocardial Necrosis Trial. Am Heart J. 2012 May;163(5):835.e1-7. doi: 10.1016/j.ahj.2012.02.009.

270. Vranckx P, Campo G, Anselmi M, Bolognese L, Colangelo S, Biondi-

Zoccai G, Moreno R, Piva T, Favero L, Prati F, Nazzaro M, Díaz Fernández JF, Ferrari R, Valgimigli M. Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction. EuroIntervention. 2012 May 15;8(1):71-8.

271. Kalesan B, Pilgrim T, Heinimann K, Räber L, Stefanini GG, Valgimigli M, da Costa BR, Mach F, Lüscher TF, Meier B, Windecker S, Jüni P. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012 Apr; 33(8):977-87.

272. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fucà G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R. Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial. Circulation. 2012 Apr 24;125(16):2015-26. doi: 10.1161/ CIRCULATIONAHA.111.071589

273. Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M,

Parrinello G, Ferrari R; FABOLUS PRO Investigators. Prasugrel Versus Tirofiban Bolus With or Without Short Post-Bolus Infusion With or Without Concomitant Prasugrel Administration in Patients With Myocardial Infarction Undergoing Coronary Stenting: The FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) Trial. JACC Cardiovasc Interv. 2012 Mar;5(3):268-77.

274. Amadesi S, Reni C, Katare R, Meloni M, Oikawa A, Beltrami AP, Avolio

E, Cesselli D, Fortunato O, Spinetti G, Ascione R, Cangiano E, Valgimigli M, Hunt SP, Emanueli C, Madeddu P. Role for Substance-P Based Nociceptive Signaling in Progenitor Cell Activation and Angiogenesis during Ischemia in Mice and in Human Subjects. Circulation. 2012 Apr 10;125(14):1774-86.2

275. Valgimigli M, MD, PHD, Saia F, MD, PHD, Guastaroba P, MSC, Menozzi

A, MD, Magnavacchi P, MD, Santarelli A, MD, Passerini F, MD, Sangiorgio P, MD, Manari A, MD, Tarantino F, MD, Margheri M, MD, Benassi A, MD, Sangiorgi M, PHD, Tondi S, MD, Marzocchi A, MD, on behalf of the REAL Registry Investigators. Transradial Versus Transfemoral Intervention for Acute Myocardial Infarction A Propensity Score-Adjusted and -Matched Analysis From the REAL (REgistro regionale AngiopLastiche dell’Emilia-Romagna) Multicenter Registry. JACC Cardiovascular Interventions. 2012 Jan;5(1):23-35.

73

276. Ferrante G, MD, Presbitero P, Corrada E, MD Campo G, MD Bolognese

L, MD Vassanelli C, MD Colangelo S, MD De Cesare N, MD Rodriguez A, MD, PhD Bramucci E, MD Moreno P, MD Piva T, MD Sheiban I, MD Pasquetto G, MD Prati F, MD Nazzaro M, MD, PhD Ferrari R, MD, PhD Valgimigli M, MD, PhD. Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial. Am Heart J. 2012 Jan; 163;1:104-111.

277. Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romagnoli E,

Sangiorgi G, Angiolillo D, Valgimigli M, Testa L, Gaita F, Sheiban I. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol. 2011 Aug;150;3:325-331.

278. Vranckx P, Boersma E, Garg S, Valgimigli M, Van Es GA, Goedhart D,

Serruys PW. Cardiovascular risk profile of patients included in stent trials; a pooled analysis of individual patient data from randomised clinical trials: insights from 33 prospective stent trials in Europe. EuroIntervention. 2011 Nov 15;7(7):859-71. doi: 10.4244/EIJV7I7A134.

279. Ferrante G, Presbitero P, Valgimigli M, Morice MC, Pagnotta P, Belli G,

Corrada E, Onuma Y, Barlis P, Locca D, Eeckhout E, Di Mario C, Serruys PW. Percutaneous coronary intervention versus bypass surgery for left main coronary artery disease: a meta-analysis of randomised trials. EuroIntervention. 2011 Oct 30;7(6):738-46. doi: 10.4244/EIJV7I6A117.

280. Meliga E, Fiorina C, Valgimigli M, Belli R, Gagnor A, Sheiban I, Resmini

C, Tizzani E, Aranzulla T, Scrocca I, DE Benedictis M, Conte MR. Early Angio-Guided Complete Revascularization versus Culprit Vessel PCI Followed by Ischemia-Guided Staged PCI in STEMI Patients with Multivessel Disease. J Interv Cardiol 2011 Oct 20. doi: 10.1111/j.1540-8183.2011.00666.x.

281. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM,

Golia B, Ricciardelli B, Condorelli G; REMEDIAL II Investigators. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011 Sep 13;124(11):1260-9.

282. De Servi S, Valgimigli M. The BASKET-PROVE study. G Ital Cardiol

(Rome). 2011 Oct;12(10):625-9. doi: 10.1714/945.10346. Italian.

283. Garg S, Sarno G, Girasis C, Vranckx P, de Vries T, Swart M, Bressers M, Garcia-Garcia HM, van Es GA, Räber L, Campo G, Valgimigli M, Dawkins KD, Windecker S, Serruys PW. A patient-level pooled analysis assessing the impact

74

of the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials. JACC Cardiovasc Interv. 2011 Jun;4(6):645-53.

284. Brar S, MD MPH FACC, ten Berg J, MD, PhD, Marcucci R, MD, Price M,

MD (4), Valgimigli M, MD PhD, Kim HS, MD, PhD (6), Patti G, MD, Breet N, DiSciascio G, MD, Cuisset T, MD PhD, Dangas G, MD, PhD. Impact of Platelet Reactivity on Clinical Outcomes after Percutaneous Coronary Intervention: Collaborative Meta-analysis of Individual Participant Data. J Am Coll Cardiol. 2011 Nov 1;58(19):1945-54.

285. Valgimigli M, MD, PhD, Campo G, MD, Gambetti S, BSc, Bolognese L,

MD, Ribichini F, MD, Colangelo S, MD, de Cesare N, MD, Rodriguez AE., MD, PhD, Russo F, MD, Moreno R, MD, Piva T, MD, Sheiban I, MD, Penzo C, MD, Prati F, MD, PhD, Nazzaro MS, MD, PhD, Díaz Fernández JF, MD, Vassanelli C, MD, Parrinello G, PhD, Ferrari R, MD, Ph.D, For the MULTIcentre evaluation of Single high-dose bolus TiRofiban versus Abciximab with sirolimus eluting sTEnt or Bare Metal Stent in Acute Myocardial Infarction studY (MULTISTRATEGY) investigators. Three-year Follow-up of the MULTIcentre Evaluation of Single high-dose Bolus TiRofiban Versus Abciximab With Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). Int J Cardiol 2013;165(1):134-41.

286. Verheugt FW, MD, Steinhubl SR, MD, Hamon M, MD, Darius H, MD,

PHD, Steg PG, MD, Valgimigli M, MD, PHD, Marso SP, MD, Rao SV, MD, Gershlick AH, MD, A. Lincoff M, MD, Mehran R, MD, Stone GW, MD. Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Non access Site Bleeding in Percutaneous Coronary Intervention. JACC: Cardiovasc Interv 2011;4:2.

287. Cangiano E, Cavazza C, Campo G, Valgimigli M, Francolini G, Malagutti

P, Pratola C and Ferrari R. Different clinical models of CD34 + cells mobilization in patients with cardiovascular disease. J Throm Thrombolysis DOI: 10.1007/s11239-010-0543-8

288. Campo G, MD, Parrinello G, PhD, Ferraresi P, BsC, Lunghi B, BsC, Tebaldi M, MD, Miccoli M, MD, Bernardi F, BsC, PhD, Ferrari R, MD, PhD Valgimigli M, MD, PhD. Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients treated with Percutaneous Coronary Intervention. Relationship with Gene Polymorphisms and Clinical Outcome. J Am Coll Cardiol. 2011 Jun 21; 57 (25): 2474-83.

289. Garg S, MB, CHB, MRCP, Sarno G, MD, PHD, Serruys PW, MD, PHD,

Rodriguez AE, MD, PHD, Bolognese L, MD, Anselmi M, MD, De Cesare N, MD, Colangelo S, MD, Moreno R, MD, Gambetti S, BSC, Monti M, BSC, Bristot L, BSC, Bressers M, MSC, Garcia-Garcia HM., MD, PHD, Parrinello G, PHD,

75

Campo G, MD, Valgimigli M, MD, PHD on behalf of the STRATEGY and MULTISTRATEGY Investigators. Prediction of 1-Year Clinical Outcomes Using the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) Score in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 2011 Jan;4(1):66-75.

290. Valgimigli M, MD, PHD, Campo G, MD, Malagutti P, MD, Anselmi M, MD,

Bolognese L, MD, Ribichini F, MD, Boccuzzi G, MD, de Cesare N, MD, Rodriguez AE, MD, PHD, Russo F, MD, Moreno R, MD, Biondi-Zoccai G, MD, Penzo C, MD, Dıaz FJ, MD, Parrinello G, PHD, Ferrari R, MD, PHD. Persistent Coronary No Flow After Wire Insertion Is an Early and Readily Available Mortality Risk Factor Despite Successful Mechanical Intervention in Acute Myocardial Infarction: A Pooled Analysis From the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) Trials. JACC: Cardiovasc Interv 2011;10.

291. Zoccai GB, Valgimigli M. The SORT OUT III study. G Ital Cardiol (Rome).

2010 Dec;11(12):865-9.

292. Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, Colangelo S, Brugaletta S, Ferrari R, Valgimigli M; 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol. 2010 Oct 26;56(18):1447-55.

293. Sciahbasi A, Biondi-Zoccai G, Romagnoli E, Valgimigli M, Rasoul S,

Van't Hof A, Lioy E, Stone GW. Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: A meta-analysis of randomized trials. Int J Cardiol 2010 Oct 27.

294. Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romagnoli E,

Sangiorgi G, Angiolillo DJ, Valgimigli M, Testa L, Gaita F, Sheiban I. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol 2010 Sep 7

295. Valgimigli M, MD, PhD, Campo G, MD, Percoco G, MD, Monti M, BSc,

Ferrari F, MD, Tumscitz C, MD, Zuffi A, MD, Colombo F, MD, Kubbajeh M, MD, Cavazza C, MD, Cangiano E, MD, Tebaldi M, MD, Minarelli M, MD, Arcozzi C, MD, Scalone A, MD, Borghesi M. MD, Parrinello G, Ph.D, Ferrari R, MD, Ph.D. Randomized comparison of six versus twenty-four months clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all comer patients

76

undergoing percutaneous coronary intervention. Design and rationale for the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). American Heart Journal DOI: 10.1016/j.ahj.2010.07.034

296. Onuma Y, Girasis C, Piazza N, Garcia-Garcia HM, Kukreja N, Garg S,

Eindhoven J, Cheng JM, Valgimigli M, van Domburg R, Serruys PW; Interventional Cardiologists at Thoraxcenter 2000-2005. Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries. JACC Cardiovascular Intervention 2010 Jun;3(6):584-94.

297. Valgimigli M, Campo G, Tebaldi M, Monti M, Gambetti S, Scalone A,

Parrinello G, Ferrari R; on behalf of the FABOLUS SYNCHRO (Facilitation through Abciximab By dropping Infusion Line in patients Undergoing coronary Stenting. SYNergy with Clopidogrel at High loading dOse Regimen) investigators. Randomized, double blind, comparison of abiciximab bolus only versus on-label regimen on ex vivo platelet inhibition in responders to clopidogrel undergoing coronary stenting. J Thromb Haemostasis. 2010;8(9):1903-11.

298. Cuisset T, Valgimigli M, Mudra H, Muller O, Wijns W, Huber K. Rationale

and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update. EuroIntervention. 2010 May;6(1):39-45. doi: 10.4244

299. Latib A, Ferri L, Ielasi A, Cosgrave J, Godino C, Bonizzoni E, Romagnoli

E, Chieffo A, Valgimigli M, Penzo C, Carlino M, Michev I, Sangiorgi GM, Montorfano M, Airoldi F, Colombo A. Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts. Circ Cardiovasc Interv. 2010;3(3):249-56.

300. Dibra A, Tiroch K, Schulz S, Kelbæk H, Spaulding C, Laarman GJ,

Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Campo G, Thuesen L, Vink MA, Schalij MJ, Violini R, Schömig A, Kastrati A. Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clin Res Cardiol. 2010;99(6):345-57.

301. Campo G, Valgimigli M, Frangione A, Luccarelli S, Cangiano E, Cavazza

C, Fileti L, Ferrari R; 3T/2R Investigators. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel). J Am Coll Cardiol. 2010 Jan 19;55(3):255-6.

302. Tebaldi M, Arcozzi C, Campo G, Percoco G, Ferrari R, Valgimigli M;

STRATEGY Investigators. The 5-year clinical outcomes after a randomized

77

comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2009;54(20):1900-1.

303. Valgimigli M, Airoldi F, Zimarino M. Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents? J Cardiovasc Med (Hagerstown). 2009 Oct;10(Suppl.):17-26.

304. Onuma Y, Girasis C, Piazza N, Garcia-Garcia H, Kukreja N, Garg S,

Eindhoven J, Cheng J, Valgimigli M, van Domburg R, Serruys P. TRA*CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J. 2009 Sep;15

305. Campo G, Valgimigli M, Carletti R, Fileti L, Ferrari R. Long-term outcome

after percutaneous coronary intervention in patients with essential thrombocythemia. J Thromb Haemost. 2009 Jul;7

306. Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AW, Campo G,

Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J 2010 Jan;31(1):35-49.

307. De Luca G, Valgimigli M, Spaulding C, Menichelli M, Brunner-La Rocca

HP, van der Hoeven BL, Di Lorenzo E, Diaz de la Llera LS, Pasceri V, Pittl U, Percoco G, Violini R, Stone GW. Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. J Thromb Thrombolysis. 2009 Aug;28(2):200-10.

308. Vranckx P, Schultz CJ, Valgimigli M, Eindhoven JA, Kappetein AP,

Regar ES, Van Domburg R, Serruys PW. Assisted circulation using the TandemHeart during very high-risk PCI of the unprotected left main coronary artery in patients declined for CABG. Cath Cardiovasc Interv. 2009 Aug 1

309. Niccoli G, D'amario D, Spaziani C, Cosentino N, Marino M, Rigattieri S,

Schiavo PL, De Vita MR, Tarantino F, Bartorelli A, Fabbiocchi F, Prati F, Imola F, Valgimigli M, Ferrari R, Crea F. Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol. J Cardiovasc Med (Hagerstown). 2009 Jul;10

310. Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Intensifying Platelet Inhibition with Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective

78

Coronary Intervention: results from the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Circulation. 2009 Jun 30;119(25):3215-22.

311. Merlini PA, Valgimigli M. [The FATA study]. Giornale Italaliano Cardiology (Rome). 2009 Jun;10

312. Iijima R, Byrne RA, Dibra A, Ndrepepa G, Spaulding C, Laarman GJ,

Menichelli M, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Suttorp MJ, Violini R, Schömig A, Kastrati A. Drug-eluting stents versus bare-metal stents in diabetic patients with ST-segment elevation acute myocardial infarction: a pooled analysis of individual patient data from seven randomized trials. Rev Esp Cardiol. 2009 Apr;62(4):354-64.

313. Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A,

Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation. 2009 Jun 30;119(25):3215-22.

314. Zohlnhöfer D, Dibra A, Koppara T, de Waha A, Ripa RS, Kastrup J,

Valgimigli M, Schömig A, Kastrati A. Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor for Myocardial Recovery After Acute Myocardial Infarction: A Meta-Analysis J Am Coll Cardiol 2008;51;1429-1437.

315. Meliga E, Garcia-Garcia HM, Valgimigli M, Chieffo A, Biondi-Zoccai G,

MD, O. Maree A, MD, Cook S, MD, Reardon L, MD, Moretti C, MD, De Servi S, MD, Palacios IF, MD, FACC, Windecker S, Colombo A, van Domburg R, PHD, Sheiban I, MD, Serruys PW. Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease The DELFT (Drug Eluting stent for LeFT main) Registry. J Am Coll Cardiol 2008;51:23.

316. Chieffo A, Park SJ, Meliga E, Sheiban I, Lee MS, Latib A, Kim YH,

Valgimigli M, Sillano D, Magni V, Biondi-Zoccai G, Montorfano M, Airoldi F, Rogacka R, Carlino M, Michev I, Lee CW, Hong MK, Park SW, Moretti C, Bonizzoni E, Sangiorgi GM, Tobis J, Serruys PW, Colombo A. Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry Eur Heart J 2008;29(17):2108-2115.doi: 10.1093

79

317. Steendijk P, Meliga E, Valgimigli M, Ten Cate F J, Serruys PW. Acute effects of alcohol septal ablation on systolic and diastolic left ventricular function in patients with hypertrophic obstructive cardiomyopathy. Heart. 2008 Oct;94(10):1318-22.

318. Biondi-Zoccai G, Valgimigli M, Sheiban I, Margheri M, Marzocchi A, Prati F, Vischi M, Lettieri C, Violini R, Sardella G, Stabile A, Clementi F, Romeo F, Colombo A, Sangiorgi G. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. J Cardiovasc Med 2008;9:9.

319. Valgimigli M, Campo G, de Cesare N, Vranckx P, Hamon M, Angiolillo

D, Sabatè M, Ferrari F, Furgieri A, Tumscitz C, Repetto A, Colangelo S, Meliga E, Kubbajeh M, Parrinello G, Percoco G, Ferrari R. Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design. Cardiovasc Drugs Ther 2008;22:313–320.

320. Biondi-Zoccai GG, Lotrionte M, Moretti C, Meliga E, Agostoni P,

Valgimigli M, Migliorini A, Antoniucci D, Carrié D, Sangiorgi G, Chieffo A, Colombo A, Price MJ, Teirstein PS, Christiansen EH, Abbate A, Testa L, Gunn JP, Burzotta F, Laudito A, Trevi GP, Sheiban I. A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. Am Heart J 2008 Feb;155(2):274-83.

321. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C,

Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R; for the Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators. Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The MULTISTRATEGY Randomized Trial. JAMA. 2008 Mar 30; 299(15):1788-99.

322. Meliga E, Steendijk P, Valgimigli M, Ten Cate FJ, Serruys PW.

Cardiomyopathy on systolic and diastolic left Effects of percutaneous transluminal septal myocardial ablation for obstructive hypertrophic ventricular function assessed by pressure-volume loops. Am J Cardiol. 2008 Apr 15;101(8):1179-84.

323. De Luca G, Stone GW, Suryapranata H, Laarman GJ, Menichelli M,

Kaiser C, Valgimigli M, Di Lorenzo E, Dirksen MT, Spaulding C, Pittl U, Violini R, Percoco G, Marino P. Efficacy and safety of drug-eluting stents in ST-

80

segment elevation myocardial infarction: A meta-analysis of randomized trials. Int J Cardiol 2008 Apr 2

324. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli

M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syvänne M, Suttorp MJ, Violini R, Schömig A. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007 Nov;28(22):2706-13.

325. G. Lotrionte M, Biondi-Zoccai GG, Agostoni P, Abbate A, Angiolillo DJ,

Valgimigli M, Moretti C, Meliga E, Cuisset T, Alessi MC, Montalescot G, Collet JP, Di Sciascio G, Waksman R, Testa L, Sangiorgi G, Laudito A, Trevi GP, Sheiban I. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2007 Oct 15;100(8):1199-206.

326. Campo G, Valgimigli M, Gemmati D, Percoco G, Catozzi L, Frangione

A, Federici F, Ferrari F, Tebaldi M, Luccarelli S, Parrinello G, Ferrari R. Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism? Evidence from a Clopidogrel to Ticlopidine Crossover Study. J Am Coll Cardiol. 2007, Sep 18;50(12):1132-7.

327. Rodriguez-Granillo GA, de Winter S, Bruining1 N, Ligthart J, Garcıa-

Garcıa HM, Valgimigli M, de Feyter PJ. on behalf of the EUROPA/ PERSPECTIVE Investigators . Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study. European Heart Journal (2007) 28, 2326–2331

328. Ince H, Valgimigli M, Petzsch M, Suarez de Lezo J, Kuethe F,

Dunkelmann S, Biondi-Zoccai G, Nienaber C A. Cardiovascular events and re-stenosis following administration of G-CSF in acute myocardial infarction: systematic review and meta-analysis. Heart. 2008 May;94(5):610-6. Epub 2007 Aug 29

329. Valgimigli M, Mittmann N, Cohen DJ, Campo G, Isogai PK, Seung S J,

Dulisse B, Arcozzi C, Squasi P, Percoco G, Ferrari R. A Strategy to Offset the extra cost of Sirolimus-eluting Stent in Patients undergoing Intervention for Acute Myocardial Infarction. International Journal of Cardiology. 11 May 2007

330. Gemmati D, Federici F, Campo G, Tognazzo S, Serino ML, De Mattei M,

Valgimigli M, Malagutti P, Guardigli G, Ferraresi P, Bernardi F, Ferrari R, Scapoli GL, Catozzi L. Factor XIIIA-V34L and factor XIIIB-H95R gene variants: effects on survival in myocardial infarction patients. Mol Med. 2007 Jan-Feb;13(1-2):112-20

81

331. Chieffo A, Park SJ, Valgimigli M, Kim YH, Daemen J, Sheiban I, Truffa A, Montorfano M, Airoldi F, Sangiorgi G, Carlino M, Michev I, Lee CW, Hong MK, Park SW, Moretti C, Bonizzoni E, Rogacka R, Serruys PW, Colombo A Favorable long-term outcome after drug-eluting stent implantation in nonbifurcation lesions that involve unprotected left main coronary artery: a multicenter registry. Circulation. 2007 Jul 10;116(2):158-62.

332. Valgimigli M, Bolognese L, Anselmi M, Campo G, Rodriguez AE, de

Cesare N, Cohen DJ, Sheiban I, Colangelo S, Pasquetto G, Hamon M, Vranckx P, Ferrario M, Prati F, Agostoni P, Malagutti P, Arcozzi C, Parrinello G, Vassanelli C, Ferrari R, Percoco G. Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial. Am Heart J 2007 Jul;154(1):39-45.

333. M. Valgimigli, G. Campo, C. Arcozzi, P. Malagutti, R. Carletti, F. Ferrari,

D. Barbieri, G. Parrinello, G. Percoco, R. Ferrari Two-year Clinical Follow-up After Sirolimus-eluting Versus Bare Metal Assisted by Systematic Infusion In Patients with Acute Myocardial Infarction. Results from the Single High-Dose BoluS TiRofibAn and Sirolimus Eluting STEnt versus Abciximab and Bare Metal Stent in Acute MYocardial Infarction (STRATEGY) Study. J Am Coll Cardiol. 2007 Jul 10;50(2):138-45.

334. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Valgimigli M, Abbate A,

Sangiorgi G, Moretti C, Sheiban. Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression. American Heart Journal 2007 Apr;153(4):587-93.

335. Valgimigli M, Serruys PW, Tschucida K, Vaina S, Morel MA, van der

Brand M, Colombo A, Morice MC, Dawkins K, de Bruyne B, Kornowski R, de Servi S, Guagliumi G, Jukema JW, Mohr FW, Kappetein AP, Wittebols K, Stoll HP, Boersma E, Parrinello G. Cyphering the complexiity of coronary artery disease using the Syntax score to predict clinical outcome in patients with three vessel lumen obtruction undergoing percutaneous coronary intervention. American Journal Cardiology. 2007 Apr 15;99(8):1072-81.

336. Kastrati MA, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H,

Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfister ME, Schoemig A. Analysis of 14 trials comparing sirolimus-eluting stents versus bare-metal stents. New England Journal Med. 2007 Mar 8;356(10):1030-9

337. Valgimigli M, Chieffo A, Lefevre A, Colombo A, Morice MC, Serruys PW

on behalf of the Executive committee of the Syntax Study. Revisiting the incidence and temporal distribution of cardiac and sudden death in patients undergoing elective intervention for unprotected left main coronary artery stenosis in the drug eluting stent era. EuroIntervention, 2007 (8) 434-443.

82

338. Valgimigli M, Biondi Zoccai GG, Agostoni P. Keeping a high standard in

quantitative analysis, meta-analyses and systematic reviews. Eur Heart J 2007 Feb;28(4):516-517.

339. Valgimigli M, Dawkins K, Macaca C, de Bruyne B, Teiger E, Fajadet J,

Gert R, De Servi S, Ramando A, Wittebols K., Rademaker T, Serruys PW. Impact of Stable versus Unstable coronary artery on 1-year outcome in elective patients undergoing multivessel revascularization with sirolimus-eluting stents. J Am Coll Cardiol 2007;49:431-41.

340. Valgimigli M, Rodriguez-Granillo GA, Garcia-Garcia HM, Vaina S,

Tsuchida K, Regar E, De Jaegere P, De Feyter P, Serruys PW. Plaque Composition in the Left Main Stem Mimics the Distal but not the Proximal Tract of the Left Coronary Artery. Influence of Clinical Presentation, Length of the Left Main Trunk, Lipid Profile and Systemic Inflammatory Status. J Am Coll Cardiol 2007;49:23-31.

341. Biondi-Zoccai GG, Lotrionte M, Abbate A, Valgimigli M, Testa L, Burzotta

F, Crea F, Agostoni P. Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients. Int J Cardiol. 2007 Jan 2;114(1):104-5.

342. Hoye A, Iakovou I, Ge L, van Mieghem CA, Ong AT, Cosgrave J,

Sangiorgi GM, Airoldi F, Montorfano M, Michev I, Chieffo A, Carlino M, Corvaja N, Aoki J, Rodriguez Granillo GA, Valgimigli M, Sianos G, van der Giessen WJ, de Feyter PJ, van Domburg RT, Serruys PW, Colombo A. Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: predictors of an adverse outcome. J Am Coll Cardiol. 2006 May 16;47(10):1949-58.

343. Rodriguez-Granillo GA, Garcia-Garcia HM, Valgimigli M, Vaina S, van

Mieghem C, van Geuns RJ, van der Ent M, Regar E, de Jaegere P, van der Giessen W, de Feyter P, Serruys PW. Global characterization of coronary plaque rupture phenotype using three-vessel intravascular ultrasound radiofrequency data analysis. Eur Heart J. 2006 Aug;27(16):1921-7.

344. Van Mieghem CA, Cademartiri F, Mollet NR, Malagutti P, Valgimigli M,

Meijboom WB, Pugliese F, McFadden EP, Ligthart J, Runza G, Bruining N, Smits PC, Regar E, van der Giessen WJ, Sianos G, van Domburg R, de Jaegere P, Krestin GP, Serruys PW, de Feyter PJ. Multislice spiral computed tomography for the evaluation of stent patency after left main coronary artery stenting: a comparison with conventional coronary angiography and intravascular ultrasound. Circulation. 2006 Aug 15;114(7):645-53.

345. Campo G, Valgimigli M, Ferraresi P, Malagutti P, Baroni M, Arcozzi C,

Gemmati D, Percoco G, Parrinello G, Ferrari R, Bernardi F. Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with

83

genotype and adverse events. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2800-6.

346. Rodriguez-Granillo GA, Vaina S, Garcia-Garcia HM, Valgimigli M,

Duckers E, van Geuns RJ, Regar E, van der Giessen WJ, Bressers M, Goedhart D, Morel MA, de Feyter PJ, Serruys PW. Reproducibility of intravascular ultrasound radiofrequency data analysis: implications for design of longitudinal studies. Int J Cardiovasc Imaging 2006;22;621-631.

347. Rodriguez-Granillo GA, Garcia-Garcia HM, Valgimigli M, Schaar J,

Pawar R, van der Giessen WJ, Regar E, van der Steen AFW, de Feyter P, Serruys PW. In vivo relationship between compositional and mechanical imaging of coronary arteries: insights from intravascular ultrasound radiofrequency data analysis. Am Heart J 2006,151:1025.e6.

348. Hamon M, Biondi-Zoccai GGL, Malagutti P, Agostani PF, Morello R,

Valgimigli M, Hamon M. Diagnostic performance of multislice spiral computed tomography of coronary arteries as compared with conventional invasive coronary angiography: a meta-analysis. J Am Coll Cardiol 2006;48: 1896-1910.

349. Rodriguez-Granillo GA, McFadden EP, Valgimigli M, Van Mieghem C,

Regar E, de Feyter PJ, Serruys PW. Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radio frequency data analysis, is related to clinical presentation. Am Heart J 2006,151:1020-4.

350. Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli

G, Catozzi L, Anselmi M, Vassanelli C, Scapoli G, Ferrari R. Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention. Insights into the Single High-Dose BoluS TiRofibAn and Sirolimus Eluting STEnt versus Abciximab and Bare Metal Stent in Acute MYocardial Infarction (STRATEGY) Study. J Am Coll Cardiol 2006,48:2178-2185.

351. Valgimigli M, Malagutti P, Rodrieguez-Granillo GA, Tsuchida K, Garcia-

Garcia H, Van Mieghem C, Regar E, van der Giessen WJ, de Feyter P, de Jaegere P, Serruys PW. Single vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug eluting stent era. clinical and angiographic insights into RESEARCH and T-SEARCH registries. Am Heart J 2006,151(5):1025.

352. Valgimigli M, Campo G, Percoco G, Pellegrino L, Guardigli G, Ferrari R.

Tirofiban: a critical reapraisal of the clinical use, recent developments and future perspectives. Future cardiol 2006;2(1):17-27.

353. PC Smits, Nienaber C, Colombo A, Ince H, Carlino M, Theuns DAMJ,

Biagini E, Valgimigli M, Onderwater EEM, Steendijk P, Peters NS, Goedhart DM, Serruys PW. Myocardial repair by percutaneus cell transplantation of

84

autologous skeletal myoblast as a stand alone procedure in post myocardial infarction chronic heart failure patients. EuroIntervention 2006;(1)417-24.

354. Valgimigli M, P.Malagutti, C.A.G.van Mieghem, S.Vania, J.M.Ligthart,

G.Sianos, P.W.Serruys. Persistence of neointimal growth 12 months after intervention and occurrence of delayed restenosis in patients with left main coronary artery disease treated with drug eluting stents. J Am Coll Cardiol. 2006 Apr 4;47(7):1491-4.

355. Valgimigli M, Malagutti P, Aoki J, Garcia-Garcia H, Rodrieguez-Granillo

GA, Van Mieghem C, Ligthart JM, Ong ATL, Sianos G, Regar E, van Domburg RT, de Feyter P, de Jaegere P, Serruys PW. Sirolimus- Versus Paclitaxel-Eluting Stent Implantation for the Percutaneous Treatment of the Left Main Coronary Artery Disease. A Combined Research and T-Search Long Term Analysis. J Am Coll Cardiol, 2006 Feb 7;47(3):507-14.

356. Van Mieghem CA, McFadden EP, de Feyter PJ, Bruining N, Schaar JA,

Mollet NR, Cademartiri F, Goedhart D, de Winter S, Granillo GR, Valgimigli M, Mastik F, van der Steen AF, van der Giessen WJ, Sianos G, Backx B, Morel MA, van Es GA, Zalewski A, Serruys PW. ˚Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities: the Integrated Biomarker and Imaging Study (IBIS). J Am Coll Cardiol. 2006 Mar 21;47(6):1134-42.

357. Biagini E, Valgimigli M, Smits PC, Poldermans D, Schinkel AF, Rizzello

V, Onderwater- EE, Bountioukos M, Serruys PW. Stress and tissue Doppler echocardiographic evidence of effectiveness of myoblast transplantation in patients with ischaemic heart failure. Eur J Heart Fail. 2006 Oct;8(6):641-8.

358. Agostoni P, Valgimigli M, Biondi-Zoccai GG, Abbate A, Garcia Garcia

HM, Anselmi M, Turri M, McFadden EP, Vassanelli C, Serruys PW, Colombo A. Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era. Am Heart J 2006 Mar;151(3):682-9.

359. Steendijk P, Smits PC, Valgimigli M, van der Giessen WJ, Onderwater

EE, Serruys PW. Intramyocardial injection of skeletal myoblasts: long-term follow-up with pressure-volume loops. Nat Clin Pract Cardiovasc Med. 2006 Mar;3 Suppl 1:S94-100.

360. Biondi-Zoccai GG, Abbate A, Agostoni P, Valgimigli M, Sangiorgi GM.

Drawbacks of nonrandomized trials in acute coronary syndromes irect and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients. Am J Cardiol. 2006 Jan 1;97(1):151.

85

361. Agostoni P, Valgimigli M, Abbate A, Cosgrave J, Pilati M, Biondi-Zoccai GG. Is late luminal loss an accurate predictor of the clinical effectiveness of drug-eluting stents in the coronary arteries? Am J Cardiol. 2006 Mar 1;97(5):603-5.

362. Rodriguez-Granillo GA, Garcia-Garcia HM, Wentzel J, Valgimigli M,

Tsuchida K, van der Giessen W, de Jaegere P, Regar E, de Feyter PJ, Serruys PW. Plaque composition and its relationship with acknowledged shear stress patterns in coronary arteries. J Am Coll Cardiol. 2006 Feb 21;47(4):884-5.

363. Biondi-Zoccai GG, Lotrionte M, Abbate A, Testa L, Remigi E, Burzotta F,

Valgimigli M, Romagnoli E, Crea F, Agostoni P. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ. 2006 Jan 28;332(7535):202-9.

364. Valgimigli M, Rodriguez Granillo GA, Garcia-Garcia HM, Malagutti P,

Regar E, de Jaegere P, de Feyter PJ, Serruys PW. Distance from the ostium as an independent determinant of coronary plaque composition in vivo: an intravascular ultrasaund study based radiofrequency data analysis in humans. European Heart Journal 2006 Mar;27(6):655-63.

365. Tsuchida K, Garcia-Garcia HM, Ong AT, Valgimigli M, Aoki J,

Rademaker TA, Morel MA, van Es GA, Bruining N, Serruys PW. Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial. Cat Cardiovasc Interv. 2006 Feb;67(2):188-97.

366. Hoye A, Ong AT, Aoki J, van Mieghem, Rodriguez CA, Granillo GA,

Valgimigli M, Sianos G, McFadden EP, van der Giessen WJ, de Feyter PJ, van Domburg RT, Serruys PW. Drug-eluting stent implantation for chronic total occlusion: comparison between the Sirolimus- and Paclitaxel- eluting stent. Eurointervention 2005(1):193-97.

367. Hoye A, van Mieghem CA, Ong AT, Aoki J, Rodriguez Granillo GA,

Valgimigli M, Tsuchida K, Sianos G, McFadden EP, van der Giessen WJ, de Feyter PJ, van Domburg RT, Serruys PW. Treatment of de novo bifurcation lesion: comparison of Sirolimus- and Paclitaxel- eluting stents. Eurointervention 2005 May;1(1):24-30.

368. Rodriguez-Granillo GA, Garcia-Garcia HM, Mc Fadden EP, Valgimigli M,

Aoki J, de Feyter P, Serruys PW. In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol. 2005 Dec 6;46(11):2038-42.

369. Aoki J, Ong AT, Rodriguez Granillo GA, McFadden EP, van Mieghem CA,

Valgimigli M, Tsuchida K, Sianos G, Regar E, de Jaegere PP, van der Giessen WJ, de Feyter PJ, van Domburg RT, Serruys PW. Full metal jacket" (stented

86

length > or =64 mm) using drug-eluting stents for de novo coronary artery lesions. American Heart Journal. 2005 Nov;150(5):994-9.

370. Pedone C, Vijayakumar M, Ligthart JM, Valgimigli M, Biagini E, De Jong

N, Serruys PW, Ten Cate FJ. Intracardiac echocardiography guidance during percutaneous transluminal septal myocardial ablation in patients with obstructive hypertrophic cardiomyopathy. Int J Cardiovasc Interv 2005;7(3):134-7.

371. Rodrieguez-Granillo GA, Valgimigli M, Ong ATL, Aoki J, Van Mieghem

C, Hoye A, Tsuchida K, McFadden EP, de Feyter P, Serruys PW. Paclitaxel-Eluting Stents for the treatment of Angiographically non-significant Atherosclerotic Lesions. Int J Cardiovasc Interv 2005;7(2):68-71.

372. Rodrieguez-Granillo G.A, Valgimigli M, Garcia-Garcia H, Ong A.T.L,

Aoki J, Van Mieghem C, Tsuchida K, Sianos G, Regar E, McFadden EP, van der Giessen WJ, de Feyter P, van Domburg RT, Serruys PW. One-year clinical outcome after coronary stenting of very small vessels using 2.25 MM Sirolimus- and Paclitaxel-Eluting Stents: A Comparison between the research and T-Search Registries. J Invasive Cardiol 2005;17(8):409-12.

373. Tsuchida K, Ong ATL, Aoki J, Van Mieghem MC, Rodrieguez-Granillo

GA, Valgimigli M, Sianos G, Regar E, McFadden EP, van der Giessen WJ, de Jaegere P, de Feyter P, van Domburg RT, Serruys PW. Immediate and one-year outcome of percutaneous intervention of Saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol 2005;96(3):395-8.

374. Ong ATL, Aoki J, Van Mieghem MC, Rodrieguez-Granillo GA, Valgimigli M, Tsuchida K, Schennenschein K, Regar E, van der Giessen WJ, de Jaegere P, Sianos G, McFadden EP, de Feyter P, van Domburg RT, Serruys PW. Comparison of Short (one month) and long (twelve month) term outcomes of sirolimus versus paclitaxel eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T SEARCH registries) Am J Cardiol 2005;96(3):358-62.

375. Van Mieghem C, Bruining N, Schaar JA, McFadden EP, Mollet N,

Cademartiri F, Mastik F, Ligthart JM, Rodrieguez-Granillo GA, Valgimigli M, Sianos G, J. Van der Giessen W, Backx B, Morel MA, Es GA, Sawyer J.D, Kaplow J, Zalewski A, Steen AF, de Feyter P, Serruys PW. Rationale and methods of the integrated biomarker and imaging study (IBIS): combining invasive and non invasive imaging with biomarkers to detect subclinical atherosclerosis imaging with biomarkers to detect subclinical atherosclerosis and assess coronary lesion biology. Int J Cardiovasc Imaging 2005;21(4)425-41.

376. Rodrieguez-Granillo GA, Aoki J, Ong AT, Valgimigli M, Van Mieghem

MC, Regar E, McFadden EP, de Feyter P, Serruys PW. Methodological

87

Considerations And Approach To Cross-Technique Comparisons Using In Vivo Coronary Plaque Characterization Based On Intravascular Ultrasound Radiofrequency Data Analysis: Insights From The Integrated Biomarker And Imaging Study (Ibis). Int J Cardiovasc Intervent 2005;7(1):52-8.

377. Hoye A, Van Mieghem C, Ong ATL, Aoki J, Rodrieguez-Granillo GA,

Valgimigli M, Tsuchida K, Sianos G, McFadden E, van der Giessen WJ, de Feyter PJ, van Domburg RT, Serruys PW. Percutaneous Therapy Of Bifurcation Lesions With Drug-Eluting Stent Implantation: The Culotte Technique Revisited. Int J Cardiovasc Interv 2005;7(1):36-40.

378. Rodrieguez-Granillo GA, Serruys PW, Garcia-Garcia HM, Valgimigli M,

Van Mieghem C, McFadden EP, de Jaegere PP, de Feyter P, Coronary Artery Remodelling Is Related To Plaque Composition. Heart. 2006 Mar;92(3):388-91.

379. Hofma SH, Ong ATL, Aoki J, Van Mieghem MC, Rodrieguez-Granillo GA,

Valgimigli M, Regar E, de Jaegere PP, McFadden EP, Sianos G, van der Giessen WJ, de Feyter P, van Domburg RT, Serruys PW. One Year Clinical Follow-Up Of Paclitaxel- Eluting Stents For Acute Myocardial Infarction Compared To Sirolimus-Eluting Stents. Heart. 2005 Sep;91(9):1176-80.

380. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri

Cicchitelli G. D, McFadden E, Merlini F, Ansani L, Guardagli G, Bettini A, Parrinello G, Boersma E, Ferrari R. for the STRATEGY Investigators. Tirofiban And Sirolimus Eluting Stent Vs Abciximab And Bare Metal Stent For Acute Myocardial Infarction: A Randomized Trial. JAMA 2005; 293(17):2109-17.

381. Valgimigli M, Rigolin GM, Cittanti C, Malagutti P, Curello S, Percoco GF,

Bugli AM, Porta MD, Bragotti LZ, Ansani L, Mauro E, Lanfranchi A, Giganti M, Feggi L, Castoldi GL, Ferrari R. Use Of Granulocyte Colony Stimulating Factor During Acute Myocardial Infaction To Enhance Bone Marrow Stem Cell Mobilization In Humans: Clinical And Angiographic Safety Profile. Eur Heart J 2005 Sep;26(18):1838-45.

382. Agostoni F, Valgimigli M, Van Mieghem CA, Rodrieguez-Granillo GA,

Aoki J, Ong AT, Tsuchida K, McFadden EP, de Feyter P, Smits PC, Regar E, van der Giessen WJ, Sianos G, de Jaegere P, van Domburg RT, Serruys PW. Comparison Of Early Outcome Of Percutaneous Coronary Intervention For Unprotected Left Main Coronary Artery Disease In The Drug Eluting Stent Era With Versus Without Intravascular Ultrasonic Guidance. Am J Cardiol 2005;95(5):644-647.

383. Ong ATL, Serruys PW, Aoki J, Hoye A, Van Mieghem MC, Rodrieguez-

Granillo GA, Valgimigli M, Schennenschein K, Regar E, de Jaegere P, de Feyter P, McFadden EP, Sianos G, van der Giessen WJ, van Domburg RT. The Unrestricted Use Of Paclitaxel- Versus Sirolimus- Eluting Stents For Coornary Artery Disease In An Unselected Population. One Year Results Of The Taxus-

88

Stent Evaluated At Rotterdam Cardiology Hospital (T-Search) Registry. J Am Coll Cardiol 2005;45:1135-1141.

384. Valgimigli M, Van Mieghem C, Ong ATL, Aoki J, Rofrieguez-Granillo GA,

McFadden EP, Kappetein AP, de Feyter P, Smits PC, Regar E, van der Giessen WJ, Sianos G, de Jaegere P, van Domburg RT, Serruys PW. Short And Long Term Clinical Outcome After Drug-Eluting Stent Implantation For The Percutaneous Treatment Of The Left Main Coronary Artery Disease. Insights From The Rapamycin Eluting- And Taxus- Stent Evaluated At Rotterdam Cardiology Hospital Registries (Research And T-Search). Circulation 2005;111:1383-1389.

385. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O,

Francolini G, Cicchitelli G, Olivares A, Parrinello G, Guardigli G, Mele D, Pirani R, Percoco G, Ferrari R. for the Cytokine-Activation and long-term prognosis in Myocardial Infarction (C-ALPHA) Study Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation 2005;111:1209-1212.

386. Valgimigli M, Rigolin GM, Fucili A, Della Porta M, Soukhomoskaia O,

Malagutti P, Bugli AM, Zenone Bragotti L, Francolini G, Mauro E, Castoldi GL, Ferrari R. CD34+ And Endothelial Progenitor Cells In Patients With Various Degrees Of Congestive Heart Failure. Circulation 2004;101:1209-1212.

387. Valgimigli M, Percoco G, Cicchitelli G, Barbieri D, Ferrari F, Ansani L,

Guardigli G, Parrinello G, Soukhomoskaia O, Ferrari R. The Additive Value Of Tirofiban Administered With High-Dose Bolus In The Prevention Of Ischemic Complications During High-Risk Coronary Angioplasty. The Advance Trial. J Am Coll Cardiol 2004;44 (1):14-19.

388. Valgimigli M, Percoco G, Cicchitelli G, Ferrari F, Barbieri D, Ansani L,

Guardagli G, Parrinello G, Malagutti P, Soukhomoskaia O, Bettini A, Campo G, Ferrari R. High Dose Bolus Tirofiban And Sirolimus Eluting Stents Versus Abciximab And Bare Metal Stent In Acute Myocardial Infarction (Statregy). Study Protocol Desing And Demography Of The First 100 Patients. Cardiovasc Drugs Ther 2004;18(3):225-30.

389. Valgimigli M, Merli E, Malagutti P, Soukhomoskaia O, Cicchitelli G,

Antelli GA, Canistro D, Francolini G, Macrì G, Matrorilli F, Paolini M, Ferrari R. Hydroxyl radical generation, levels of tumor necrosis factor-alpha and progression to heart failure after acute myocardial infarction. J Am Coll Cardiol 2004;43(11):2000-8.

390. Valgimigli M, Agnoletti L, Curello S, Comini L, Francolini G, Mastrorilli F,

Merli E, Pirani R, Guardagli G, Grigolato PG, Ferrari R. Serum from patients with

89

acute coronary syndromes displays a proapoptotic effect on human endothelial cells. A possible link to pan-coronary syndromes. Circulation 2003;107:264-270.

391. Valgimigli M, Merli E, Mastrorilli F, Soukhomovskaia O, Malagutti P, Macrì G. Quale Futuro per il Trattamento dello scompenso cardiaco? La Cardiologia nella pratica clinica 2002;9:224-236.

392. Valgimigli M, Valgimigli L, Trerè D, Gaiani S, Pedulli GF, Gramantieri L,

Bolondi L. Oxidative stress EPR-measurement in human liver by radical-probe technique. Correlation with etiology, histology, and cell proliferation. Free Radic Res,2002;36:939-948.

393. Battelli MG, Musiani S, Valgimigli M, Gramantieri L, Tommassoni F,

Bolondi L, Stirpe F. Serum Xanthine Oxidoreductase in Human Liver Disease Am J Gastroenterol 2001;96:1194-9.

394. Piscaglia F, Valgimigli M, Rapezzi C, Ferlito M, Gaiani S, Siringo S,

Gramantieri L, Bolondi L. Left ventricular volumes in liver cirrhosis. Dig Liver Dis 2000;32:392-7.

395. Valgimigli L, Valgimigli M, Gaiani S, Peduli GF, Bolondi L. Measurement of oxidative stress in human liver by EPR spin-probe technique. Free Radic Res 2000;33:167-78.

396. Piscaglia F, Siringo S, Hermida RC, Legnani C, Valgimigli M, Donati G,

Palareti G, Gramantieri L, Gaiani S, Burroughs AK, Bolondi L. Diurnal changes of fibrynolisis in patients with liver cirrhosis and sophage al varices. Hepatology 2000;31:349-57.

397. Gramantieri L, Chieco P, Di Tommaso M, Masi L, Piscaglia F, Brillanti S,

Valgimigli M, Mazziotti A., Bolondi L. Aberrant FHIT transcripts in primary hepatocellular carcinoma and liver cirrhosis. Clin Cancer Res 1999;5:3468-75.

398. Piscaglia F, Zironi G, Gaiani S, Mazziotti A, Cavallari A, Gramantieri L,

Valgimigli M., Bolondi L. Systemic and Splanchnic Hemodynamic changes after liver translpantation for cirrhosis: a long term prospective study. Hepatology 1999,30:58-64.

7.2.2 Review Articles

1. Mitsis A, Valgimigli M. Device profile of the XIENCE V and XIENCE Sierra stents for the treatment of coronary artery disease: an overview of safety and efficacy. Expert Rev Med Devices. 2020 May;17(5):383-390. doi: 10.1080/17434440.2020.1747434. Epub 2020 Apr 10. PubMed PMID: 32274941.

90

2. Mitsis A, Spirito A, Valgimigli M. Complete revascularisation in STEMI:

consider the benefits but do not forget the risks! Ann Transl Med. 2019 Dec;7(Suppl 8):S331. doi: 10.21037/atm.2019.09.121. PubMed PMID: 32016049; PubMed Central PMCID: PMC6976442.

3. Gragnano F, Manavifar N, Valgimigli M. A call for action in bleeding prevention. Aging (Albany NY). 2019 Jan 11. doi: 10.18632/aging.101745.

4. Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA

Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison. J Am Coll Cardiol. 2018 Dec 11;72(23 Pt A):2915-2931. doi: 10.1016/j.jacc.2018.09.057.

5. Costa F, Valgimigli M. The optimal duration of dual antiplatelet therapy after

coronary stent implantation: to go too far is as bad as to fall short. Cardiovasc Diagn Ther. 2018 Oct;8(5):630-646. doi: 10.21037/cdt.2018.10.01.

6. Capodanno D, Mehran R, Valgimigli M, Baber U, Windecker S, Vranckx P,

Dangas G, Rollini F, Kimura T, Collet JP, Gibson CM, Steg PG, Lopes RD, Gwon HC, Storey RF, Franchi F, Bhatt DL, Serruys PW, Angiolillo DJ. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol. 2018 Aug;15(8):480-496. doi: 10.1038/s41569-018-0049-1.

7. Vranckx P, Valgimigli M, Heidbuchel H. The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. Arrhythm Electrophysiol Rev. 2018 Mar;7(1):55-61. doi: 10.15420/aer.2017.50.1.

8. Gaudino M, Burzotta F, Bakaeen F, Bertrand O, Crea F, Di Franco A, Fremes S, Kiemeneij F, Louvard Y, Rao SV, Schwann TA, Tatoulis J, Tranbaugh RF, Trani C, Valgimigli M, Vranckx P, Taggart DP; The Radial Artery for Percutaneous Coronary Procedures or Surgery? Arterial Grafting International Consortium Alliance. J Am Coll Cardiol. 2018 Mar 13;71(10):1167-1175. doi: 10.1016/j.jacc. 2018.01.013.

9. Vranckx P, Windecker S, Welsh RC, Valgimigli M, Mehran R, Dangas G. Thrombo-embolic prevention after transcatheter aortic valve implantation. Eur Heart J. 2017 Jul 25. doi: 10.1093/eurheartj/ehx390.

10. Costa F, Windecker S, Valgimigli M. Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. Drugs. 2017 Oct;77(16):1733-1754. doi: 10.1007/s40265-017-0806-1.

11. Gargiulo G, Valgimigli M, Capodanno D, Bittl JA. State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives. EuroIntervention. 2017 Aug 25;13(6):717-733. doi: 10.4244/EIJ-D-17-00468.

91

12. Ariotti S, Gargiulo G, Valgimigli M. Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. Curr Cardiol Rep. 2017 Jan;19(1):2

13. Gargiulo G, Windecker S, Vranckx P, Gibson CM, Mehran R, Valgimigli M. A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More? Circulation. 2016 Dec 6;134(23):1881-1906

14. Gargiulo G, Valgimigli M. Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. G Ital Cardiol (Rome). 2016 Jun;17(6):4-10

15. Andò G, Costa F, Trio O, Oreto G, Valgimigli M. Impact of vascular access on acute kidney injury after percutaneous coronary intervention. Cardiovasc Revasc Med. 2016 Jul-Aug;17(5):333-8

16. Santucci A, Gargiulo G, Ariotti S, Marino M, Magnani G, Baldo A, Piccolo R, Franzone A, Valgimigli M. Radial versus femoral approach in STEMI: what do we know so far? Minerva Cardioangiol. 2016 Jun;64(3):219-37

17. Gargiulo G, Moschovitis A, Windecker S, Valgimigli M. Developing drugs for use before, during and soon after percutaneous coronary intervention. Expert Opin Pharmacother. 2016;17(6):803-18

18. Gargiulo G, Collet JP, Valgimigli M. Antithrombotic therapy in TAVI patients: changing concepts. EuroIntervention. 2015 Sep;11 Suppl W:W92-5

19. Costa F, Ariotti S, Valgimigli M, Kolh P, Windecker S; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization: Fifty Years of Revascularization: Where Are We and Where Are We Heading? J Cardiovasc Transl Res. 2015 May 19.

20. Felix C, Everaert B, Diletti R, Van Mieghem N, Daemen J, Valgimigli M, de Jaegere PP, Zijlstra F, Regar E, Simsek C, Onuma Y, van Geuns RJ. Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. Neth Heart J. 2015 Mar;23(3):153-60. doi: 10.1007/s12471-015-0652-2

21. Cortese B, Sebik R, Valgimigli M. The conundrum of antithrombotic drugs before, during and after primary PCI. EuroIntervention. 2014 Aug;10 Suppl T:T64-73. doi: 10.4244/EIJV10STA11.

22. Romaguera R, Brugaletta S, Gomez-Lara J, Pinar E, Jiménez-Quevedo P, Gracida M, Roura G, Ferreiro JL, Teruel L, Gómez-Hospital JA, Montanya E, Alfonso F, Valgimigli M, Sabate M, Cequier A. Rationale and study design of the RESERVOIR trial: A randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable

92

polymer in patients with diabetes mellitus. Cat Cardiovasc Interv. 2014 Nov 7. doi: 10.1002/ccd.25728.

23. Valgimigli M. Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified. Circulation. 2014 Nov 18;130(21):1891-903; discussion 1903. doi: 10.1161/CIRCULATIONAHA.114.011319. R

24. Huber K, Bates ER, Valgimigli M, Wallentin L, Kristensen SD, Anderson JL, Lopez Sendon JL, Tubaro M, Granger CB, Bode C, Ohman EM, Steg PG. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? Am Heart J. 2014 Nov;168(5):611-21. doi: 10.1016/j.ahj.2014.06.014.

25. Wallentin L, Kristensen SD, Anderson JL, Tubaro M, Sendon JL, Granger CB, Bode C, Huber K, Bates ER, Valgimigli M, Steg PG, Ohman EM. How can we optimize the processes of care for acute coronary syndromes to improve outcomes? Am Heart J. 2014 Nov;168(5):622-31. doi: 10.1016/j.ahj.2014.07.006.

26. Valgimigli M, Biscaglia S. Stable angina pectoris. Curr Atheroscler Rep. 2014 Jul;16(7):422. doi: 10.1007/s11883-014-0422-4.

27. Rodriguez-Granillo GA, Rodriguez AE, Bruining N, Milei J, Aoki J, Tsuchida K, del Valle-Fernández R, Arampatzis CA, Ong AT, Lemos PA, Ayala F, Garcia-Garcia HM, Saia F, Valgimigli M, Regar E, McFadden E, Biondi-Zoccai G, Barbenza E, Schoenhagen P, Serruys PW. Quantification of scientific output in cardiovascular medicine: a perspective based on global data. EuroIntervention. 2013 Dec;9(8):975-8. doi: 10.4244/EIJV9I8A163.

28. Valgimigli M. Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests. J Cardiovasc Med (Hagerstown). 2013 Dec;14 Suppl 1:S8-S15. doi:10.2459/JCM.0b013e328364bd25.

29. Fileti L, Campo G, Valgimigli M. Latest clinical data on testing for high on-treatment platelet reactivity. Rev Cardiovasc Med. 2011;12 Suppl 1:S14-22.

30. Musumecia G, Di Lorenzo E, Valgimigli M. Dual antiplatelet therapy duration: what are the drivers? Current Opinion Cardiology. 2011 Dec;26 Suppl 1:S4-14.

31. Valgimigli M, Minarelli M. Triple antiplatelet therapy in acute coronary syndromes. Drugs. 2011 Sep 10;71(13):1703-19.

32. Valgimigli, M. Clinical dilemmas on managing antiplatelet therapies after percutaneous coronary intervention: benefits versus risks. Current Opinion Cardiology. 2011 Dec;26 Suppl 1.

93

33. Vranckx P, Valgimigli M, Serruys P. Looking back into the future: desirudin in acute coronary syndromes and coronary stenting. EuroIntervention. 2011 Jun;7(2):263-9. doi: 10.4244

34. Campo G, Miccoli M, Tebaldi M, Marchesini J, Fileti L, Monti M, Valgimigli M,

Ferrari R. Genetic determinants of on-clopidogrel high platelet reactivity. Platelets. 2011;22(6):399-407.

35. Fileti L, Campo G, Valgimigli M, Marchesini J, Ferrari R. Current options to

manage clopidogrel poor responsiveness. G Ital Cardiol (Rome). 2010 Dec;11(12):881-9.

36. Testa L, Biondi Zoccai GG, Valgimigli M, Latini RA, Pizzocri S, Lanotte S,

Laudisa ML, Brambilla N, Ward MR, Figtree GA, Bedogni F, Bhindi R. Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents. Advances in Hematology. 2010;2010:595934. Epub 2010 Dec 5.

37. Valgimigli M, Minarelli M. Antiplatelet and antithrombotic treatment after primary

percutaneous coronary intervention: balancing safety and efficacy. American Heart Journal 2010 Dec;160(6 Suppl):S36-41

38. Valgimigli M, De Servi S. I nuovi atitrombotici possano influenzare la vostra pratica interventistica? G Ital Cardiol 2010;11(1Suppl 2).

39. Valgimigli M, Tebaldi M. Safety Evaluation of Tirofiban. Expert Opinion Drug

Safety 2010 Sep;9(5):801-19.PMID: 20670206.

40. Testa L, Bhindi R, Van Gaal WJ, Latini RA, Pizzocri S, Lanotte S, Biondi Zoccai GG, Valgimigli M, Laudisa ML, Brambilla N, Banning AP, Bedogni F. What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. QJM. 2010 Jun;103(6):367-77.

41. Campo G, Fileti L, Valgimigli M, Tebaldi M, Cangiano E, Cavazza C, Marchesini

J, Ferrari R. Poor response to clopidogrel: Current and Future Options For its Management. The Journal of Thrombosis and Thrombolysis. 2010 Oct;30(3):319-31.

42. Valgimigli M, DE SERVI S. I Nuovi Antitrombotici Possono Influenzare La

Vostra Pratica Interventistica? Giornale Italiano Di Cardiologia 2010 Feb; 11:1 n. 2.

43. Leone AM, Valgimigli M, Giannico MB, Zaccone V, Perfetti M, D'Amario D,

Rebuzzi AG, Crea F. From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells. Eur Heart J 2009 Apr;30(8):890-9.

94

44. Van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100.

45. M. Valgimigli, P.Agostoni, PW.Serruys. Acute coronary syndrome: enphasis

shift from treatment to prevention. The enduring challenge of vulnerable plaque detection in the cardiac catheterization laboratory. J Cardiovasc Med (Hagerstown). 2007 Apr;8(4):221-9.

46. Valgimigli M, Squasi PA, Gaitani S, Arcozzi C, Martano S, Ferrari R. Markers

of coronary damage. From diagnosis to prognosis. Recenti Prog Med. 2005 Nov;96(11):566-72. Italian.

47. Valgimigli M, Percoco GF, Cicchitelli G, Campo G, Gardini E, Pellegrino L,

Malagutti P, Giretti C, Ferrari R. New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios. Eur Heart J 2005 Oct;7:K31-K35 Suppl.

48. Malagutti P, Valgimigli M, de Feyter PJ. EuroPCR highlights 2005.

EuroIntervention, 2005 Sep; 2

49. Valgimigli M, Merli E, Malagutti P, Soukhomoskaia O, Cicchitelli G, Macrì G, Ferrari R. Endothelial Dysfunction in acute and chronic coronary syndromes. Evidence for a pathogenetic role of oxidative stress. Archieves in Biochemistry and Biophysics. 2003;420(2):255-261.

50. Ferrari R, Guardigli G, Mele D, Valgimigli M, Ceconi C. Myocardial ischaemia: new evidence for angiotensin-converting enzyme inhibition Eur Heart J. 2003 Jul;5:E11-E17 Suppl.

51. Valgimigli M, Ferrari R, Masson S, Latini R. Advanced Heart Failure. Tumor

Necrosis Factor-alfa and endothelin I antagonisms in humans: two promises still to be taken. Ital Heart J 2002;3(8):793-803 Suppl.

52. Ferrara R, Mastrorilli F, Pasanisi G, Censi S, D’Aiello N, Fucili A, Valgimigli M,

Ferrari R. Neurohormonal modulation in chronic heart failure. Eur Heart J. Suppl. 2002;4:D3-D11.

53. Ferrari R, Valgimigli M. Quanto si estende la finestra terapeutica nell’infarto miocardico trattato con trombolisi. Conoscere e curare il Cuore 2002:139-144.

54. Ferrari R, Guardigli G, Cicchitelli G, Valgimigli M, Merli E, Soukhomoiaskaia O,

Ceconi C. Angiotensin II overproduction: enemy of the vessel wall. Eur Heart J. 2002;4 (Suppl A):A26-A30.

55. Valgimigli M, Ferrari R. Myocardial Regeneration Through Stem cells. The new

frontier. www.guidant.com/hf-contakt/vol-13/stem.htm

95

56. Agnoletti L, Curello S, Malacarne F, Airo P, Cargnoni A, Valgimigli M, Ferrari R. Immune activation in severe heart failure. Does etiology play a role? Eur Heart J. 2004;6(Suppl F):F22-F29.

57. Valgimigli M, Curello S, Ceconi C, Agnoletti L, Comini L, Bachetti T, E. Merli R.

Ferrari Neurohormones, Cytokines and Programmed cell death in heart failure. A new paradigm for the remodeling heart. Cardiovasc Drugs Ther.2001 Nov;15(6):529-37.

58. Ferrari R, Guardigli G, Cicchitelli G, Valgimigli M, Soukhomovskaia O, Ceconi

C. Cardioprotection with ACE inhibitors: non-angiotensin II-related mechanisms. Eur Heart J 2000;2(Suppl I):I22-I28.

7.2.2 Guidelines and Consensus Articles

1. Bernat I, Aminian A, Pancholy S, Mamas M, Gaudino M, Nolan J, Gilchrist IC, Saito S, Hahalis GN, Ziakas A, Louvard Y, Montalescot G, Sgueglia GA, van Leeuwen MAH, Babunashvili AM, Valgimigli M, Rao SV, Bertrand OF; RAO International Group. Best Practices for the Prevention of Radial Artery Occlusion After Transradial Diagnostic Angiography and Intervention: An International Consensus Paper. JACC Cardiovasc Interv. 2019 Nov 25;12(22):2235-2246. doi: 10.1016/j.jcin.2019.07.043. Review. PubMed PMID: 31753298.

2. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C,

Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019 Aug 31. pii: ehz425. doi: 10.1093/eurheartj/ehz425. [Epub ahead of print].

3. Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong YH, Mehran R, Moliterno DJ, Neumann FJ, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF, Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo DJ. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2019 Jun 10. pii: S1936-8798(19)30831-3. doi: 10.1016/j.jcin.2019.03.034. [Epub ahead of print] Review

4. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC.

96

Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation. 2019 Jul 16;140(3):240-261. doi: 10.1161/ CIRCULATIONAHA. 119.040167. Epub 2019 May 22.

5. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019 May 22. pii: ehz372. doi: 10.1093/eurheartj/ehz372. [Epub ahead of print]

6. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium for High Bleeding Risk. Circulation. 2019 May 22. doi: 10.1161/ CIRCULATIONAHA. 119.040167. [Epub ahead of print]

7. Valgimigli M, Garcia Garcia H, Vrijens B, Vranckx P, McFadden EP, Costa F, Pieper K, Vock DM, Zhang M, Van Es GA, Tricoci P, Baber U, Steg G, Montalescot G, Angiolillo DJ, Serruys PW, Farb A, Windecker S, Kastrati A, Colombo A, Feres F, Jüni P, Stone GW, Bhatt DL, Mehran R, Tijssen JGP. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC).Eur Heart J. 2018 Jul 9. doi: 10.1093/eurheartj/ehy377

8. Rossini R, Tarantini G, Musumeci G, Masiero G, Barbato E, Calabrò P,

Capodanno D, Leonardi S, Lettino M, Limbruno U, Menozzi A, Marchese UOA, Saia F, Valgimigli M, Ageno W, Falanga A, Corcione A, Locatelli A, Montorsi M, Piazza D, Stella A, Bozzani A, Parolari A, Carone R, Angiolillo DJ; Italian Society of Interventional Cardiology (SICI-GISE); Italian Society for the Study of Haemostasis and Thrombosis (SISET); Italian Society of Anesthesia and Intensive Care Medicine (SIAARTI); Italian Society of Surgery (SIC); Italian Society for Cardiac Surgery (SICCH); Italian Society of Vascular and Endovascular Surgery (SICVE); Italian Society of Urology (SIU); Italian Orthopaedic Society (SIOT); Italian Society of Thoracic Surgeons (SICT); Italian Federation of Scientific Societies of Digestive System Diseases (FISMAD); Italian Society of Digestive Endoscopy (SIED); Italian Association of Hospital Gastroenterology and Digestive Endoscopy (AIGO); Italian Association of Gastroenterology and Digestive Endoscopy (SIGE); Italian Society of Maxillofacial

97

Surgery (SICMF); Italian Society of Reconstructive Plastic Surgery and Aesthetics (SICPRE); Italian Society of Gynecology and Obstetrics (SIGO); Italian Society of Neurosurgery (SINch); Italian Association of Hospital Pulmonologist (AIPO); Italian Society of Periodontology (SIdP); Italian Society of Ophthalmology (SOI); Italian Association of Hospital Otorhinolaryngologist (AOOI); Italian Association of Hospital Surgeons (ACOI); Association of Obstetricians Gynecologists Italian Hospital (AOGOI). A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 JACC Cardiovasc Interv. 2018 Mar 12;11(5):417-434. doi: 10.1016/j.jcin.2017.10.051. Review

9. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD;

ESC Scientific Document Group. Reviewer Valgimigli M. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2018 Aug 25. doi: 10.1093/eurheartj/ehy462. Reviewer

10. Pristipino C, Sievert H, D'Ascenzo F, Mas JL, Meier B, Scacciatella P, Hildick-

Smith D, Gaita F, Toni D, Kyrle P, Thomson J, Derumeaux G, Onorato E, Sibbing D, Germonpré P, Berti S, Chessa M, Bedogni F, Dudek D, Hornung M, Zamorano J; European Association of Percutaneous Cardiovascular Interventions (EAPCI); European Stroke Organisation (ESO); European Heart Rhythm Association (EHRA); European Association for Cardiovascular Imaging (EACVI); Association for European Paediatric and Congenital Cardiology (AEPC); ESC Working group on GUCH; ESC Working group on Thrombosis; European Haematological Society (EHA); European Underwater and Baromedical Society (EUBS). European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. EuroIntervention. 2018 Aug 25. pii: EIJ-D-18-00622. doi: 10.4244/EIJ-D-18-00622.

11. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau

D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF, Valgimigli M, Huber K; ESC Scientific Document Group 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2018 Jul 21.

12. Pristipino C, Sievert H, D'Ascenzo F, Louis Mas J, Meier B, Scacciatella P, Hildick-

Smith D, Gaita F, Toni D, Kyrle P, Thomson J, Derumeaux G, Onorato E, Sibbing D, Germonpré P, Berti S, Chessa M, Bedogni F, Dudek D, Hornung M, Zamorano J; Evidence Synthesis Team; Eapci Scientific Documents and Initiatives

98

Committee; International Experts. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J. 2018 Oct 25. doi: 10.1093/eurheartj/ehy649.

13. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio

ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Kardiol Pol. 2018;76(2):229-313. doi: 10.5603/KP. 2018.0041

14. Valgimigli M.'Ten Commandments' of the 2017 ESC DAPT focused update

Guidelines. Eur Heart J. 2018 Jan 14;39(3):186. doi: 10.1093/eurheartj/ehy007. 15. Valgimigli M. The ESC DAPT Guidelines 2017. Eur Heart J. 2018 Jan

14;39(3):187-188. doi: 10.1093/eurheartj/ehx768. 16. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P,

Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL. Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Rev Esp Cardiol (Engl Ed). 2018 Jan;71(1):42. doi: 10.1016/j.rec. 2017.11.020. English, Spanish. No abstract available. Erratum in: Rev Esp Cardiol (Engl Ed). 2018 Apr 11;

17. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P,

Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Peticevic M, Roffi M, Steg PG, Windecker S, Zamorano JL. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Kardiol Pol. 2017;75 (12):1217-1299. doi: 10.5603/KP.2017.0224

18. Ibánez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio

ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed). 2017 Dec;70(12):1082. doi: 10.1016/j.rec.2017.11.010. English, Spanish.

19. Collet JP, Roffi M, Byrne RA, Costa F, Valgimigli M; Task Force for the

Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) ; ESC Scientific Document Group ; Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) . Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. Eur Heart J. 2018 Jan 14;39(3):e1-e33. doi: 10.1093/eurheartj/ehx503.

99

20. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, Gurbel PA, Hochholzer W, De Luca L, Bonello L, Aradi D, Cuisset T, Tantry US, Wang TY, Valgimigli M, Waksman R, Mehran R, Montalescot G, Franchi F, Price MJ. International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies. Circulation. 2017 Nov 14;136(20): 1955-1975.doi:10.1161/CIRCULATIONAHA.117.031164. Epub 2017 Oct 30.

21. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P,

Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. ESC Scientific Document Group. Eur J Cardiothorac Surg. 2018 Jan 1;53(1):34-78. doi: 10.1093/ejcts/ezx334.

22. Jeppsson A, Petricevic M, Kolh P, Valgimigli M. 2017 European Society of

Cardiology (ESC) focused update on dual antiplatelet therapy in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2018 Jan 1;53(1):3-4. doi: 10.1093/ejcts/ezx333.

23. Damluji AA, Nelson DW, Valgimigli M, Windecker S, Byrne RA, Cohen F, Patel

T, Brilakis ES, Banerjee S, Mayol J, Cantor WJ, Alfonso CE, Rao SV, Moscucci M, Cohen MG. Transfemoral Approach for Coronary Angiography and Intervention: A Collaboration of International Cardiovascular Societies.JACC Cardiovasc Interv. 2017 Nov 27;10(22):2269-2279. doi: 10.1016/j.jcin. 2017.08.035.

24. Collet JP, Roffi M, Byrne RA, Costa F, Valgimigli M; Task Force for the

Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC); ESC Scientific Document Group; Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC). Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease: The Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017 Aug 26. doi: 10.1093/eurheartj/ehx503.

25. International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting

Therapies. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, Gurbel PA, Hochholzer W, De Luca L, Bonello L, Aradi D, Cuisset T, Tantry US, Wang TY, Valgimigli M, Waksman R, Mehran R, Montalescot G, Franchi F, Price MJ. Circulation. 2017 Nov 14;136(20):1955-1975. doi: 10.1161/CIRCULATIONAHA.117.031164.

26. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P,

Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M,

100

Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2017 Aug 26. doi: 10.1093/ejcts/ezx334.

27. Jeppsson A, Petricevic M, Kolh P, Valgimigli M. 2017 European Society of

Cardiology (ESC) focused update on dual antiplatelet therapy in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2017 Sep 26. doi: 10.1093/ejcts/ezx333.

28. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P,

Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017 Aug 26. doi: 10.1093/eurheartj/ehx419.

29. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio

ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017 Aug 26.

30. Adamo M, Bonmassari R, Bernardi G, Colombo P, Esposito G, Ferlini M, La

Manna AG, Limbruno U, Marchese A, Mauro C, Menozzi A, Nicosia A, Rigattieri S, Tarantini G, Tarantino F, Valgimigli M, Varbella F, Musumeci G. Bioequivalence and excipients: the case of tirofiban. A warning from the Italian Society of Interventional Cardiology (SICI-GISE). G Ital Cardiol (Rome). 2017 Feb;18(2 Suppl 1):35S-36S.

31. Roffi M, Müller C, Valgimigli M, Windecker S, Gencer B. [Highlights from the 2015

ESC NSTE-ACS Guidelines]. Rev Med Suisse. 2016 May 25;12(520):1014-9 32. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger

MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol Ç, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip GY,

101

Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis Zamorano J; Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315

33. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger

MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S. 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Rev Esp Cardiol (Engl Ed). 2015 Dec;68(12):1125

34. Collet JP, Roffi M, Mueller C, Valgimigli M, Patrono C, Baumgartner H,

Gaemperli O, Zamorano JL. Questions and answers on antithrombotic therapy: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation†. Eur Heart J. 2015 Aug 29

35. Mueller C, Patrono C, Valgimigli M, Collet JP, Roffi M. Questions and answers

on diagnosis and risk assessment: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation†. Eur Heart J. 2015 Aug 29

36. Valgimigli M, Patrono C, Collet JP, Mueller C, Roffi M; Authors. Questions and

answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2015 Aug 29

37. Barbato E, Carrié D, Dardas P, Fajadet J, Gaul G, Haude M, Khashaba A, Koch

K, Meyer-Gessner M, Palazuelos J, Reczuch K, Ribichini FL, Sharma S, Sipötz J, Sjögren I, Suetsch G, Szabó G, Valdés-Chávarri M, Vaquerizo B, Wijns W, Windecker S, de Belder A, Valgimigli M, Byrne RA, Colombo A, Di Mario C, Latib A, Hamm C. European expert consensus on rotational atherectomy. EuroIntervention. 2015 May 19;11(1):30-6. doi: 10.4244/EIJV11I1A6.

38. Capodanno D, Lip GY, Windecker S, Huber K, Kirchhof P, Boriani G, Lane D,

Gilard M, Collet JP, Valgimigli M, Byrne RA. Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. EuroIntervention. 2015 Jan 22;10(9):1015-21. doi: 10.4244/EIJV10I9A174.

39. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer

J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A,

102

Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A; Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278.

40. Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm

C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol Ç, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; EACTS Clinical Guidelines Committee, Sousa Uva M, Achenbach S, Pepper J, Anyanwu A, Badimon L, Bauersachs J, Baumbach A, Beygui F, Bonaros N, De Carlo M, Deaton C, Dobrev D, Dunning J, Eeckhout E, Gielen S, Hasdai D, Kirchhof P, Luckraz H, Mahrholdt H, Montalescot G, Paparella D, Rastan AJ, Sanmartin M, Sergeant P, Silber S, Tamargo J, ten Berg J, Thiele H, van Geuns RJ, Wagner HO, Wassmann S, Wendler O, Zamorano JL. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014 Oct;46(4):517-92. doi: 10.1093/ejcts/ezu366.

41. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm

C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Uva MS, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization. Rev Esp Cardiol (Engl Ed). 2015 Feb;68(2):144.

42. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm

C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2015 Jan;10(9):1024-94. doi: 10.4244/EIJY14M09_01.

43. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG,

Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D; Document Reviewers, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL. Management of antithrombotic therapy in atrial fibrillation patients

103

presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014 Dec 1;35(45):3155-79. doi: 10.1093/ eurheartj/ehu298.

44. Gorenek B, Blomström Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks

G, Huber K, Kirchhof P, Kuck KH, Kudaiberdieva G, Lin T, Raviele A, Santini M, Tilz RR, Valgimigli M, Vos MA, Vrints C, Zeymer U. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. EuroIntervention. 2015 Jan 22;10(9):1095-108.

45. Gorenek B, Lundqvist CB, Terradellas JB, Camm AJ, Hindricks G, Huber K,

Kirchhof P, Kuck KH, Kudaiberdieva G, Lin T, Raviele A, Santini M, Tilz RR, Valgimigli M, Vos MA, Vrints C, Zeymer U. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Eur Heart J Acute Cardiovasc Care. 2014 Sep 1. pii: 2048872614550583.

46. Gorenek B, Blomström Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks

G, Huber K, Kirchhof P, Kuck KH, Kudaiberdieva G, Lin T, Raviele A, Santini M, Tilz RR, Valgimigli M, Vos MA, Vrints C, Zeymer U, Lip GY, Potpara T, Fauchier L, Sticherling C, Roffi M, Widimsky P, Mehilli J, Lettino M, Schiele F, Sinnaeve P, Boriani G, Lane D, Savelieva I. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace. 2014 Nov;16(11):1655-73. doi: 10.1093/europace/euu208. Epub 2014 Aug 29.

47. De Luca L, Bolognese L, Valgimigli M, Ceravolo R, Danzi GB, Piccaluga E, Rakar

S, Cremonesi A, Bovenzi FM; Gruppo di Lavoro dell'Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO); Societa Italiana di Cardiologia Invasiva (SICI-GISE).[ANMCO/SICI-GISE document on antiplatelet therapy in patients with acute coronary syndrome]. G Ital Cardiol (Rome). 2013 Dec;14(12):839-66. doi: 10.1714/1371.15242. Italian.

48. 2013 Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti

F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P,

104

Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eht296. Erratum in: Eur Heart J. 2014 Sep 1;35(33):2260-1.

49. Task Force on the management of ST-segment elevation acute myocardial

infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215.

50. Autores/Miembros del Grupo de Trabajo, Steg G, James SK, Atar D, Badano LP,

Blomstrom Lundqvist C, A Borger M, di Mario C, Dickstein K, Ducrocq G, Fernández-Avilés F, H Gershlick A, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, J Lenzen M, W Mahaffey K, Valgimigli M, Van't Hof A, Widimsky P, Zahger D; Comité de la ESC para guías de práctica clínica (CGPC), J Bax J, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S; Revisores del Documento: David Hasdai (Coordinador de la Revisión del CGPC) (Israel), Astin F, Astrom-Olsson K, Budaj A, Clemmensen P, Collet JP, Fox KA, Fuat A, Gustiene O, Hamm CW, Kala P, Lancellotti P, Pietro Maggioni A, Merkely B, Neumann FJ, Piepoli MF, Werf FV, Verheugt F, Wallentin L. Grupo de Trabajo para el manejo del infarto agudo de miocardio con elevación del segmento ST de la Sociedad Europea de Cardiología (ESC). Rev Esp Cardiol. 2013 Jan;66(1):53.e1-53.e46. doi: 10.1016/j.recesp.2012.10.014.

51. Authors/Task Force Members, Hamm CW, Bassand JP, Agewall S, Bax J,

Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D; ESC Committee for Practice Guidelines, Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Windecker S, Achenbach S, Badimon L, Bertrand M, Bøtker HE, Collet JP, Crea F, Danchin N, Falk E, Goudevenos J, Gulba D, Hambrecht R, Herrmann J, Kastrati A, Kjeldsen K, Kristensen SD, Lancellotti P, Mehilli J, Merkely B, Montalescot G, Neumann FJ, Neyses L, Perk J, Roffi M, Romeo F, Ruda M, Swahn E, Valgimigli M, Vrints CJ, Widimsky P. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients

105

presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011 Dec;32(23):2999-3054.

52. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott

SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011 Jun 14;123(23):2736-47.

7.2.4 Editorials 1. Valgimigli M, Gragnano F. The Use of Radial Access for Cardiac Catheterization:

Slowly, But Yet it Moves. JACC Cardiovasc Interv. 2019 Aug 22. pii: S1936-8798(19)31517-1. doi: 10.1016/j.jcin.2019.06.052. [Epub ahead of print]

2. Valgimigli M. The remarkable story of a wonder drug, which now comes to an end in the primary prevention setting: say bye-bye to aspirin! Eur Heart J. 2019 Feb 14;40(7):618-620. doi: 10.1093/eurheartj/ehy872.

3. Valgimigli M, Gargiulo G Activated Clotting Time During Unfractionated Heparin-

Supported Coronary Intervention: Is Access Site the New Piece of the Puzzle? JACC Cardiovasc Interv. 2018 Jun 11;11(11):1046-1049. doi: 10.1016/j.jcin. 2018.02.022. Epub 2018 May 16

4. Jolly SS, Valgimigli M. Transradial left main PCI is safe and effective EuroIntervention. 2018 Nov 20;14(10):1073-1075. doi: 10.4244/EIJV14I10A192.

5. Valgimigli M, Costa F. Chronic Thrombocytopenia and Percutaneous Coronary

Intervention: The Virtue of Prudence. JACC Cardiovasc Interv. 2018 Sep 24;11(18):1869-1879. doi:10.1016/j.jcin.2018.06.051 Epub 2018 Aug 29

6. Gargiulo G, Valgimigli M. Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle. J Thorac Dis. 2017 Nov;9(11):4260-4265. doi: 10.21037/jtd.2017.10.28.

7. Gargiulo G, Valgimigli M. Long-term dual antiplatelet therapy and concomitant

optimal medical therapy following percutaneous coronary intervention. Cardiovasc Diagn Ther. 2017 Jun;7(Suppl 2):S102-S106.

8. Ukena C, Leonardi S, Palmerini T, Lansky A, Montalescot G, Valgimigli M. Will

PIONEER AF-PCI change my practice? EuroIntervention. 2017 Aug 4;13(5):e609-e612. doi: 10.4244/EIJV13I5A95.

106

9. Valgimigli M, Gargiulo G. DAPT Duration After Drug-Eluting Stent Implantation: No News Is Good News. JACC Cardiovasc Interv. 2017 Jun 26;10(12):1211-1214.

10. Valgimigli M, Gargiulo G. Deciding on the Duration of Dual Antiplatelet Therapy-

When the Choice Between 2 Evils Is Still Evil. JAMA Cardiol. 2017 May 1;2(5):488-489.

11. Gargiulo G, Valgimigli M. Bivalirudin Versus Unfractionated Heparin for Acute

Coronary Syndromes: Do We Have a Winner? Rev Esp Cardiol (Engl Ed). 2016 Aug;69(8):721-4

12. Valgimigli M, Gargiulo G. Bivalirudin in Current Practice: Melius Abundare Quam

Deficere? JACC Cardiovasc Interv. 2016 Jul 11;9(13):1321-3 13. Ariotti S, Gargiulo G, Windecker S, Valgimigli M. Time for science to catch up

with clinical practice? J Thorac Dis. 2015 Dec;7(12):E603-6 14. Valgimigli M, Ariotti S, Costa F. Duration of dual antiplatelet therapy after drug-

eluting stent implantation: will we ever reach a consensus? Eur Heart J. 2015 May 21;36(20):1219-22.

15. Valgimigli M. Shifting the focus to recurrences: so good we can afford it or too

bad we cannot avoid it? JACC Cardiovasc Interv. 2014 Oct;7(10):1114-6. doi: 10.1016/j.jcin.2014.07.006.

16. Biondi-Zoccai G, Valgimigli M. Deferred angioplasty and stenting in primary

percutaneous coronary intervention: one step back, two steps forward? EuroIntervention. 2013 Feb 22;8(10):1119-23. doi: 10.4244/EIJV8I10A173.

17. Valgimigli M, Leonardi S. Peri-procedural myocardial infarction and troponism: a

quick journey through the land of confusion. Heart. 2012 Oct;98(19):1400-1. doi: 10.1136/heartjnl-2012-302612.

18. Valgimigli M. AMI on the move. EuroIntervention. 2011 Aug;7(4):415,417,419.

doi: 10.4244/EIJV7I4A68. 19. Garcia-Garcia H. M, Valgimigli M, Beyond crossing a chronic total occlusion. Are

the drug-eluting stents the solution for this old problem? Eurointervention 2005(2):129-31.

20. Valgimigli M. Direct comparisons of sirolimus-eluting and paclitaxel-eluting stents

are needed. Evid Based Cardiovasc Med. 2005 Dec;9(4):294-6.

7.2.5 Letter to the Editor

107

1. Gargiulo G, Goette A, Vranckx P, Valgimigli M. Higher risk of stent thrombosis

with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help. Eur Heart J. 2020 May 1;41(17):1701-1702. doi: 10.1093/eurheartj/ehaa076. PubMed PMID: 32060541.

2. Vranckx P, Valgimigli M, Eckardt L, Gargiulo G, Goette A. Antithrombotic treatment strategies after PCI - Authors' reply. Lancet. 2020 Mar 14;395(10227):867-868. doi: 10.1016/S0140-6736(20)30033-7. PubMed PMID: 32171407.

3. Storey RF, Valgimigli M, Cuisset T, Capodanno D, Wijns W, Knuuti J. Intolerance to aspirin in patients undergoing percutaneous coronary intervention in the setting of chronic coronary syndromes: perspectives from the ESC 2019 Chronic Coronary Syndromes guidelines. Eur Heart J. 2020 Jan 14;41(3):483-484. doi: 10.1093/eurheartj/ehz894. PubMed PMID: 31872254.

4. Costa F, van Klaveren D, Steyerberg E, Valgimigli M; PRECISE-DAPT Study Investigators. Reply: Use of Clinical Risk Score in an Elderly Population: Need for Ad Hoc Validation and Calibration. J Am Coll Cardiol. 2019 Jul 9;74(1):162-163. doi: 10.1016/j.jacc.2019.05.005.

5. Gragnano F, Calabrò P, Valgimigli M. Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? Eur Heart J. 2019 Jan 7;40(2):216-217. doi: 10.1093/eurheartj/ehy675.

6. Valgimigli M, Gargiulo G. Response by Valgimigli and Gargiulo to Letter

Regarding Article, "A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?" Circulation. 2017 May 9;135(19):e1037-e1038.

7. Costa F, Daemen J, Diletti R, Kauer F, Geuns RJ, Ligthart J, Witberg K, Zijlstra

F, Valgimigli M, Van Mieghem NM, van Leeuwen MA. Response by Costa et al to Letter Regarding Article, "The Rotterdam Radial Access Research: Ultrasound-Based Radial Artery Evaluation for Diagnostic and Therapeutic Coronary Procedures". Circ Cardiovasc Interv. 2016 Jul;9(7)

8. Santucci A, Valgimigli M. Digital Gangrene Following Transradial Coronary

Angiogram. JACC Cardiovasc Interv. 2016 May 9;9(9):980-1 9. Valgimigli M, Santucci A. Bivalirudin in Acute Coronary Syndromes. Authors

reply. N Engl J Med. 2016 Jan 21;374(3):285-6 10. Valgimigli M, Gargiulo G, Jüni P. Radial versus femoral access for cardiac

catheterisation - Authors' reply. Lancet. 2015 Dec 12;386(10011):2394

108

11. Costa F, Valgimigli M. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015 Sep 24;373(13):1271-2

12. Costa F, Valgimigli M. Impact of Clinical Presentation on Dual Antiplatelet

Therapy Duration: Let's Re-Evaluate Our Priorities. J Am Coll Cardiol. 2015 Sep 8;66(10):1203-4

13. Cortese B, Valgimigli M. Letter by Cortese and Valgimigli regarding article,

"Antithrombotic therapy in patients with chronic kidney disease". Circulation. 2012 Nov 20;126(21):e333; author reply e334. doi: 10.1161/CIRCULATIONAHA. 112.124180.

14. Vranckx P, Valgimigli M. Letter by Vranckx and Valgimigli regarding article,

"validation of the bleeding academic research consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention". Circulation. 2012 Oct 23;126(17):e276; author reply e277. oi:10.1161/CIRCULATIONAHA.112.105023.

15. Ferraresi P, Campo G, Marchetti G, Pinotti M, Valgimigli M, Gemmati D, Ferrari

R, Bernardi F. Temporal and genotype-driven variation of factor VII levels in patients with acute myocardial infarction. Clin Appl Thromb Hemost. 2009 Feb;15(1):119-22.

16. Valgimigli M, Biondi Zoccai GG, Agostoni P. Clinical implications of the PROTECT-TIMI 30 trial. J Am Coll Cardiol 2007;49(6):729-730.

17. Valgimigli M, GF Percoco, L. Bolognese. Drug-Eluting Stents in Primary PCI.

New England Journal Med 2006;355(23)2483-2486 18. Tricoci P, Harrington RA, Valgimigli M. Letter regarding article by Patti et al,

"Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study". Circulation. 2005 Oct 25;112(17).

19. Valgimigli M, Agostoni P, Biondi Zoccai GG. Complete Myocardial

Revascularisation: Between Myth And Reality. Eur Heart J.2005 Sep;26 (17):1809-10.

20. Valgimigli M, Piscaglia F, Bolondi L. Splanchnic arterial Doppler parameters in

portal hypertension. Hepatology, 1999; 29 (5):1610-16123.

7.2.6 Case Reports

109

1. Malik V, Safaa A, Clugston R, Noc M, Fister M, Vranckx P, Valgimigli M, Heidbuchel H. How should I treat this unusual anterolateral ST-elevation myocardial infarction with recurrent ventricular fibrillation and cardiac arrest? EuroIntervention. 2016 Sep 18;12(7):928-32

2. Campo G, Valgimigli M, Carrescia C, Carletti R, Ferrari R. Tailored Medical and

Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting. Clin Appl Thromb Hemost. 2009 Jun 10.

3. Valgimigli M, Malagutti P. The heart of coronary arteries. Eur Heart J 2007 Mar

16.

4. Malagutti P, Ligthart JMR, Cademartiri F, Meijboom WB, Valgimigli M. Plaque sealing: are the benefits outweighing the risks? Int J Cardiol. 2007 Feb 7;115(2):265-6.

5. Biondi-Zoccai GG, Abbate A, Valgimigli M, Testa L, Agostoni P. From chaotic to

coordinated clinical research: the case of acetylcysteine. Arch Intern Med. 2006 Aug 14-28;166(15):1668

6. Valgimigli M, Steendijk P, Sianos G, Onderwater E, Serruys PW. Left Ventricular

Unloading And Concomitant Total Cardiac Output Increase By The Use Of Percutaneous Impella Recover Lp 2.5 Assist Device During High-Risk Coronary Intervention. Cath Cardio Int 2005;65(2):263-7.

7. Placci A, Melandri G, Cecilioni L, Valgimigli M, Bolondi L, Branzi A. Late

appearing cholestaticicterus after a month of treatment with ticlopidine Ital Heart J Suppl 2001; 2 (11): 1240-1242.

8. Piscaglia F, Valgimigli M, Serra C, Donati G, Gramantieri L, Bolondi l. Duplex

Doppler Findings in Splenic Arteriovenous Fistula. J Clin Ultrasound 1998,26(2):103-105.

9. Casali A, Gaiani S, Piscaglia F, Gramantieri L, Masi L, Valgimigli M, Bolondi L.

A case of extracranial vertebral artery dissection with spontaneous recovery diagnosis and follow up by duplex and color doppler. Eur J Ultrasound. 1997 Dec 1;6(3):197-201.

7.2.7 Book Chapters

1. Gargiulo G, Valgimigli M. Stent and Tent Thrombosis. Interventional Cardiology 1133 Questions: An International Board Review. Chapt 20, pages 218 – 236 Ed: Wolters Kluwer third edition 2019

110

2. Valgimigli M, Vant’Hof A, Hamm C. Tirofiban From: Antiplatelet therapy in Cardiovascular disease 2014, edited by Ron Waskmann, Paul A. Gurbel, Michale A. Gaglia Jr, Wiley Blackwell ISBN: 978118275757.

3. Ceconi C, Valgimigli M. Inibizione del Sistema Renina-Angiotensina e

Cardiprotezione. From “Infarto Miocardico Acuto. Fisiopatologia, Clinica e Terapia”, pages (233-248) Ed: Salvatore Fabio Vajola Press, 2001.

4. Bolondi L, Piscaglia F, Valgimigli M, Gaiani S. Doppler Ultrasound in Portal

Hypertension Pages (57-76) from P Rossi (Ed.) Portal Hypertension. Diagnostic imaging and imaging-guided therapy. Spinger-Verlag, 2001, ISBN 3-540-65797-5

5. Valgimigli M, Siminiak T, Kurpisz M, Giessen W, Serruys PW, Clinical Utilization

of Skeletal Myoblasts. In An essential guide to cardiac cell therapy. Edited by Emerson C. Perin, Guilherme V. Silva, James.T. Willerson. (ISBN: 10: 1 841844719) 2006 Informa UK limited.

6. Tebaldi M, Valgimigli M. Fractional Flow Reserve. Diagnostica Coronarica e

Cardiaca Avanzata 2011Vol 1, Chapt. 4, p;98 7. Cavazza C, Valgimigli M. Tomografia a Coerenza Ottica (OCT) Diagnostica

Coronarica e Cardiaca Avanzata 2011Vol 1, Chapt. 5, p;126 8. Vranckx P, Valgimigli M, Serruys PW. Aortic Counterpulsation. Encyclopedia of

intensive care medicine, DOI 10.1007 9. Biscagli S, Valgimigli M. Thrombectomy and distal protection devices. EuroPCR 10. Valgimigli M. Stenting in Acute Myocardial Infarction, Edited by Matthew J.

Price181 Questions and Answers in Heart Failure. Authors: R. Ferrari, L Tavazzi, C. Opasich. David Masson Editor, 2003

11. Come è cambiata la percezione dei farmaci cardiovascolari: dagli effetti

farmacologici a quelli biologici (How the perception of cardiovascular pharmacology has changed: from pharmacological to biological action of drugs) Editor R. Ferrari Pacini Editore, 2003

12. Cardiac Remodeling. Authors: R. Ferrari and Collaborators, Italian Society of

Cardiology 13. Valgimigli M and Gargiulo G. Post-Procedural Management and Antithrombotic

therapy. Chapter 4 “Post-Procedural Care: Post-Procedural Management and Antithrombotic Therapy” of the CathSAP 5 (fifth edition of the self-assessment program covering cardiac catheterization and interventional cardiology) from the American College of Cardiology, 2017. Editors: Sunil Rao, David Kandzari. Sunil V. Rao (Editor in Chief), Ajay J. Kirtane (Chair, Question Writing Group), Subhash

111

Banerjee, Aloke V. Finn, Allen Jeremias, David E. Kandzari, Matthew J. Price, Arnold H. Seto, Mehdi H. Shishehbor.

14. Gargiulo G and Valgimigli M. Chapter 20 “Stents and Stent Thrombosis” of the

3rd Edition of “1003 Questions: An Interventional Cardiology Board Review” 2017. Editors: Debabrata Mukherjee, Richard Lange, Leslie Cho, Saurav Chatterjee, and David J. Moliterno.

15. Costa F and Valgimigli M. “Radial and Femoral access in percutaneous

intervention”. Controversies in Cardiology Textbook 16. Costa F, Valgimigli M. “Parental Antiplatelet Agents”. Kapadia: Interventional

Cardiology Textbook

112

7.3 The five most important original papers 1. Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P,

Garducci S, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg D, Jüni P, Vranckx P; MATRIX Investigators. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med. 2015 Sep 10;373(11):997-1009. doi: 10.1056/NEJMoa1507854.

2. Piccolo R, Bonaa KH, Efthimiou O, Varenne O, Baldo A, Urban P, Kaiser C, Remkes W, Räber L, de Belder A, van 't Hof AWJ, Stankovic G, Lemos PA, Wilsgaard T, Reifart J, Rodriguez AE, Ribeiro EE, Serruys PWJC, Abizaid A, Sabaté M, Byrne RA, de la Torre Hernandez JM, Wijns W, Jüni P, Windecker S, Valgimigli M; Coronary Stent Trialists' Collaboration. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2019 Jun 22;393(10190):2503-2510. doi: 10.1016/S0140-6736(19)30474-X. Epub 2019 May 2

3. Valgimigli M, Frigoli E, Leonardi S, Vranckx P, Rothenbühler M, Tebaldi M, Varbella F, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andó G, Ferrario M, Limbruno U, Garbo R, Sganzerla P, Russo F, Nazzaro M, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, de Cesare N, Tosi P, van ’t Hof A, Omerovic E, Brugaletta S, Windecker S, Heg D, Jüni P, on behalf of the MATRIX Investigators Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet. 2018 Sep 8;392(10150):835-848.

4. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK,

Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017 Mar 11;389(10073):1025-1034.

5. Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, Rubartelli P,

Briguori C, Andò G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbühler M, Vranckx P, Jüni P; MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015 Jun 20;385(9986):2465-76.